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Abstract 
Hospital acquired infection (HAI) is one of the most frequent adverse event in healthcare 
worldwide, affecting hundreds of millions of patients annually. In both developed and 
developing countries, this burden falls mainly on the critically ill. In Vietnam, HAI data are 
limited, particularly from the intensive care units (ICUs). Robust data are needed to evaluate 
these problems. This thesis addresses this need.  
A point prevalence survey (PPS) of HAI and antibiotics use was conducted monthly at 15 
ICUs of 14 tertiary and provincial hospitals across Vietnam from October 2012 to September 
2013. Subsequently an observational study focused on ventilator associated pneumonia 
(VAP) and ventilator associated respiratory infections (VARI) at the ICUs of three referral 
hospitals in Hanoi and Ho Chi Minh City from November 2013 to November 2015.  
Analysis of 3287 patients in the PPS showed that 29.5% patients had at least one HAI on the 
surveyed day of which 80% was hospital acquired pneumonia. Antibiotics were being 
administered to 84.8% patients. A. baumannii, P. aeruginosa, and K. pneumoniae accounted 
for > 50% of HAI pathogens with carbapenem resistance rates of 89.2%, 55.7%, and 14.9% 
respectively. The presence of an invasive device was associated with significantly higher risk 
for HAI.  
The incidence of VAP and VARI in 374 patients analysed as part of the second study was 
9.9% and 24.6% respectively with corresponding incidence densities of 7.6 and 21.4 
episodes/1000 ventilation days respectively. Patients with VARI had an excess ICU stay of 11 
days, ventilation duration 12.5 days, antibiotic consumption 11 DOT; and ICU cost 2189 US$ 
compared with those without VARI. Given an estimated 22,570 patients admitted to the ICUs 
of 14 surveyed hospitals in 2012 and VARI prevalence of 24.6%, we would expect 5552 
patients developed VARI leading to an extra 69,403 ventilation days, 61,074 ICU days, 
61,074 DOT antibiotic consumption, and an extra ICU cost of 12,153,810 US$. With a total 
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of 40 tertiary and 304 provincial acute care hospitals across Vietnam, the extra cost for VARI 
nationally would be many times higher.  
In conclusion, this thesis provides compelling evidence that the burden of HAI in Vietnamese 
ICUs, particularly VAP/VARI, is substantial. There is also a high level of antibiotic 
consumption and widespread bacterial resistance to carbapenem antibiotics. Effective 
infection control measures and antibiotic stewardship programmes are urgently needed to 
address these problems in Vietnamese ICUs. 
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Chapter 1 
General introduction on hospital acquired infections 
Hospital acquired infection is one of the most frequent adverse event in healthcare worldwide. 
In Europe over 4 million patients are estimated to be affected by hospital acquired infection 
every year, with an estimated prevalence of 7.1%. In the United States of America (USA) 
figures are similar with a 4.5% prevalence rate affecting an estimated 1.7 million patients 
annually. Data from developing countries is sparse with only 23 out of 147 countries 
reporting national-level data. However in these countries prevalence rates are generally 
higher, ranging from 5.7 – 19.1% [1].  
Based on these figures, the World Health Organization (WHO) estimates hundreds of 
millions of patients are affected annually by a healthcare associated infection. In both 
developed and developing countries, the critically ill are disproportionately affected. Infection 
rates are significantly higher in developing countries, with levels at least twice those in the 
USA [1]. 
1.1. Definitions of terms  
Nosocomial infections, healthcare associated infections (HCAI) and hospital-acquired 
infections (HAI) generally have similar, overlapping meanings. WHO defines healthcare 
associated infection as ‘an infection occurring in a patient during the process of care in a 
healthcare facility which was not present at the time of admission’. Whilst this is similar to 
the definition of hospital-acquired infection (see below) it importantly also includes patients 
in long-stay residential or nursing homes. Nosocomial infection may refer to either HCAI or 
HAI but has a less clear definition and this term will therefore not be used in this thesis. 
According to the WHO, “Hospital-acquired infections are infections acquired during hospital 
care which are not present or incubating at admission” [2]. The time frame for diagnosis of 
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HAI is dependent on the incubation period of the disease. However, infections that manifest 
over 48 hours after admission are generally accepted to be HAI [2, 3]. Thus all HAIs are by 
definition HCAIs, whilst HAI represent a subset of HCAI.  
The use of epidemiological terms of HAI disease burden can vary between different studies 
and different reports. Here we have used prevalence of HAI to refer to proportion of subjects 
affected during a point prevalence survey (i.e. at a single point in time), incidence is used to 
describe the proportion of patients who may be affected during their hospital stay and 
incidence density is a term used for the frequency of infection per person day at risk (or more 
commonly 1000 person days at risk). Where the HAI is related to a device (see section 1.2 
below) this may be expressed as a rate per 1000 device days to emphasize that the subject is 
only at risk when the device is in place. 
1.2 Epidemiology of hospital acquired infections 
1.2.1. HAI in high income countries 
In many high-income settings there are robust national surveillance systems in place for 
reporting of HAI. These usually include reports of both the site and nature of infection and 
also the case-mix of patients. These systems employ a variety of surveillance techniques 
including mandatory reporting of certain HAIs (e.g. Clostridium difficile colitis, surgical site 
infections and Staphylococcus aureus bacteriemia in the United Kingdom (UK) and 
intermittent point prevalence surveys.  
HAIs are classified according to the major site of infection, for example urinary tract 
infection, blood stream infection, surgical site infection or pneumonia. The most common 
HAIs are lower respiratory tract infections (including pneumonia), surgical site infections, 
urinary tract infections, and blood stream infections. HAIs can be further classified depending 
on whether they relate to a device, which is specific for the infection site; endotracheal tube or 
tracheostomy tube and mechanical ventilation for pneumonia (generating the HAI designated 
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ventilator associated pneumonia or VAP), central venous catheter for blood stream infection 
(generating catheter related/associated blood stream infection or CRBSI/CABSI), urinary 
catheter for urinary tract infection (catheter associated UTI or CAUTI). 
The European Centre for Disease Prevention and Control (ECDC) reported that the 
prevalence of HAIs in European industrialized countries ranged from 3.5% to 10.5%, with a 
mean of 7.1% based upon data collected during period 1996 to 2007 [4]. During 2011 – 2012, 
the ECDC conducted a point prevalence survey looking at HAIs in European acute care 
hospitals and reported HAI prevalence was 6.0% of all patients [5].  This ECDC report also 
showed that the HAI prevalence varied by hospital types, being highest in tertiary hospitals at 
7.4%, then specialized hospitals at 6.0%, and dropping to 5.0% in both secondary and 
primary hospitals [5]. In the USA, there was an estimated incidence of HAI of 4.5% in 2002, 
corresponding to 9.3 infections per 1000 patient days and 1.7 million affected patients [6]. A 
point prevalence survey of 183 acute care hospitals in the USA conducted almost a decade 
later found remarkably consistent results, showing that 4.0% of over 11,000 patients surveyed 
had HAI [7]. 
ICU patients, neonates and those with transplants or burns are at greatest risk of HAI. ECDC 
surveillance in European hospitals in 2011 – 2012 found that 19.5% patients in ICUs had at 
least one HAI compared to a mean rate of 5.2% for all other specialties [5]. In the USA, more 
than 4000 health-care facilities regularly report data on ICU-acquired infections to the 
National Healthcare Safety Network (NHSN) established by US Centers for Disease Control 
and Prevention (CDC: http://www.cdc.gov/nhsn/). In one of the largest recent studies, Magill 
et al, looking at 183 acute care hospitals in the United States in 2011, showed that HAI 
prevalence in ICUs was 9.1%, as compared to 2.9% on general wards [7]. Looking 
specifically at device associated infections in the USA, Dudeck et al. demonstrated that 
variations occur depending on the type of ICU; for example, incidence density of central line 
related blood stream infection (episodes/1000 device-days) varied from 0.8 in surgical 
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cardiothoracic ICUs to 1.4 in trauma ICUs and 2.9 in burn ICUs whilst VAP incidence 
density ranged from zero in respiratory ICUs to 4.7 in trauma ICU and 4.9 in burn ICUs [8]. 
Hospital–wide European data from 2008 showed the most frequent HAIs were pneumonia 
(19.4% of all HAI), surgical site infections (SSI) (19.6%), urinary tract infection (UTI) (19%), 
bloodstream infections (BSI) (10.6)%, and gastro-intestinal infections (7.6%) [5]. Similarly 
the more recent point prevalence data from acute care hospitals confirmed UTI was the most 
frequent type of HAI, accounting for 36% of HAI, followed by SSI (20% of HAI), BSI and 
pneumonia (11% HAI) [6]. 
The most common HAIs in the European ICUs were respiratory infections (pneumonia and 
lower respiratory tract infections, accounting for > 40% of HAIs) and BSI (about 18% of 
HAIs) [5].  Similar data were reported in a comprehensive WHO review in 2011; the most 
common HAIs in adult ICUs across developed countries were VAP (32% of HAIs), followed 
by CAUTI (20%), and CRBSI (20%). The pooled incidence density/1000 device-days of 
VAP was 7.9 episodes,  CAUTI was 4.1 episodes, and CRBSI were 3.5 episodes [1]. All 
these common HAIs in ICUs are associated with the use of invasive devices, emphasizing 
that the high use of invasive devices puts ICU patients at increased risk of HAI. The USA 
National Nosocomial Infections Surveillance system also highlighted this, showing that 83% 
of episodes of hospital-acquired pneumonia were associated with mechanical ventilation, 
97% of UTIs occurred in catheterized patients, and 87% of primary BSI in patients with a 
central line [9].  
1.2.2 HAI in low and middle-income countries  
There is little information on HAIs from low and middle income countries (LMICs). In 2010, 
only 23 out of 147 developing countries (16%) reported a functioning national surveillance 
system and 97 of 147 (66%) developing countries had no published data at all [1].  
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Figure 1 – 1: Prevalence of healthcare-associated infection in low- and middle-income 
countries, 1995-2010. Reproduced from [1] 
Nevertheless, HAI appears to be at least as important a problem in resource-limited settings. 
WHO reports that in LMICs, the prevalence of HAI ranges from 5.7% to 19.1% (Figure 1 – 
1), with an average of 10.1 HAIs per 100 patient admissions (95% CI 8.4 – 12.2) [1]. Whilst it 
has been observed that the prevalence of HAI in resource limited settings in high-quality 
studies is higher than in low-quality studies (15.5% vs 8.5%) [10], the WHO report noted that 
over half the studies were of low quality. Of note both low and high quality studies give 
estimates that are higher than those in developed countries. The most frequent types of HAI 
were: SSI (29.1% of all HAI), UTI (23.9%), BSI (19.1%), hospital acquired pneumonia 
(HAP; 14.8%), and other infections (13.1%) [10]. One of the few studies to gather 
longitudinal data was a study in Kenya that was limited to paediatric admissions and BSI 
found an incidence density of 1 per 1000 patient days [11]. 
In LMICs, similar to better resourced settings, HAI incidence is higher in ICU compared to 
other hospital settings. HAI incidence ranged widely between reports from 4.4% to 88.9% 
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with a pooled incidence of 35.2% and pooled incidence density of HAI was 42.7 episodes per 
1000 patient-days [1].  
1.2.3 Surveillance and diagnosis of VAP and VARI 
For accurate surveillance of HAI good and robust definitions are required. These may be 
different to those used in routine clinical care and diagnosis. For many HAIs definitions are 
relatively straight-forward and can be defined using guidelines such as those provided by 
CDC from 1988 or later updates by CDC and the European Centre for Disease Control 
(ECDC) [12-14].  These definitions will usually include clinical criteria such as fever 
combined with positive microbiological findings. However definitions vary and when 
interpreting published literature it is important to take into account the exact definitions used.  
1.2.3.1 Ventilator associated respiratory infections (VARI) - definitions and diagnosis 
One particularly problematical area is the diagnosis of ventilator-associated respiratory 
infections, comprising ventilator associated pneumonia (VAP) and ventilator associated 
tracheobronchitis (VAT), which causes much debate and controversy [15]. This is in part due 
to the lack of consensus over what actually constitutes VAP clinically combined with the lack 
of a gold standard diagnosis. It should be noted that there is a clear distinction between the 
criteria used for VAP diagnosis by clinicians managing patients in the ICUs and by 
surveillance. There is also difference in definitions of VAP between different studies as 
guidelines for VAP diagnosis have changed over time. Surveillance of VAP has also been 
proposed as a marker of quality of service (implying that with the correct care and attention 
incidence can be reduced significantly) and in some situations there may be strong financial 
incentives not to report the condition further complicating data interpretation [15]. In response 
to the apparently low surveillance rates of VAP (sometimes 0%) reported in some centres in 
the US [8] which were at odds with clinical data, definitions were changed towards what was 
felt to be more objective ones. However criteria are still subjective and non-specific due to the 
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complexity of both the disease and the critically-ill patients affected. Thus there are no 
universally-accepted standard surveillance criteria for VAP [16].  
Currently international consensus is that clinically, VAP should be suspected when the patient 
intubated for over 48 hours, has new and persistent infiltrates on the chest x-ray, with a 
deterioration in gas exchange, signs of infection (fever, leukocytosis, increased purulent 
sputum), and positive culture of a lower respiratory tract specimen [13, 17-19]. However, 
radiographic criteria are neither specific nor sensitive, and many other clinical syndromes 
common in ICU patients, such as congestive heart failure, atelectasis, pulmonary embolus and 
systemic sepsis can lead to deterioration in gas exchange and other so-called signs of VAP 
[13, 20, 21]. In an attempt to resolve this, improve the accuracy of VAP surveillance and 
permit electronic record based capture of cases modified criteria which assess more objective 
changes in the ventilation setting, like fraction of inspired oxygen (FiO2) and positive end-
expiratory pressure (PEEP), have been proposed [22]. Chest radiograph has also been 
removed from these criteria and a new classification of ventilator associated conditions (a 
subgroup of which is VAP) proposed  in 2013 by CDC [23]. In 2016, further changes in the 
VAP definition, possible and probable VAP were removed and now only one type of possible 
VAP is possible based on three sign groups: oxygenation deterioration, clinical 
signs/symptom of infection and antibiotic use, and microbiology results [24]. X-ray criteria 
have not been in CDC surveillance definitions for VAP since 2013, yet remain important to 
many clinicians and academics seeking clear end points for studies. CDC and some common 
criteria for identifying VAP is presented in Table 1 – 1. Detailed criteria of CDC/NHSN 2013 
and 2016 for recognizing VAP are presented in Figure 1 – 2 and Figure 1 – 3. 
 
 
 
 8 
Table 1 - 1. Summary of published criteria for VAP diagnosis in common use 
Criteria	 CDC/NHSN	2013	-	possible	VAP	
[23]	
CDC/NHSN	2008	–	PNU1	[13]	 CPIS	(suspect	VAP	if	score	>		6)	[25]	 HELICS	[26]	 ACCP	[27]	 Johanson’s	
criteria	[17]	
Pulmonary	
clinical	
signs	
Worsening	oxygenation	after	≥	
2	calendar	days	of 	stable	or	
improving	period:	Minimum	
daily	FIO2		 increase	≥	0.20	
remain	2	days	OR	minimum	
daily	PEEP	values	 increase	≥	3	
cm	H2O	 remain	2	days	
At	least	two	of:	
- New	purulent	 sputum	or	change	
in	 character	
- New	onset	or	worsening	cough,	
dyspnea,	or	tachypnea	
- Auscultation	suggestive	worsening	
gas	exchange	 (desaturation,	
PaO2/FiO2	≤	240,	increasing	FIO2	
or	ventilation	requirements)	
PaO2/FiO2	≤	240	and	no	ARDS:	2	 At least one of these (2 if qualitative 
aspirate culture or if culture is 
negative): 
- New	purulent	 sputum	or	change	 in	
character	
- New	onset	or	worsening	cough,	
dyspnea,	or	tachypnea	
- Auscultation	suggestive	worsening	
gas	exchange	 (desaturation,	
PaO2/FiO2	≤	240,	increasing	FIO2	 or	
ventilation	requirements)	
	 	
Systemic	
response	
At	least	one	of:	
- Temperature	>	38°C	or	<	
36°C	
- WBC	>	12.000/mm3	or	<			
4.000/mm3		
AND	
- New	antimicrobials	use	for	>	4	
days	
At	least	one	of:	
- Temperature	>	38°C	or	<	36°C	
- WBC	>	12.000/mm3	or	<			
4.000/mm3	
- Altered	mental	status	with	no	
other	 cause	for	patient	>	70	
years	old	
- Temperature	≥	38.5°C	and	≤	38.9°C:	1	
- Temperature	≥	39°C	or	≤	36.5°C:	2	
- WBC	>	11.000/mm3	or	<			4.000/mm3:	
1	
- WBC	>	11.000/mm3	or	<			4.000/mm3	
AND	band	form≥	500:	2	
At	least	one	of:	
- Temperature	>	38°C	or	<	36°C	
- WBC	>	12.000/mm3	or	<			
4.000/mm3	
At least two of: 
- Temperature	>	38°C	
or	<	36°C	
- WBC > 12.000/mm3 
or <   4.000/mm3 
- Purulent	 secretions	
- Decreased	PaO2	
Fever	and	
Leukocytosis	
Chest	x-ray	 	 One	of	these	on	≥	2	series	x-rays	for	
patients	with	underlying	diseases	or	
≥	1	x-ray	for	patients	without	
- New	or	progressive	and	persistent	
infiltrate	
- Consolidation	
- Cavitation	
Diffuse	infiltrate:	1	
Localized	infiltrate:	2	
Image	suggestive	of	pneumonia	
(two	or	more	required	for	 patients	
with	underlying	cardiac	or	pulmonary	
disease)	
New	alveolar	infiltrates	
or	an	air	bronchogram	
sign,	or	if	the	findings	
have	worsened	
New	or	
progressive	
infiltrate	
Respiratory 
specimen 
examination 
- Purulent	respiratory	secretions	
defined	as	that	contain	>25	
neutrophils	and	<10	squamous	
epithelial	cells	per	low	power	
field.	
- Positive	culture	(qualitative,	
semi-quantitative	or	
quantitative)	of	sputum	
	 - Secretions	but	not	purulent:	1	points	
- Purulent	respiratory	secretions:	2	
- Semiquantitative	culture	of	tracheal	
aspirate	>1+:	1	point	
- Semiquantitative	culture	of	tracheal	
aspirate	>1+	and	same	pathogenic	seen	
on	Gram	stain	>	1+:	2	
Positive	quantitative	culture	 	 Purulent	
respiratory	
secretions	
CDC/NHSN = US Centers for Disease Control and Prevention/National Healthcare Safety Network; PNU1 = clinically deﬁned pneumonia; ACCP = American College of Chest Physicians; CPIS = Clinical Pulmonary Infection 
Score; HELICS = Hospital in Europe Link for Infection Control through Surveillance; VAP = ventilator-associated pneumonia.  
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Figure 1 - 2. CDC criteria for ventilator associated events surveillance 2013. 
Reproduced from [23] 
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Figure 1 - 3. CDC criteria for ventilator associated events surveillance 2016. 
Reproduced from [24] 
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There has been increasing awareness of ventilator-associated tracheobronchitis (VAT) as a 
syndrome, and attempts to distinguish ventilator-associated infection of the lower respiratory 
tract (VAT) from VAP. Like VAP, there are no standard criteria for VAT, and perhaps even 
less consensus as to its significance, with some authors seeing it as a milder form of infection 
and others as an early stage of VAP [28]. Most common used VAT definitions include fever 
> 38oC or leucocytosis without other cause, purulent tracheal secretion, positive tracheal 
aspirate culture (³ 105 colony forming units (cfu)/ml), and the absence of new infiltrate on 
chest radiograph in patients ventilated for > 48 hours [29-33]. These VAT criteria overlap 
with clinical VAP definitions, fundamentally distinguished by the absence of radiographic 
changes [18]. However in practice, the differentiation between VAT and VAP is challenging 
and may represent timing of radiological examination or its interpretation. Removing the 
requirement for new and persistent infiltrate on chest x-ray from VAP criteria has been 
proposed [34] due to its subjective nature and difficulty excluding other non-infective causes 
of chest x-ray changes. Also the term ventilator associated respiratory infection (VARI) has 
been used to encompass both VAT and VAP [35].  
The results of microbiological tests form one of the criteria for both VAP and VAT diagnosis, 
however microbiological results alone are not sufficient for a diagnosis of VAP or VAT. In 
intubated patients the lower airway is often no longer sterile and colonization with bacteria is 
common. Endotracheal aspirates may consequently show significant growth of bacteria 
commonly associated with VARI in the absence of systemic or even local signs of infection. 
Although bacteriological criteria are felt to be objective they may be dependent on the 
procedure used to take the specimen and confounded by the presence of colonizing organisms 
in intubated patients.  Quantitative culture, to determine how heavy the bacteria growth is, 
and the presence of pus cells have been used as a way of differentiating true infection from 
colonization but there is no consensus regarding what density of bacteria growth differentiates 
the two [36, 37]. In general samples from deeper in the respiratory tree require lower numbers 
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of organisms to be considered significant. When combined with histological or clinical 
parameters, bronchoalveolar lavage (BAL, >104 cfu/ml), protected BAL (>104 cfu/ml), 
endotracheal aspirate (>105 cfu/ml) were associated with sensitivities of 22-50% and 
specificities of 45-100% in diagnosis of VAP using histological reference tests [20]. When 
histological and bacteriological tests were combined, sensitivities were 19-87% and 31-100% 
specificity [20].  Again the lack of gold standard diagnosis of VAP is a major problem when 
interpreting these results, developing diagnostic criteria and comparing different studies. 
Despite these uncertainties, many studies used quantitative culture of endotracheal aspirate 
specimens with ≥ 105 cfu/ml or semi-quantitative culture results showing moderate to heavy 
growth as meeting microbiological criteria for VAT or VAP definitions, as detailed in the 
review by Craven et al. [35]. However, although using higher cut-off’s increases the 
likelihood of true pathogen isolation, it also lowers sensitivity and may lead to underdiagnosis 
of VARI in some cases. Conversely, lower cut-off values would increase sensitivity to detect 
pathogens and diagnose VARI, but have higher possible of false positive rates (ie isolates are 
not pathogens, just coloniser) [38]. Such an approach could lead to unnecessary antibiotic use 
and thereby increase antibiotic resistance.  
1.2.3.2 Epidemiology of VAP and VARI 
VAP is one of the most common HAIs in ICU. In the period from 2006 through 2008 in the 
United States pooled VAP incidence density was 2.97 episodes/1000 ventilation days, 
ranging from 0.5 to 10.7 episodes/1000 ventilation days [39]. ECDC surveillance in European 
ICUs in 2007 found that 7.0% of patients who stayed > 2 days in ICU developed pneumonia 
and incidence density of intubation-associated pneumonia ranged from 7.2 episodes/1000 
intubation days to 22 episodes/1000 intubation days [40]. Lambert et al analysed the 
European database of ICU admissions between January 1st 2005 to December 31 2008, 
finding that 7.0% (8525/119699) of patients staying > 2 days in ICU developed hospital-
acquired pneumonia, of which 90% (7675/8525) was VAP [41], giving a VAP incidence of 
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6.4% for patients staying in European ICUs for > 48 hours. Martin-Loeches et al found the 
incidence of VAP was 12% (8.8 episodes/1000 ventilation days) through a prospective 
international multicenter observational study on adult patients ventilated for > 48 hours at 114 
ICUs in eight countries in Europe and South America between September 1st 2013 to July 31st 
2014. In this study clinical, white blood cell, radiology, and quantitative culture criteria were 
used for the diagnosis of VAP and VAT [32]. Kollef et al. conducted a prospective 
observational study in 11 upper-middle and high income countries in four global regions over 
six months between March 2011 to March 2012, enrolling 1873 adult patients who were 
ventilated for between 48 hours and 7 days. They found that VAP incidence over the 30 days 
following enrolment was 15.6% globally, 13.5% in the United State, 13.8% in Latin America, 
and 16.0% in Asia Pacific in Europe (VAP being defined by local investigators) [42]. 
The epidemiology of VAT is less well studied, however there are some data. Nseir et al. 
conducted a prospective surveillance study for nosocomial tracheobronchitis (definition based 
on the Center for Disease Control criteria in 1988) in a 30 bed medical/surgical ICU in France 
from March 1993 to September 1999 on all patients ventilated for > 48 hours [29]. This study 
found that VAT incidence was 10.6% (201 among 1889 included patients) and that VAT was 
associated with an increase in mechanical ventilation time and ICU stay of about 14 days and 
17 days respectively compared with those patients without VAT. In the study described above 
by Martin-Loeches et al. the VAT rate was 11% (10.2 episodes/1000 ventilation days) [32]. 
Agrafiotis et al. conducted a systematic review and meta-analysis including 17 studies on 
VAT published up to September 2008 found that  rate of VAT was 11.5% [43]. Craven et al. 
also found that VAT incidence (diagnosed by two clinical signs and quantitative endotracheal 
aspirate culture) was 11% in patients ventilated for > 48 hours and 29% of these patients 
developed VAP later [30]. Karvouniaris et al. conducted a prospective observational study of 
236 patients ventilated for > 48 hours between 2009 to 2011 in University Hospital Greece 
and found that VAT incidence was 18% (42/236) [44]. Dallas et al. conducted a prospective 
cohort study on intubated patients for > 48 hours at the surgical and medical ICUs of a tertiary 
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hospital in the USA over 1 year found that VAT incidence was just 1.4% while VAP 
incidence was 4.0% [31]. As a result, VAT incidence among ICU patients ventilated for > 48 
hours ranged from 1.4% to 18% depended on surveyed sites. 
1.2.3.3 VAP in resource-limited settings 
In developing countries, VAP is also perceived to be a major problem. Rosenthal et al 
conducted a prospective multicenter surveillance study for device-associated HAI in 43 
countries from Latin America, Asia, Africa, and Europe that were participating in the 
International Nosocomial Infection Control Consortium (INICC). The authors found that 
VAP incidence density (using the 2008 CDC definition) was 19.5 (18.7 – 20.3) episodes/1000 
ventilation days in the period 2002-2007, decreasing to 14.7 (14.5 – 14.9) episodes/1000 
ventilation days in period 2007 – 2012 [45]. Mathai and colleagues conducted a prospective 
study at a tertiary hospital ICU in India from December 1st 2010 to November 30th 2011 on 
patients ventilated for > 48 hours found that 38% (95/250) of enrolled patients developed 
VAP and the incidence density of VAP was 40.1 episodes/1000 ventilation days [46]. Song et 
al. reported VAP incidence of 25% vs 26.7% and incidence density of 29.7 and 27.4 episodes 
/1000 ventilation days in medical and surgical ICU respectively, at a 1500 bed university – 
tertiary hospital in China between January 2011 and June 2012 [47]. Arabi et al. conducted a 
systematic review on published papers on VAP from developing countries from January 1966 
to April 2007 including 18 papers and reported the VAP incidence density ranged from 10 
episodes in Thailand to 41.7 episodes/1000 ventilation days in Brazil [48]. Consequently, 
VAP incidence and incidence density ranged from 25% to 38% and 14.7 to 41.7 
episodes/1000 ventilation days depended on settings. 
1.3 Pathogenesis of hospital acquired infections 
HAIs are caused by infectious agents originating from either endogenous or exogenous 
sources. Endogenous sources are the patient’s own body sites, such as the skin, nose, mouth, 
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gastrointestinal tract etc. that are normally colonized by local microbial flora. These 
microorganisms can become invasive under certain favorable conditions and cause infection. 
Exogenous sources are those external to the patient, such as health care workers, visitors, 
medical devices, or the health care environment.  
In hospitalized patients, the normal flora changes due to the use of antibiotics, and 
colonization by new bacteria present in the environment. Antibiotic use leads to a selective 
pressure on normal flora, i.e susceptible bacteria will be killed while bacteria resistant to the 
antibiotics used will survive, multiply and become predominant. In hospital, patients will also 
be in contact with the hospital environment and acquire local bacteria which are commonly 
antibiotic resistant as they are able to survive in the hospital environment where antibiotics 
are used commonly. Further the death of susceptible normal flora resulting from antibiotic use 
can open these sites to colonization by resistant flora from the environment. Finally the use of 
invasive devices, which use synthetic materials, allows bacteria that have adapted to survive 
on such artificial materials (for example the plastic of an endotracheal tube or central venous 
catheter) to reproduce and become dominant, whilst bacteria adapted to surviving on human 
tissue are disadvantaged and die off.  These factors explain why the pathogens associated with 
hospital acquired infections are usually resistant to many antibiotics and are often different 
species to those encountered commonly in community acquired infections.  
A report by WHO in 2011 on the global burden of HAI showed that the most frequent 
pathogens causing HAI were Escherichia coli (20.1%), Staphylococcus aureus (17.8%), 
Pseudomonas spp. (11.5%), Enterobacteriaceae (10.6%), Candida spp. (11.5%), Enterococci 
(6.5%), Acinetobacter spp. (5.8%), and coagulase-negative staphylococci (5.3%); and in ICUs 
they were S. aureus (21.8%), Enterobacteriaceae (20.2%), Pseudomonas spp. (17.2%), 
Enterococci (10.0%), E. coli (9.1%), Candida spp. (8.8%), coagulase-negative staphylococci 
(7.0%), and Acinetobacter spp. (5.1%). [1] 
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A point prevalence survey of HAI in European hospitals conducted by the European Center 
for Disease Control (ECDC) in 2011-2012 showed that the most common microorganisms 
reported for HAIs were broadly similar: E. coli (15.9%), S. aureus (12.3%), Enterococcus 
spp. (9.6%), Pseudomonas aeruginosa (8.9%), Klebsiella spp. (8.7%), Coagulase-negative 
staphylococci (7.5%), Candida spp. (6.1%), Clostridium difficile (5.4%), Enterobacter spp. 
(4.2%), Proteus spp. (3.8%), Acinetobacter spp. (3.6%). In this report, 41.2% of S. aureus 
was methicillin resistant (MRSA) [5]. Vancomycin resistance was reported in 10.2% of 
isolated enterococci and higher among Enterococcus faecium (19%) than Enterococcus 
faecalis (5.5%). Enterobacteriaceae non-susceptible to third generation cephalosporins and 
carbapenems were 33.4% and 7.6%, respectively. Non susceptibility to carbapenems was also 
reported in 31.8% of P. aeruginosa and 81.2% of Acinetobacter baumannii [5]. A report by 
ECDC on European hospitals for 2004 to 2006 showed that the most common pathogens of 
ICU-acquired pneumonia were P. aeruginosa 19.0%, then S. aureus 18.0% with MRSA 
representing 42.8% of these [4]. A study at a 15-bed surgical and neurosurgical ICU in 
Croatia, from September 2009 to March 2013 found that most common bacteria causing VAP 
were Staphylococcus aureus (21.1%), followed by Pseudomonas aeruginosa (19.0%) and 
Acinetobacter species (13.6%) [49]. Chi et al. reported that among 108 pathogens from 91 
VAP patients in South Korea between January 2008 to December 2009, most common 
isolates were S. aureus 44%, A. baumannii 30%, P. aeruginosa 12%, and Stenotrophomonas 
maltophilia 7%, K. pneumoniae 6%, and serratia marcescens 2%; with 69% of A. baumannii 
isolates resistant to imipenem [50]. In a study on VAT from March 1993 to September 1999, 
Nseir et al. found that common pathogens of VAT in surgical and medical ICU (respectively) 
were P. aeruginosa (31.8% vs 28%), S. aureus (20.4% vs 17.8%), and A. baumannii (13.6% 
vs 26.5%) [29]. A review by Nseir et al. showed that the most common among 369 
microorganisms isolated from 302 VAT episodes were P. aeruginosa 27% (101/369), S. 
aureus 20% (76/369) of which methicillin resistant S. aureus (MRSA) accounted for 69.7% 
(53/76), and A. baumannii 18% (67/369) [33]. 
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In developing countries, the most common bacteria causing HAI are Gram-negative bacilli.  
A systematic review of 220 studies from 1995 to 2008 across 6 regions (Africa, the Americas, 
Europe, southeast Asia, eastern Mediterranean, and western Pacific) found that the most 
frequent pathogens identified for HAP (included VAP) was Pseudomonas spp. (29%) and 
Acinetobacter spp (24.0%) and for BSI was S. aureus (19%) and Acinetobacter spp (17.7%) 
[10].  A retrospective cohort study in the medical intensive care unit of Chaing Mai 
University Hospital, Thailand on VAP from January 2005 – December 2009 found that the 
major associated pathogens were A. baumannii (54.3%), P. aeruginosa (35.2%), and MRSA 
(15.1%). Most A. baumannii (90.2%) comprised drug-resistant strains [51]. A review by 
Rajesh Chawla on HAP and VAP in ten Asian countries showed that four most common 
pathogens of HAP including VAP in nine countries were Pseudomonas spp. (15 – 23%), A. 
baumannii (9 – 58.5%), MRSA (5 – 23%), and K. pneumoniae (5.8 – 23%); for Philippines, 
most common VAP pathogens were Pseudomonas spp. 42.1%, K. pneumoniae 26.3%, and A. 
baumannii 13.1% [52]. A study on pathogens causing nosocomial bacteremia among 
paediatric patients in a district hospital in Kenya from 2002 to 2009 found that most common 
isolates were Escherichia coli (44/212), Klebsiella pneumoniae (43/212), Staphylococcus 
aureus (20/212), Acinetobacter spp (19/212), group D streptococci (18/212), and 
Pseudomonas aeruginosa (16/212), these pathogens accounted for three-quarters of 
nosocomial infections [11]. Recently, a study at nine provincial hospitals in the Northeast of 
Thailand showed that most common pathogens of hospital-acquired bacteremia in a period 
from 2004 to 2010 were Acinetobacter spp. (501/2101), Klebsiella pneumoniae (455/2101), 
Staphylococcus aureus (446/2101), Escherichia coli (403/2101), Pseudomonas aeruginosa 
(179/2101), and Enterococcus spp. (117/2101) with the rate of multidrug resistance (defined 
as non-susceptibility to at least one agent in three or more antimicrobial categories) among 
those pathogens were 75%, 66%, 50%, 63%, 25%, and 3%, respectively [53]. 
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1.4 Risk factors for hospital acquired infection and VAP 
WHO data from high income countries, show the most common factors independently 
associated with HAI occurrence are: older age (> 65 years), admission to an emergency or 
intensive care unit, hospital stay longer than 7 days, placement of a central venous catheter, 
indwelling urinary catheter, or an endotracheal tube, undergoing surgery, trauma induced 
immunosuppression, neutropenia, a rapid or ultimate fatal disease, and coma or impaired 
functional status [1]. Similar risk factors were identified in low- and middle-income countries 
(LMIC) with the addition of other risk factors, although not demonstrated as independent risk 
factors: poor infection control practices, inadequate numbers of trained infection control staff, 
understaffed hospital unit, and insufficient equipment and supplies [1]. Gravel et al. through 
multivariate logistic regression analysis for HAI found that ICU admission was not risk factor 
for HAI but hospital stay > 7 days, having central vascular catheter, tracheal tube, or urinary 
catheter were independently associated with higher risk for HAI [54]. 
In addition to the above risk factors for HAI in general, many studies have looked at specific 
risk factors for VAP. Interpretation and comparison of studies is again hampered by 
variations in definitions of VAP used and prospective versus retrospective methods of data 
collection. However several consistent risk factors emerge: duration of mechanical 
ventilation, increased age and severity of underlying disease, use of muscle relaxants and 
paralysis. A prospective cohort study for one year (2003 – 2004) on 51 patients ventilated for 
over 48 hours in a tertiary critical care units in Mumbai, India, by Panwar et al. found that 
VAP incidence increased along with prolonged duration of mechanical ventilation and higher 
severity of underlying disease at ICU admission [55]. The nature of the underlying disease is 
also important, for example in burns patients, VAP developed in 44.6% and 27% of patients 
with and without inhalational injury, respectively [56]. In a prospective study of trauma 
patients in Iran, type 2 diabetes was found to be a risk factor for VAP development, 
associated with a hazard ratio of 10.1 after adjustment for confounders [57]. Charles et al 
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found that supine head position was significant risk factor for VAP [58]. Liu et al. found that 
prolonged mechanical ventilation > 4 days and ICU stay > 9 days, and high APACHE II 
score > 9 points were associated with higher risk for ventilator associated tracheobronchitis in 
patients > 65 years old [59]. A case control study using electronic database in the United 
States in 2011 found that mandatory ventilation mode and positive fluid balances were 
significant risk factors for ventilator associated conditions and commencing benzodiazepines 
before intubation, total opioid exposures, and paralytic medications were possible risk factors 
for infection-related ventilator associated complications [60]. A randomized trial evaluated 
impact of no sedative versus interrupted sedative use on ventilation time on 113 critical ill 
adult patients ventilated in Odense University Hospital, Denmark, from April 2007 to 
December 2008 [61]. This trial found that patients with no sedative had statistically 
significant shorter ICU and hospital stays and lower mortality in ICU than those patients used 
sedative, but there was no significant difference in VAP incidence between the two groups. 
An expert review on HAI conducted in Asian countries specifically considered risk factors for 
VAP. The following were identified: male sex, preexisting pulmonary disease, multiple organ 
system failure, the presence of intubation or enteral feeding, mechanical ventilation, and 
supine position. In addition to these, the panel considered elderly age, APACHE II score > 15 
points, previous use of antibiotics for more than 2 weeks, diabetes, immunosuppression, 
dialysis, reintubation due to failed weaning, use of paralytic sedative, and length of ICU stay 
to be additional risk factors [52]. However, the data used in this report were often local 
hospital data without prospective collection or standard definitions and these risk factors were 
identified by discussion of the panel members, and presented without any statistical analysis. 
Thus there are relatively few high-quality data on VAP risk factors in Asian and developing 
countries. 	
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1.5 Impact of hospital acquired infections 
1.5.1 Impact of general hospital acquired infection (HAI) 
HAI affects a large number of patients every year and is a significant global health problem 
[4, 6, 10] due to its significant impact on costs, prolonged hospital stay, attributable mortality, 
and other complications [62-64]. As described earlier VAP is one of the most common HAIs. 
Based mainly on data from high-income countries, WHO estimates that VAP has an 
attributable mortality between 7% and 30% and attributable costs at US$ 10,000 – 25,000 per 
case [1]. 
European estimates indicate that HAIs cause 16 million extra days of hospital stay, 37,000 
attributable deaths annually, and contributed to an additional 110,000 deaths [4]. In the USA, 
around 99,000 deaths were attributed to HAI in 2002 [6]. Of these, approximately 36,000 
were due to pneumonia, 31,000 to BSI, 13,000 to UTI, 8,200 to SSI, and 11,062 to other 
infections. 
The burden of HAI is also reflected in significant financial losses. These infections account 
for approximately 7 billion euro in Europe, in direct costs alone [4]. The annual economic 
impact of HAI in the USA was estimated to be approximately 6.5 billion US$ in 2004 [6]. 
Another report showed that the overall annual direct medical costs of HAI ranged from 28.4 
to 45 billion US$ for the United States, and suggested that the benefits of effective infection 
control interventions can range from 5.7 to 6.8 billion US$ (if 20% of HAI prevented) to as 
high as 25.0 to 31.8 billion US$ (if 70% of HAI prevented) [65]. Recently, the annual societal 
burden of HAI in the USA was estimated to be 96 –  147 billion US$ in 2013 [66]. The WHO 
estimated that overall, for each 100 patients admitted to hospital, 10 patients will develop a 
HAI [1]. Due to lack of human resources, equipment and inadequate recognition of HAI, the 
real burden of HAI may be much higher [2]. From available data in 2011 WHO reported that 
the crude excess mortality in adult patients was 18.5% for CR-UTI, 23.6% for CR-BSI, and 
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highest at 29.3% for VAP, and increase in length of stay varied between 5 and 30 days for 
patients with HAI [1]. In Mexican ICUs, the overall average cost of a HAI episode was 
12,155 US$ and in Argentina ICUs, the overall extra-cost estimates for CR-BSI and HAP 
averaged 4,888 US$ and 2,255 US$ per case, respectively [1]. 
1.5.2 Impact of Ventilator Associated Pneumonia (VAP) 
When considering VAP in particular there are conflicting data with many studies using 
retrospective study designs with increased risk of bias and difficulty in correcting for 
confounding variables such as length of ventilation or severity of underlying disease. Some 
well conducted studies reported significant increases in attributed mortality with VAP ranging 
from 1 to 1.5% [16]. However a retrospective study analyzing data from a large database in 
the United States did not find a significant difference in mortality between patients with and 
without VAP [67]. Possibly the best estimate of the mortality impact of VAP comes from an 
individual patient meta-analysis of 6284 patients from 24 randomized VAP prevention trials 
by Melsen et al [68]. The use of randomized patient data should eliminate confounding that 
complicates other study designs. This study found an attributable mortality of 13% and this 
effect was concentrated in surgical patients and those with mid-level severity scores 
(APACHE II 20 – 29 points). A recent meta-analysis assessing mortality prediction in 
patients with VAP evaluated 7 different prediction methods in studies including over 5000 
patients but did not find any superior – only some were much more complicated than others 
[69].  
Data from resource-limited settings regarding mortality and VAP are often of poor quality 
and difficult to interpret. A review by Chawla has suggested that VAP is associated with 
increased mortality in some ICU settings where 22.5% of Thai patients were reported to die 
from VAP, in India an attributable mortality of 37% was reported, and in China a study has 
shown attributable mortality of 14% due to VAP [52].  
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Irrespective of mortality, most studies have found that VAP is associated with prolonged ICU 
stay and ventilation time with mean extra hospital cost ranging from 10,000 to 40,000 US$ 
per VAP case in high income countries [16, 67]. Mathai et al. conducted a study in a tertiary 
hospital ICU in Northern India between October 2010 to September 2011 found that VAP 
patients had significantly longer hospital stays compared with patients without VAP (21 vs 11 
days) and the attributable cost per VAP case was 5,200 US$ [70]. However, that study found 
no significant difference in mortality between patients with VAP (68.4%) and without VAP 
(61.3%), p = 0.200. A retrospective study on 621 patients diagnosed VAP in medical ICU in 
Chiang Mai university hospital from 2005 to 2011 found that mortality was 44.4% [51]. 
1.5.3 Impact of Ventilator Associated Tracheobronchitis (VAT) 
Studies looking at VAT again show conflicting data regarding its effect on outcome and 
relationship to VAP. A study by Nseir et al. found that in medical ICU, mortality of VAT 
patients was 38.7% compared with 32.1% in patients without VAT but this difference was not 
statistically significant [29]. That study also showed that VAP incidence among VAT patients 
was lower than in patients without VAT, and VAT patients who used antibiotics had 
significant lower mortality than who were not. In another study, Nseir et al. found that VAT 
was statistically associated with increase in ventilation time and ICU stay compared without 
VAT [71]. A prospective observational study of 114 ICUs in Spain, France and South 
America comparing VAT and VAP in ICU patients found that VAT was associated with a 
lower mortality than VAP (mortality rate was 29% in VAT compared to 40% in VAP and 
30% in those developing no respiratory infection [32]. The authors also compared the use of 
appropriate antibiotics and found those patients with VAT treated initially with appropriate 
antibiotics were less likely to ‘progress’ to VAP. 
 23 
1.6 Management of hospital acquired infections 
1.6.1 Prevention of hospital acquired infection 
There are many guidelines and interventions to limit and control HAIs (standard barrier 
precautions, hand hygiene, isolation etc.), specific site infections (hospital acquired 
pneumonia, ventilator associated pneumonia, central venous catheter related blood stream 
infection, catheter related urinary tract infection, and surgical site infections), and specific 
pathogens (multidrug resistant organisms, carbapenem resistant Enterobacteriaceae, MRSA 
etc.) developed by agencies such as CDC, WHO and some developed countries (Guidelines 
by CDC available at https://www.cdc.gov/hicpac/pubs.html) [2, 72-78]. Many hospitals in 
developed countries will have integrated some of these into local guidelines, increasingly 
spurred on by financial systems and management interventions that penalise healthcare 
facilities that have high rates of HAI. 
Recognising the potential global health problem of HAIs, WHO  issued guidelines for 
prevention of HAIs in 2002 [2]. In 2009, WHO Guidelines on hand hygiene in health care 
published evidence that good hand hygiene reduced HAIs, although hand hygiene compliance 
was low, ranging from 5% to 89% with a pooled rate of 38.7% [75]. This guideline also 
indicated that the reasons for low hand hygiene compliance included lack of hand hygiene 
guidelines, the opportunities for hand hygiene during patient care, and knowledge about risk 
for transmission of HAI by healthcare worker’s hand. In 2016 WHO has issued an update for 
guidelines on the core components of infection prevention and control (IPC) programmes at 
the national and acute care facility level with the main aim being to supply recommendations 
required to prevent HAIs and combat antimicrobial resistance (AMR) through IPC good 
practice [72]. This guideline includes eight core components which are Infection prevention 
and control (IPC) programmes; IPC guidelines; IPC education and training; Surveillance; 
Multimodal strategies; Monitoring/audit of IPC practices and feedback; Workload, staffing 
and bed occupancy; and Built environment, material and equipment for IPC at the facility 
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level. Of which, the six first components are for both national and acute care facility level and 
two last components are only for acute care facility. Also in 2016, WHO published 
Guidelines for prevention of surgical site infections [74].  
Environmental cleaning has an important role in reducing the reservoir of microorganisms 
causing HAIs. A review by Otter et al found that there was evidence that the contaminated 
hospital surface environment played a role in the pathogenesis of hospital acquired infection 
pathway and that effective cleaning and disinfection of hospital surfaces resulted in a decrease 
in HAIs [79]. CDC also developed guidelines for environment infection control in healthcare 
facilities in 2003 [80]. More recently patient mouth care, selective digestive tract 
decontamination and oral care have also been shown to reduce HAI, although generally in 
high income settings [81]. 
Regarding prevention of VAP, CDC had issued Guidelines for prevention of nosocomial 
pneumonia in 1997 and healthcare-associated pneumonia in 2003 [76, 82]. At present, there 
are many guidelines developed and issued by CDC, available at 
https://www.cdc.gov/hicpac/pubs.html [78]. Recently, the Infectious Diseases Society of 
America and the American Thoracic Society have issued clinical practice guidelines for 
managements of adults with hospital-acquired and ventilator-associated pneumonia [83] 
Many interventions have been postulated to reduce the incidence of VAP: hand-hygiene, 
body position, subglottic suction tubes, and continuous endotracheal cuff pressure control. 
Whilst individual components may be deployed, lowered rates of VAP are particularly seen 
when care bundles consisting of several components are deployed [84]. Many prevention 
bundles comprising multiple interventions targeting a specific HAI have been developed, 
implemented universally and been shown to be effective in decreasing HAIs [85-87]. To 
encourage and improve compliance with such policies, punitive reimbursement has been 
proposed recently in an attempt to reduce the rate of HAI [88]. This policy compels hospitals 
to pay for HAI treatment cost, so the hospitals have to raise awareness and enhance methods 
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to limit HAI including VAP. These measures were mainly implemented in developed 
countries and the HAI prevalence in those countries has shown a decreasing trend [4, 5]. Even 
the organization, management, and structure of hospitals have been evaluated for the 
prevention of HAIs [89]. While in developing countries, the literature about VAP prevention 
remains limited and the capacity to implement such significant control systems is reduced by 
lack of resources, understanding of the problem and political will [10].  
1.6.2 Antibiotics selection guidelines for HAI and VAP/VARI 
HAI treatment varies according to site, severity and the potential pathogens. The HAI 
treatment can often be difficult because the causative bacteria are commonly highly resistant 
to antibiotics. This means the antibiotics chosen for HAI are usually very broad spectrum, 
costly, and may even be more toxic. In settings of high antibiotic resistance the usual choices 
include anti-Pseudomonal beta-lactams or cephalosporins, carbapenems and colistin 
sometimes combined with an anti-staphylococcal agent to which local strains (usually 
MRSA) are susceptible. When empiric treatment for HAI is needed for a critically ill patient it 
may include a combination of two or more broad spectrum antibiotic agents to cover all 
potential pathogens because in these situations delays in effective antibiotics therapy may lead 
to increased mortality parallel with delay time.  
Guidelines for VAP management have been developed by organizations in Europe, the 
United State, Canada, and Asia [77, 83, 90, 91]. The Infectious Diseases Society of America 
and the America Thoracic Society issued guidelines for management HAP & VAP in 2005 
and updated these in 2016. These guidelines recommend that all empiric treatment for 
suspected VAP in patients with high risk for acquiring multidrug resistant bacteria include 
antibiotics agents to cover for MRSA, P. aeruginosa and other gram negative bacilli [38, 83]. 
As discussed above inappropriate initial antibiotics may be associated with worse outcome in 
both VAP and VAT however due to large variations in local resistance patterns there are 
significant limitations on the value of national or even regional guidelines. Unfortunately the 
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use of broad spectrum agents is likely to drive antimicrobial resistance to the point where 
there are no effective antibiotics for common bacteria. Thus it has been proposed that the best 
way to manage these infections is to combine treatment with effective prevention methods 
and antimicrobial stewardship to limit overuse of broad spectrum antibiotics and reduce the 
impact on antimicrobial resistance (AMR) due to selective pressure. A 2013 meta-analysis 
concluded that there was no difference in short versus long courses of antibiotics in terms of 
outcome or relapse rate, although there was a strong trend towards reduced relapse rate with 
long-course antibiotic [92].  More recently shorter courses of antibiotics for VAP treatment 
have been proposed, and are widely adopted particularly in developed countries [93]. 
The value of any VAT treatment had been questioned for a long time. However recent 
evidence is that there is benefit from treatment – reducing the progression to VAP and 
improving outcome. However as some authors maintain that most VAT will not progress to 
VAP and may have no effect on outcome then the use of broad spectrum antibiotics for its 
treatment remains controversial [18, 33, 94, 95] 
1.7 Antimicrobial use in intensive care units 
ICUs are significant utilizers of antibiotics. Antibiotic use can be presented in terms of daily 
defined doses (DDDs) to allow comparison between different antibiotics and across sites. 
Meyer et al reported that antimicrobial consumption in 40 German ICUs from 2001 to 2004 
ranged from 427 to 2798 defined daily doses (DDD)/1000 patient days with median 1351 
DDD/1000 patient days. There was no statistically significant change in total antimicrobial 
use over period from 2001 to 2004 [96]. A report by Hohn et al. showed that antimicrobial 
consumption in a surgical ICU of a 500 - bed hospital in Germany was 1005.0 DDD/1000 
patient days in 2010, decreased to 935.5 in 2011 then to 791.9 DDD/1000 patient days in 
2012 after an intervention using procalcitonin level as a guide for stopping antimicrobial use 
in 2011 [97]. A point prevalence survey by ECDC between 2011 – 2012 in European 
hospitals showed that antimicrobial use was highest in ICUs with 56.5% of ICU patients 
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using antimicrobials on the surveyed day and 37.3% of the total antimicrobial agent use in 
ICUs was for hospital acquired infections [5]. Magill et al. conducted a one day prevalence 
study at 183 hospitals in 10 states of the USA between May and September 2011 and also 
found that prevalence of antimicrobial use was highest in ICU patients (57.7%) compared 
with patients on other wards (48.6%) [98]. Dulhunty et al. reported on antimicrobial use in 37 
ICUs of Australia and New Zealand in May 2007 from a one day point prevalence survey, 
finding that among 422 patients in the ICUs, 195 patients (46%) were using antimicrobials for 
the treatment of infection, 104 patients (25%) for prophylaxis, and 123 patients (29%) used 
no antimicrobials [99]. There were 331 antimicrobial agents used for 225 infections in 193 
patients, so on average one patient received 1.7 antimicrobial agents. The most common 
infections were at respiratory tract (39.5%), abdominal 12.8%, and blood stream 12.3%. 
There are limited data on antimicrobial use in intensive care units in low and middle income 
countries. Sharma et al. conducted a prospective study on antimicrobial consumption in the 
ICU of a tertiary hospital over four months in 2008 in New Delhi, India, found that the total 
antimicrobial consumption was 2320 DDD/1000 patient days [100].  
1.8 Hospital acquired infections in Vietnam 
1.8.1 Introduction the Vietnamese healthcare system 
In 2014, the population of Vietnam was 90,728,900 individuals, with a proportion of males 
49.33%. It is a relative young population with a median age of 29 years, with 31.3% of the 
population below age of 20 years and 10% ≥ 60 years [101]. By comparison the UK 
population in the same year was 64,596,752 with 23.1% aged 60 years and above and 23.6% 
under the age of 20 years [102]. World bank figures show that Vietnam spends 7.1% of gross 
domestic product (GDP) on healthcare (compared with an LMIC average of 4.5% and 9.1% 
in the UK), per capita healthcare spending was 142 USD (compared with an LMIC average of 
90 and 3,935 in the UK) [103]. 
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The government healthcare system includes 48 tertiary hospitals (31,777 beds), 458 
provincial hospitals (115,006 beds), 1,191 district hospitals (77,744 beds), 11,101 communal 
healthcare stations (49,666 beds), and 758 other branches hospitals (6,020 beds). Besides the 
government system, there were 169 private hospitals (11,762 beds). There were 7.8 doctors, 
10.8 nurses, and 25.6 beds per 10,000 population. Health insurance coverage within the 
population was 71% and life expectancy 73.2 years. Bed occupancy rate at central, local, and 
other branches were 119.1%, 112.0%, and 104.3%, respectively [101]. By comparison 
European Union official statistics cite figures of 27.9 physicians per 10,000 population for the 
UK and 22.7 beds per 10,000 population in 2014 [104], with average overnight bed occupied 
rate of 89.4%, ranged from 65.8 to 98.7% in acute and general hospital in the UK in 
December 2014 [105]. 
The Vietnam Ministry of Health categorises hospitals to area served (tertiary, provincial, and 
district hospitals) and technical levels (sequentially from highest to lowest technical level: 
extra, I, II, III and IV). Tertiary or national hospitals are reference hospitals for other tertiary, 
provincial, and district hospitals; provincial hospitals are mainly references for district 
hospitals in the same province; and district hospitals offer healthcare for the population in the 
same districts. The technical level of hospitals are depending on their score according to the 
evaluation system of the Ministry of Health [106]. The number of staff in government 
hospital is regulated by a Circulation of the Ministry of Health and Ministry of Home Affairs 
[107]. According to that document, the total staff in government hospitals depends most on 
the technical level of the hospital and the total number of beds. The maximum ratio of staff 
number per bed is 2.2 for the highest-level hospitals and 1.0 for level IV hospitals. The 
proportion of staff in different roles is distributed as follows: medical 60 – 65%, paramedical 
15 – 22%, and administrative section 18 – 20% of total staff in hospital. There are no specific 
regulations concerning staffing of intensive care units (ICU). 
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The operation of the healthcare system is based mainly on the official catchment area of the 
hospital. Community stations serve mainly for public health programmes and a variety of 
basic healthcare services and they are not categorized as hospitals. The majority of primary 
care occurs in the district level hospitals. There is a significant difference in capability and 
available medical equipment between district hospitals and provincial hospitals, and also 
between provincial and tertiary hospitals. The Ministry of Health reported that equipment at 
district and provincial hospitals was commonly inadequate, that district hospitals were 
supplied only 30 – 50% of total equipment needed, and were not able to implement 27.9% of 
total healthcare services which were designated [108]. Similarly, provincial level hospitals 
were not able to do 3.2% - 24.1% of total healthcare service procedures that they were 
designated to. If patients require more care than what can be delivered by the district level 
hospital to which they are admitted, they will be transferred to the provincial level hospital or 
to tertiary (national) hospitals, these hospitals are usually level I or higher. Given the under 
provision of resources in the district and provincial level hospitals, this may lead to an 
overload of the tertiary hospitals, while provincial and district hospitals operate below 
capacity. However, health statistics for 2014 showed that bed occupancy rate was more than 
110% in both provincial level hospitals (112.0%)  and tertiary level hospitals (119.1%) [101]. 
A study into the needs for influenza pandemic preparedness showed that there was a shortage 
of ventilators in all provincial and city hospitals in every province of Vietnam, with most 
provinces lacking more than 3 ventilators per 100,000 population [109]. These data indicate 
that the need for healthcare of the population is much more than the capacity of the health 
care system. This lack of resources may mean that there is reduced time to clean equipment 
between patients and those requiring facilities such as mechanical ventilation may receive it 
later, or for shorter durations than may otherwise be preferable. Staff have to care for 
increased numbers of patients, with fewer nurses or doctors for each patient. These factors 
mean that particularly in resource intense environments such as ICU, there could be increased 
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adverse events in hospitals including HAIs or that the impact of these may be more serious 
compared to better resourced settings 
1.8.2 Hospital acquired infections in Vietnam 
Data concerning HAIs are very limited in Vietnam as there is no national surveillance system 
for HAI in general or VARI/VAP in particular. Among the few HAI studies reported from 
Vietnam, most were done in surgical departments and focused on surgical site infections [10]. 
A large study of HAI performed in 2008 in 36 hospitals (in 14 provinces including two 
teaching, 18 provincial, and 16 district hospitals) with a total sample size of 7571 patients 
(354 ICU patients, accounting for 4.7%) showed an overall HAI prevalence of 7.8% with 
HAI incidence density of 8.3 episodes per 1000 patient-days [110]. This study found that the 
most common HAIs were pneumonia and surgical site infection, accounting for 41.9% and 
27.5% of total HAIs respectively and the highest prevalence of HAI was in ICU with 23.7% 
(84/354) of ICU patients suffering from HAI at the time of the survey. Pham Duc Muc et al. 
carried out a point prevalence study on HAI at 19 hospitals (4 tertiary and 15 provincial) in 
2005, showing that 5.7% (535/9345) patients had at least one HAI and the prevalence of HAI 
was 6.0% (559/9345) [111]. Another point prevalence survey at Bach Mai Hospital (a large 
tertiary referral centre in Northern Vietnam) in October 2006 showed that 5.7% (77/1354) 
patients had HAI at the time of the survey and the prevalence of HAI was 5.9% (80 
HAIs/1354 patients), the most common HAIs were respiratory tract infections accounting for 
75% (60/80) of HAIs, urinary tract infection 10% (8/80), and digestive tract infection 5% 
(4/80) [112]. The highest prevalence of HAI was 31.3% (15/46) in ICU and most frequent 
cause of HAI were Pseudomonas aeruginosa 28.6% (6/21), Acinetobacter baumannii 23.8% 
(5/21), Klebsiella pneumoniae 19.0% (4/21), and candida 14.3% (3/21). In a specialist tetanus 
ICU in Southern Vietnam, a randomized controlled trial compared incidence of hospital-
acquired pneumonia in supine and semirecumbent positions and reported incidence of HAP 
of 20.8% and 25% in each arm respectively [113]. Some other studies on HAI in Vietnamese 
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ICUs have shown that the point prevalence of HAI in ICUs ranged from 19.3% to 31.3% 
[110, 112, 114-117].  
1.8.3 Ventilator-associated pneumonia in Vietnam 
Truong Anh Thu and colleagues reported a pooled incidence density of VAP of 34.7 episodes 
per 1000 ventilation days at three departments with ventilated beds (ICU, Emergency 
department, and the toxicology center) in Bach Mai Hospital in the period 2002 to 2003, 
incidence density was the highest in the ICU (61.3 episodes per 1000 ventilation days)  [116]. 
This study also reported that the most common microbial isolates associated with HAI in ICU 
were A. baumannii 28.1% (34/121), P. aeruginosa 25.6% (31/121), Candida spp 14% 
(17/121), K. pneumoniae 10.7% (13/121), and Escherichia coli 7.4% (9/121).  
In an earlier observational prospective study on 92 patients ventilated for over 48 hours in the 
intensive care unit in National Hospital for Tropical Diseases (a tertiary referral hospital for 
infectious diseases) in 2012, VAP prevalence was 17.4% and an incidence density of VAP 
was 11.7 episodes per 1000 ventilation days [118]. A retrospective study on all patients 
admitted to Intensive Care Unit in Bach Mai Hospital from September 2008 to April 2009 for 
more than 48 hours found that 90/477 (18.9%) patients developed VAP during their stay, with 
a VAP incidence density of 27.4 episodes per 1000 ventilation days [119]. This study also 
showed that the most common isolates from hospital-acquired pneumonia were A. baumannii 
44.7% (59/132), Candida spp. 19.7% (26/132), P. aeruginosa 17.4% (23/132), and K. 
pneumoniae 5.3% (7/132). The carbapenem resistance rate was considerable, with resistance 
in 90.7% (49/54) of A. baumannii and 68.4% (13/19) of P. aeruginosa, and one isolate of A. 
baumannii resistant to colistin with minimum inhibitor concentration (MIC) > 4 mg/L. A 
large multisite surveillance study on hospital-acquired infections (HAI) in intensive care units 
of 14 tertiary and provincial hospitals across Vietnam in 2013, performed as part of this PhD, 
has shown that the pooled prevalence of HAI was 29.5%, of which hospital-acquired 
pneumonia accounted for ~ 80% (chapter 3 [120]). In this study, the most common isolates 
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from HAI were A. baumannii 24.4% (177/726), P aeruginosa 13.8% (100/726), and K 
pneumoniae 11.6% (84/726) with carbapenem resistance rate of 89.2%, 55.7%, and 14.9%, 
respectively. 
Recently, Tran Huu Thong and colleagues reported a randomized control trial of 153 patients 
(76 in control group and 77 in interventional group) to evaluate the impact of continuously 
subglottic suction on VAP (using CPIS and microorganism criteria for VAP diagnosis) at 
Bach Mai hospital from 2009 to 2013 and showed that the incidence of VAP was 56.6% in 
conventional group and 39.0% in the interventional group (continuously subglottic suction) 
[121]. This study showed that the most common bacteria associated with VAP were A. 
baumannii 49.3% (36/73), K. pneumoniae 15.1% (11/73), and P. aeruginosa 11% (8/73) with 
carbapenem resistance rates of 75%, 15%, and 10%, respectively.  
The high level of carbapenem resistance among bacteria commonly associated with VAP and 
HAI in Vietnamese ICUs necessitates the use colistin, an antibiotic of last resort, with 
questions surrounding its dosing, efficacy, and toxicity. A study on population 
pharmacokinetics of colistimethate and formed colistin in adult critical ill patients at four 
institutions in three countries (USA, Thailand, and Greece) found that only 65% to 75% of 
patients with creatinine clearance ≥ 80 ml/min achieved target average plasma concentration 
with intravenous colistin dosage recommended by the US Food and Drug Administration and 
European Medicines Agency [122]. Trifi et al. found that a high dose of colistin (a loading 
dose of 9 MIU then a maintenance dose of 4.5 MIU every 12 hours) was associated with 
better activity without nephrotoxicity [123]. Dewan et al. also found that high dose of colistin 
in critical ill patients was not associated with significant risk of nephrotoxicity [124]. 
Whereas, other studies have shown that nephrotoxicity was associated with a higher dose of 
colistin [125-127]. 
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1.9 Summary and purpose of the thesis  
HAI and particularly VAP are important problems throughout the world. Data suggest that 
they may be even more important in developing countries but there are sparse and poor 
quality data regarding them in these settings. This data however is vital for targeting resources 
appropriately to reduce the burden of these infections and to combat the threat of 
antimicrobial resistance. 
Currently there are some data suggesting that the burden of HAI and VAP is relatively high in 
intensive care units in Vietnam. Therefore, this thesis is intended to address this issue, 
providing high quality data to inform future policy in Vietnam.  
 The objectives of this thesis are: 
1. Assess the prevalence of hospital acquired infections at ICUs of 14 hospitals across 
Vietnam. 
2. Quantify and describe antibiotic use in the ICUs of 14 hospitals across Vietnam. 
3. Assess the etiology, resistance pattern, associated antibiotic use and outcome of 
ventilator associated pneumonia (VAP) in three hospitals in Vietnam. 
To this end I, with the help of a team of research & clinical staff, carried out a point 
prevalence survey of HAI and antibiotic use in the ICUs of 14 tertiary and provincial 
hospitals across Vietnam and conducted an observational study to assess systemically the 
epidemiology, bacterial etiology, antibiotic use, and clinical outcome of VAP at three referral 
hospitals in Hanoi and Ho Chi Minh City, Vietnam. Such data is urgently needed to inform 
optimal management, prevention, antimicrobial stewardship and infection control to reduce 
HAI, particularly VAP in ICUs in Vietnam and potentially other low resource settings. 
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Chapter 2 
Material and Methods 
This chapter described the study setting, design aims, data collection, and data analysis for 
two studies in the thesis with the results were presented in next four chapter. 
2.1 Methods for chapter three and four 
2.1.1 Study aims, design and settings 
We conducted a repeated point prevalence survey (PPS) to determine the prevalence of HAIs 
and to assess antimicrobial use and antimicrobial resistance using the methodology developed 
by the European Center for Disease Prevention and Control (ECDC) [14]. The study was 
conducted on one day each month from October 2012 through September 2013 on 15 adult 
ICUs of 14 hospitals at provincial level (n = 8) or higher (n = 6), throughout Vietnam. These 
hospitals represent the main teaching hospitals in different parts throughout Vietnam (Figure 
2 - 1). In the study, names of hospitals were coded with different numbers with ordinal 
number on the map (Figure 2 – 1).  
ICUs were chosen as the initial focus because this is an area where bacteria associated with 
hospital acquired infection were seen to be resistant to most available antibiotics, and ICU 
doctors are familiar with the problems HAI present and the definitions used to categorise the 
infections.  
Training for the project was organised centrally (in Hanoi and Ho Chi Minh City): four 
workshops covered training in the protocol and data collection, and use of the survey software 
to input and export data for electronic transmission to the project statistician. The study team 
visited each participating ICU to inventory capacity and help local study doctors to implement 
the protocol and use HAI definitions correctly.  
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The survey doctors were assigned at each site, usually a member of staff at the ICU, to 
received training on ECDC definitions of HAI and the study protocol. 
The software for data management was developed from the ECDC developed software 
HelicsWin.Net version 1.3 [128]. 
Additional laboratory training and microbiology capacity development was conducted to 
ensure that identification and susceptibility testing of bacteria was performed to a sufficiently 
high and uniform standard. Laboratories were given Vietnamese translated versions of the 
Clinical and Laboratory Standards Institute guidelines (CLSI) for antimicrobial 
susceptibility testing and were enrolled in an external quality assurance program for 
identification and drug susceptibility testing (The United Kingdom National External 
Quality Assessment Service (UK NEQAS) for Microbiology) [129]. Training included 
central workshops and visits to the site laboratories at the start and during the project. 
Each ICU received a laptop with the required software installed and Vietnamese instructions. 
Every month, after the survey was completed, data were entered into the database software 
and sent to the study statistician and coordinator. These data were then checked for missing 
and outlying values for feedback to the site study doctors for further checks. The final data 
were extracted to a SPSS database for final analysis. 
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Figure 2 – 1. Location of the participating hospitals 
2.1.2 Hospital and ICU resources  
The surveyed hospitals included three specialty hospitals, one for surgery (H05, tertiary) and 
two for infectious diseases (H01 - tertiary and H15 - province). H02, H10, H13 and H16 are 
large tertiary general hospital in the North (H02), Middle (H10), and the South (H13 and 
H16), respectively. The other hospitals are provincial level general hospitals. Basic 
information on study settings was presented in Table 2 – 1. 
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Table 2 - 1. Basic information on study sites 
Participating Hospitals Participating ICU 
Hospital 
code 
Hospital name Location Type of hospital Size 
(beds) 
Specialty Size 
(beds) 
H01 National Hospital for 
Tropical Diseases 
Hanoi City Tertiary – Infection 
specialty 
280 Infection 18 
H02 Bach Mai Hospital Hanoi City Tertiary - General 1900 General 38 
H04 Saint Paul Hospital Hanoi City Provincial – General 800 Medical   20 
Surgical 17 
H05 Viet Duc Hospital Hanoi City Tertiary - Surgical 
specialty 
1050 Surgical 16 
H06 Viet Tiep Hospital Hai Phong City Provincial – General 900 Medical 16 
H07 Vietnam Sweden 
Uong Bi Hospital 
Quang Ninh Provincial – General 750 General 10 
H08 Binh Dinh General 
Hospital 
Binh Dinh Provincial – General 1050 Medical 20 
H09 Da Nang General 
Hospital 
Da Nang City Provincial – General 1500 General 47 
H10 Hue Central General 
Hospital 
Hue City Tertiary – General 2300 Medical 60 
H11 Khanh Hoa 
Provincial Hospital 
Khanh Hoa Provincial – General 1000 Medical 34 
H12 Dak Lak Provincial 
Hospital 
Dak Lak Provincial – General 750 General 20 
H13 Cho Ray Hospital Ho Chi Minh 
City 
Tertiary – General 1800 General 31 
H15 Hospital for Tropical 
Diseases 
Ho Chi Minh 
City 
Provincial - 
Infection specialty  
550 Infection 23 
H16 Can Tho Central 
General Hospital 
Can Tho City Tertiary – General 800 General 30 
 
2.1.3 Data collection  
Data collection comprised two areas: baseline data and point prevalence survey (PPS) data.  
2.1.3.1 Study settings baseline data 
Baseline data were collected form all sites at the beginning of the study. All participating 
hospitals provided data on basic infrastructure and infection control indicators at the 
beginning of the study. Baseline data included total number of beds, rooms, single bed rooms, 
number of doctors and nurses at the ICUs, admissions per year, patient days per year, alcohol 
hand rub consumption, and availability of alcohol hand rub at ICU bed. These data were 
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collected by the survey doctors from the respective general planning departments and 
infection control departments.  
2.1.3.2 Patient Data 
Patient data were collected monthly through point prevalence survey from each ICU. These 
data were collected by the survey doctors in discussion with the treating team and review of 
relevant clinical diagnostics results (radiology/microbiology).  
Patient selection 
Patients aged ³ 18 years, admitted to participating ICUs before 8 a.m. on the survey day, and 
remaining there during at the survey time were included.  
Patient data collection 
The following data were collected: origin of patient before admission to ICU (e.g. 
community, other ward in the same hospital, inter-hospital transfer), primary reason for ICU 
admission, relevant comorbidities, currently deployed interventions (eg intubation, central 
venous catheter), presence of active HAI, results of routine microbiological investigations, 
antimicrobial agent use, and involvement of patient’s family in patient care. All data were 
collected as in case record form (CRF), presented in section B – 1 Appendix B, according to 
definitions in the ECDC PPS protocol [14], with the exception of origin of patient before 
admission to ICU, primary reason for ICU admission, involvement of patient’s family in 
patient care. These are specified below. 
Origin of patient before admission to ICU, was recorded as (1) other hospital, if the patient 
was treated in another hospital and then transferred to the current ICU; (2) community, if the 
patient entered the hospital as an emergency case (either directly to ICU or via the emergency 
department or other department if less than 24 hours from hospital admission), searched 
intensive care themselves or were transferred from an outpatient clinic; (3) operation 
room/recovery, if the patient had had surgery and was transferred directly from the operation 
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or recovery room; or (4) intra-hospital, if the patient was transferred from another department 
(including emergency department) within the same hospital to the ICU in ≥ 24 hours from 
hospital admission. 
The primary reason for ICU admission was recorded as (1) elective surgery, if the patient has 
gone through an elective surgical procedure, e.g gastric-cancer surgery, and then been 
admitted to the ICU; (2) emergency surgery, if the patient has gone through or is awaiting 
acute surgical intervention, e.g appendicitis, bowel perforation, acute limb ischaemia; (3) 
trauma, if the patient was admitted after a trauma regardless of whether surgery was indicated, 
e.g. traffic accident, fall, physical violence etc. If a patient was admitted after trauma and 
emergency surgery was required, the trauma option was selected; (4) communicable diseases, 
all infectious diseases caused by microorganisms including bacteria, viruses, fungi and 
parasites; or (5) non-communicable disease, all other medical, non-infectious diseases. 
The following comorbidities were recorded: insulin-dependent diabetes mellitus, COPD on 
medication, active malignancy (this does not include benign or previously cured cancers), 
renal failure (creatinine level > 300 µmol/L prior to admission), active HBV/HCV with 
elevated transaminases, stroke, alcohol abuse as determined by doctor (ideally treating doctor 
but if not available doctor completing PPS), tetanus, induced immunosuppression, and HIV 
infection. 
Antibiotics use was measured by day of therapy (DOT) which was defined as the sum of all 
days on each antibiotic agent the patient used calculated for 100 patient days (e.g. if a patient 
used two antibiotics drugs per day for 2 days, the total antibiotics days were 4 DOT/2 patient 
days, this  equal to 200 DOT/100 patient days) [130]. Both DOT/100 patient days and defined 
daily dose (DDD)/100 patient days are used to measured antibiotics consumption, although 
they are not the same. DOT is real antibiotic dose patient used which could be different from 
patient to patient due to differences in renal or liver function and patient’s weight. Whereas, 
 40 
DDD is calculated for each drug by converting from the amount of antibiotic patients used to 
the DDD which have been already established and not changed for each drug by WHO [131]. 
Microbiological results relevant to the current HAI taken on or before the survey day were 
collected. The results of these tests must be available within two weeks of the survey. Specify 
up to three isolated microorganisms for each HAI. 
Microbiology quality assurance 
All laboratories of 14 hospitals were assessed on how they complied with the CLSI 
guidelines of susceptibility testing to ensure they use updated CLSI guidelines. The 
participating laboratories were supplied a high quality Vietnamese translation of the most 
recent CLSI guideline and we ensured that subsequent updates were translated in the future 
and distributed. The assessment included analyses of distribution of zone diameters in 
relation to breakpoints used in order to detect erroneous results. Assessment also included 
an analysis of susceptibility data they provide the clinicians and check these for 
appropriateness and inconsistencies. During the study period, the laboratories were 
enrolled in an External Quality Assurance (EQA) program organized by the United 
Kingdom (NEQAS) to monitor their progress. This EQA programme provided them 
bacterial isolates 12 times per year they need to identify according to standard methods at 
each laboratory and to perform susceptibility testing and report back to NEQAS. If sites 
failed to identify EQA isolates or susceptibility they were visited by our support team on 
microbiology for further training. Unfortunately it was not possible to save isolates for 
repeat culture and susceptibility testing as a further quality assurance measure. 
2.1.4 Statistical analysis 
For descriptive statistics, percentage, frequency, mean, and median values and 95% 
confidence interval (95% CI) or interquartile ranges (IQR) were calculated as appropriate. 
The odds ratios of risk factors for developing HAIs in ICU were calculated using data from 
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the first PPS enrolment of patients who had no HAI on ICU admission. After univariate 
analysis, all HAI risk factors were used in the multivariate logistic regression models and 
adjusted for the hospital sites. IBM SPSS Statistics software (version 22 IBM, California, 
USA) was used for data analysis. P-values < 0.05 (two-sided) were considered statistically 
significant. 
2.1.5 Ethics   
The Ethical Committee of the National Hospital of Tropical Diseases (27/HDDD-NHTD) 
approved the study protocol and waiving of informed consent as the data were anonymous 
and collected for surveillance purposes and no intervention was conducted. The study was 
also approved by the Vietnamese Ministry of Health (4921/QD-BYT).  
2.2 Methods for chapter five and six 
2.2.1 Study Design, aims and settings 
A prospective, observational study of the clinical epidemiology and etiology of ventilator 
associated respiratory infections was performed from November 2013 to May 2015 on the 
intensive care unit of the National Hospital for Tropical Diseases (NHTD), Hanoi, from July 
2014 to May 2015 on the ICU of Bach Mai Hospital (BMH), Hanoi, and from October 2014 
to November 2015 on the ICU of Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, 
Vietnam.  
The aims of the study were to assess the etiology, resistance, antibiotics use and outcome of 
ventilator associated pneumonia (VAP) in three hospitals in Vietnam 
NHTD is a national tertiary hospital, specialised in infectious diseases in Hanoi. BMH is a 
large tertiary general hospital in Hanoi. HTD has the official status of a provincial hospital, 
specialised in infectious diseases, but it serves as a tertiary referral hospital for infectious 
diseases for the Southern provinces of Vietnam. NHTD and HTD only admit patients with 
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infectious disease diagnoses, whereas BMH admits patients with all diagnoses. Basic 
information of these hospitals and their participating ICUs were presented in Table 2 – 1 with 
NHTD, BMH, and HTD were coded H01, H02, and H15, respectively. 
2.2.2 Inclusion procedure 
All patients admitted to the ICUs of participating hospitals were recruited if they met the 
following inclusion criteria: aged ≥ 18 years for NHTD and BMH, and age ≥ 16 years for 
HTD, admitted to participating ICU within the previous 48 hours, intubated or on 
tracheostomy with clear date of intubation and no suspicion or diagnosis of VAP at the time 
of enrolment. Eligible patients were approached for written inform consent form. Only 
patients having written inform consent form were enrolled to the study. 
All patients received standard of care according to local hospital practice. Once consent was 
obtained, patients were given a study number. Deidentified numbers were used on all labels, 
case record forms and the database in order to protect the patient’s identity.  
Data were collected in a standardized case record form (CRF, section B - 2 in Appendix B) 
including general demographics, comorbidities, reason for current admission, prior antibiotic 
use and laboratory and clinical data to establish severity scores (APACHE II in Table 2 – 2 
and SOFA in Table 2 – 3).  
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Table 2 – 2. Acute Physiology and Chronic Health Evaluation (APACHE II) [132] 
Parts  APACHE II SCORING SYSTEM 
A
: a
cu
te
 p
hy
si
ol
og
ic
al
 sc
or
e 
Variable +4 +3 +2 +1 0 +1 +2 +3 +4 
Temperature ³ 41 39-40.9  38.5-
38.9 
36-38.4 34-
35.9 
32-33.9 30-31.9 £ 29.9 
Mean Arterial BP ³ 160 130-159 110-129  70-109  50-69  £ 49 
Heart Rate ³ 180 140-179 110-139  70-109  55-69 40-54 £ 39 
Respiratory Rate ³ 50 35-49  25-34 12-24 10-11 6-9  £ 5 
A-aPO2 (If FiO2> 50%) 
PaO2 (If FiO2 < 50%) 
³ 500 350-499 200-349  < 200 
> 70 
 
61-70 
  
55-60 
 
< 55 
Arterial pH 
1Serum HCO3- 
³ 7.7 
³ 52 
7.6-7.69 
41-51.9 
 7.5-7.59 
32-40.9 
7.33-7.49 
23-31.9 
 7.25-7.32 
18-21.9 
7.15-7.24 
15-17.9 
< 7.15 
< 15 
Serum Na+ ³ 180 160-179 155-159 150-154 130-149  120-129 111-119 £ 110 
Serum K+ ³ 7 6-6.9  5.5-5.9 3.5-5.4 3-3.4 2.5-2.9  < 2.5 
Serum Creatinine ³ 3.5 2-3.4 1.5-1.9  0.6-1.4  < 0.6   
Hematocrit ³ 60  50-59.9 46-49.9 30-45.9  20-29.9  < 20 
WBC Count ³ 40  20-39.9 15-19.9 3-14.9  1-2.9  < 1 
Score = 15 – Actual Glasgow Coma Score (GCS) =        
B: Age adjustment  < 44 = 0 point, 45 – 54 = 2, 55 – 64 = 3, 65 – 74 = 5, > 75 = 6 points 
C: Chronic health 
adjustment 
History of any: Biopsy proven cirrhosis, New York Heart Association Class IV, Severe 
COPD (e.g., hypercapnia, home O2, pulmonary hypertension), Chronic dialysis, Immune 
compromised; then add 2 points for non-surgery or elective surgery and 5 points for 
emergency surgery. 
Total APACHE II = A (   ) + B (     ) + C (      ) =   
1Use only if no artery blood gas test available 
Table 2 – 3. The Sequential Organ Failure Assessment (SOFA) Score [133] 
 SOFA Score 
Variables 0 1 2 3 4 
Respiratory: 
PaO2/FiO2 mmHg 
> 400 ≤ 400 ≤ 300 ≤ 200* ≤ 100* 
Coagulation:  
Platelets x 103/µL  > 150 ≤ 150 ≤ 100 ≤ 50 ≤ 20 
Liver: Bilirubin, µmol/L < 20 20 - 32 33 - 100 101 - 203 > 203 
Cardiovascular: 
Hypotension 
 
No 
hypotension 
Mean artery 
pressure < 70 
mmHg 
Dop ≤ 5 or 
dob any 
dose# 
Dop > 5, epi ≤ 
0.1, norepi ≤ 
0.1# 
Dop >15, epi 
> 0.1, norepi 
> 0.1# 
Central nervous system: 
Glasgow coma score scale 15 13 - 14 10 - 12 6 - 9 < 6 
Renal: Creatinine, µmol/L < 106 106 - 168 169 - 300 301 - 433 > 434 
Norepi: norepinephrine; Dob: dobutamine; Dop: dopamine; Epi: epinephrine 
* Values are with respiratory support 
# Adrenergic agents administered for at least 1 hour (dose given in µg/kg per minute) 
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2.2.3 Ongoing Assessments 
Enrolled patients were followed up until 28 days after enrolment or until 28 days after a 
diagnosis of VAP. A daily record was made by study staff, supervised by myself (NHTD 
ICU) or local study investigators (Bach Mai ICU & HTD ICU), or study investigators 
themselves on the CRF. The data collected daily included: intubation & ventilation status, use 
of paralytic agents or sedation, minimum and maximum temperature over the 24 hours, 
minimum positive end expiratory pressure (PEEP) and fractional inspired oxygen (FiO2) over 
the 24 hours, changes in sputum production and any results of blood white cell counts and 
sputum microscopy (see microbiology below). Use of antibiotics and antifungals was 
recorded, as was the rationale (indication) for the use of any new agents.  
Where patients met criteria for VAP investigation (ventilator associated condition [23], i.e. 
patients had respiratory stability or improvement on ventilator by stable or decreasing daily 
minimum of FiO2 or PEEP for ≥ two calendar days then had indicators of worsening 
oxygenation by increase in daily minimum FiO2 ≥ 0.15 or PEEP value ≥ 2.5 cmH2O for ≥ two 
calendar days), the following data were recorded: presence of systemic signs or pulmonary 
secretion, commencement of antibiotics or taking of chest x-ray as per the below. The 
evaluation included taking of a tracheal aspirate for Gram staining, culture and susceptibility 
testing; taking of blood culture; and taking blood for assessment of clinical and laboratory 
parameters necessary for the recalculation of the SOFA score [133].  
2.2.4 Endpoints 
The primary endpoint was the incidence of VAP using VAP criteria as published by the US 
Centers for Disease Prevention and Control (Atlanta, GA [USA]) 2008 and 2013 [13, 23] 
within 28 days of enrollment. The criteria for an endpoint diagnosis of VAP were: 1) 
deterioration in ventilation following a period of stability: ≥ 2 days of stable or decreasing 
daily minimum PEEP followed by a rise in daily minimum PEEP of ≥ 2.5 cm H2O, sustained 
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for ≥ 2 calendar days OR ≥ 2 days of stable or decreasing daily minimum FiO2 followed by a 
rise in daily minimum FiO2 of ≥ 0.15 points, sustained for ≥ 2 calendar days) AND 2) 
systemic signs: fever of > 38 °C or <36°C OR WBC > 12 x 109/L or < 4 x 109/L) AND 3) 
radiological signs of pneumonia or clinician commencement of therapy: consolidation, or 
cavitation on chest radiography OR clinician starts antibiotics for lower respiratory tract 
infection within a window period of 2 days before the deterioration in ventilation to 2 days 
after AND 4) pulmonary secretions: increased/new purulent tracheobronchial secretions OR ≥ 
25 neutrophils per low power field (100 objective) on Gram stain of endotracheal aspirate. 
Additionally, the incidence of VARI (ventilator-associated respiratory infections) was 
assessed, which included VAP and patients with the following criteria: 1) clinical increased 
sputum or purulent sputum by microscope examination (≥ 25 neutrophils per low power 
(x100) field on Gram stain of endotracheal tube aspirate) AND 2) fever of > 38 °C or <36°C 
OR WBC > 12 x 109/L or < 4 x 109/L AND 3) clinician starts antibiotics within 2 days after 
symptom developed.  
VARI thus includes VAP, ventilator associated tracheobronchitis (VAT) and pneumonia (as 
evidenced by chest X-ray), not meeting the study VAP criteria (last two named ‘other 
VARI’).  
Other secondary endpoints included: 1) 28-day mortality (after enrolment, or in the case of 
VAP patients at 28 days after diagnosis of VAP); 2) length of ICU and hospital stay; 3) 
duration on mechanical ventilation; 4) VAP incidence in patients with and without 
tracheostomy; 5) appropriateness of VAP empiric antibiotic treatment defined as 
microorganisms isolated from lower respiratory tract sample susceptible to at least one of 
antibiotics used in empiric therapy; 6) antibiotic use measured by day of therapy (DOT), 
which was defined as the sum of all days on each antibiotic agent used together for 100 
patient days; 7) ICU cost was calculated based on total hospital fee for whole ICU stay period 
(including all expenditure for medicine, healthcare service, single use medical equipment, 
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ICU bed day fee, these were included in hospital bill that was collected by research team for 
each participant), which did not include patient meals, expenditure for family member who 
stayed with patient or society expenditure; and 8) the microbiological etiology of VAP as 
determined by culture of endotracheal aspirates.  
2.2.5 Microbiology evaluation 
Microbiological analysis was performed by the respective hospital microbiology laboratories, 
as per standard procedures. All hospitals were participating in an external quality assurance 
programme at the time (UK NEQAS, UK). 
Briefly, in patients investigated for VAP, 5-10 mls of blood in a single bottle of aerobic 
culture media (Bactec, Bekton Dickinson, USA) was collected and cultured for 5 days in an 
automated system. Positive samples were subcultured onto blood, chocolate and MacConkey 
media and reincubated. Endotracheal aspirates were first Gram stained to determine the 
number of polymorphonuclear leucocytes and epithelial cells per low power field. Results of 
Gram stain and microscopy were recorded as ≥ 25 or <25 polymorphonuclear cells per low 
powered field and > 10 or ≤ 10 epithelial cells per low powered field as appropriate. All 
samples were inoculated onto blood, chocolate and MacConkey agar for semi-quantitative 
culture. All resultant growth was reported. Identification of isolates from blood and ETA 
culture was done using routine microbiological methods including API and VITEK 
(bioMérieux, France). Antibiotic susceptibility was determined by disk diffusion or E-test 
according to CLSI guidelines and breakpoints [134].  
For the purposes of analysis, when a diagnosis of VAP or other VARI was established, any 
cultured bacteria was treated as a pathogen if cultured at a concentration of 105 cfu/ml or 
above in ETA specimens [35]. In semiquantitative culture, bacterium with growth at level 
+++ or more was treated as pathogen. 
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2.2.6 Sample size 
Based on a review of the available literature, the incidence of VAP among mechanically 
ventilated patients was estimated to be approximately 30%. A sample size of 600 patients 
enrolled was chosen as at this number an incidence of 30% with a 95% confidence interval of 
3.7% could be detected. 
2.2.7 Data management  
All clinical information was recorded or placed in the patient’s notes, in keeping with local 
practice. Relevant data were recorded onto a case record form (CRF) and checked for 
accuracy before single data entry onto an electronic database (CliRes, OUCRU, Vietnam). 
Internal checks of the entered data were performed to look for outliers and errors. Patients 
who spent less than 3 days on ventilators since enrolment or were treated with ECMO in the 
study period were excluded in the final analysis as the diagnostic definitions could not be 
applied to these two groups. 
For the descriptive analyses of the endpoints proportions were used for categorical data and 
mean (standard deviation (SD), 95% confidence intervals (CI)) and/or median (inter quartile 
and full ranges) for continuous data supplemented by graphical displays where relevant. 
Comparative analysis was performed using Chi Square or Fisher’s exact test for categorical 
data. For continuous data, the student’s T test, Mann Whitney U test, and Wilcoxon rank sum 
test were used for normally distributed, skewed and paired data, respectively. Logistic 
regression was used to analysis risk factors. Two-sided P values <0.05 are considered 
significant. There has been no statistical adjustment for multiplicity testing, the implications 
of which are discussed where relevant. 
2.2.8 Ethics   
The conduct of this clinical study was consistent with the principles of the Declaration of 
Helsinki [135]. The study was approved by the Institutional Review Board of the National 
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Hospital for Tropical Diseases (reference 37/HDDD-NHTD) and Bach Mai Hospital in 
Hanoi, the Hospital for Tropical Diseases in Ho Chi Minh City and the Oxford University 
Tropical Research Ethics Committee (OxTREC, reference 153-12). Written informed consent 
was obtained from all patients or their legal representatives. 
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Chapter 3 
Hospital Acquired Infections in Vietnamese Adult Intensive Care Units 
3.1 Introduction 
HAIs and AMR are growing public health problems of global importance [1, 136]. The 
prevalence of HAIs is substantially higher in LMICs than in high income countries, with an 
average prevalence of 15.5%, compared to a prevalence of 7.1% and 4.5% in Europe and 
USA, respectively [10]. HAIs are most common in ICUs, and it is here that they are often the 
result of infection with highly resistant bacteria requiring the use of extremely broad 
spectrum, expensive antibiotics. The HAI prevalence in ICUs ranges from 9.1% in the United 
States to around 23.0% in Europe and England [5, 7, 137-139], and even higher in LMICs 
with a pooled prevalence of 35.2% [1]. A recent report of the International Nosocomial 
Infection Control Consortium 2007-2012 from 503 ICUs shows that ventilator-associated 
pneumonia (VAP) is fifteen times and catheter-associated urinary tract infection four times 
higher in LMICs than in better resourced settings [45]. The ICU capacity in many LMICs has 
increased dramatically, in line with the rapid economic development in these countries. 
However there are often high occupancy rates, overcrowding, few isolation rooms, and 
inadequate resources for infection control all of which may contribute to the reported high 
incidence of HAIs and drug-resistant infections at ICU’s in these settings [1, 140, 141].  
Vietnam is one such LMIC that has had rapid economic growth and expansion of critical care 
services. Vietnam has a population of 91 million [142] and an increasingly sophisticated 
health care system, typical of countries in the region. Health expenditure per capita in 
Vietnam was around 100$ per annum in 2012, approximately a seventh of the regional 
average [142]. Prior to this study, there was no national surveillance system for HAIs in 
Vietnam and limited data about HAIs in ICUs. The few studies performed are small and only 
some included ICUs, but reported that the HAI prevalence in those ICUs ranged from 19.3% 
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to 31.3% [110, 112, 114-117]. Only one of these studies is from the international peer 
reviewed literature [110], the others are published in the Vietnamese medical literature [112, 
114-117].  
In order to provide up-to-date, systematic data and to demonstrate the feasibility of 
developing a national surveillance network for ICUs in a LMIC, we performed a prospective 
study on the prevalence and associated risk factors of HAI in ICUs across Vietnam [129]. 
3.2 Materials and Methods  
Study design, hospital and patient selection  
We conducted a repeated point prevalence survey (PPS) to determine the prevalence of HAIs, 
and to assess antimicrobial use and antimicrobial resistance using the methodology developed 
by the European Center for Disease Prevention and Control (ECDC) [14]. The survey was 
conducted on one day each month from October 2012 through September 2013 in 15 adult 
ICUs in 14 acute care hospitals, of which 6 were tertiary hospitals and 8 provincial hospitals, 
throughout Vietnam. Patients aged ³ 18 years, admitted to participating ICUs before 8 a.m. 
on the survey day, and remaining there at the survey time were included regardless after that 
time patient was discharged or remain in that ICU. Data on outcome after the survey were not 
collected. More details of the methods are provided in chapter 2. 
3.3 Results  
3.3.1 Baseline data of participating hospitals 
Hospital sizes ranged from 280 to 2362 beds (median 950; IQR 750-1650) and the 
participating ICU sizes ranged from 10 to 60 beds (median 20; IQR 18-31). Mean length of 
ICU stays per individual ICU ranged from 3.8 to 16.0 days with a median mean length of stay 
across the ICUs of 6.4 days (IQR: 4.8-9.3). At the time of the study there were no national 
antimicrobial therapy guidelines, but locally derived guidelines were used at 7 of 15 ICUs. In 
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each ICU one nurse took care of 1.9 to 5.9 beds (median 3.6, IQR: 3.1 - 4.4 beds) per 8-hour 
shift. During working hours, there was a median of 3.5 doctors (IQR: 2.5 - 4.8) for 10 ICU 
beds. Alcohol hand rub was available at the bedside in all participating ICUs. Median alcohol 
hand rub consumption per patient day was 66.4 ml (IQR: 23.7 - 100.5). More details 
concerning the hospitals and their participating ICUs are presented in Table A – 1 in 
Appendix A. 
3.3.2 Patient characteristics  
In total, 3,401 patients were screened, of whom 3287 (114 were excluded due to age < 18 
years) were enrolled from 15 ICUs of 14 participating hospitals between October 2012 and 
September 2013. Data from the medical and surgical ICUs of H04 were collected separately 
but given their small size which are presented as one general ICU. More details of patient 
characteristics were presented in Table A – 2 in Appendix A. Due to prolonged ICU stay, 162 
patients were enrolled in more than one survey leaving 3125 unique patients. There was a 
disproportionate number of patients from 2 ICUs (H10 (18%) and H09 (12%)), while most 
ICUs each contributed for 4 – 8% of the total patients. (Figure 3 – 1) 
 
Figure 3 - 1. Proportion of total patients from each of the participating ICUs 
 
H01; 203; 6% 
H02; 223; 7% 
H04; 143; 4% 
H05; 138; 4% 
H06; 148; 4% 
H07; 145; 4% 
H08;	187;	6%
H09; 403; 12% H10; 578; 18% 
H11; 223; 7% 
H12; 223; 7% 
H13; 277; 8% 
H15; 182; 6% 
H16; 214; 7% 
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Figure 3 - 2. Age distribution of surveyed patients 
The median age was 61.0 years (IQR 45.0-77.0, age distribution given in Figure 3 - 2) and 
63.9% (2101/3287) of patients were male. Most patients (46.2%; 1427/3088; 199 missing) 
were admitted directly from the community, while 30.1 % (930/3088) of the patients entered 
the ICU from another department in the same hospital and 20.7% (638/3088) were referred 
from other hospitals, and others 3% (93/3088) were from community healthcare stations, long 
term healthcare facilities or private clinics. There was substantial heterogeneity between 
hospitals in the proportions admitted to ICU via different routes, with between 0 and 73% of 
patients in tertiary hospitals surveyed admitted from the community, whilst in the provincial 
hospital this ranged from 32% to 90%.  (Figure 3 – 3) 
 
Figure 3 - 3. Location of surveyed patients before ICU admission 
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In general, infectious diseases were the most common reason for ICU admission with 46.3% 
(49.7% in provincial and 43.2% in tertiary ICUs), followed by other medical diseases (39.1%) 
and surgical diseases (14.6%). H01 and H15 were specialized hospitals on infectious diseases 
so almost all patients admitted to ICUs due to infectious diseases. H05 was specialized on 
surgery therefore nearly all patients admitted to ICU there due to surgical diseases. As with 
the route of admission to ICU, there was a great deal of heterogeneity in the cause of ICU 
admission across the ICUs surveyed. (Figure 3 - 4) 
 
Figure 3 - 4. Reason for ICU admission amongst surveyed patients 
Comorbidity was present in 39.6% of patients (1249/3151, 136 missing), of which 190 
(15.2%) patients had two or more comorbidities. The most common comorbidities were: 
stroke sequelae 27.5% (343/1249), diabetes mellitus 24.8% (310/1249), chronic obstructive 
pulmonary disease 20.7% (259/1249), renal failure 11.5% (144/1249), harmful alcohol use 
11.3% (141/1249), active malignancy 9.5% (119/1249), and induced immunosuppression 
6.1% (76/1249). The proportion of patients with the lowest (5.8%) comorbidity was found in 
a surgical ICU (H05, surgical hospital), and in the other ICUs comorbidity ranged from 
18.5% to 59.5% in tertiary ICUs and correspondingly 34.1% to 70.3% in provincial ICUs. 
(Figure 3 – 5) 
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Figure 3 - 5. Proportion of surveyed patients with any comorbidity 
Family members were involved in patient care in 63.0% (2072/3287) of patients, however 
family care was dependent upon the policies of each ICU and either did not occur in a unit (as 
it was not permitted) or occurred in close to 100% of cases in ICUs where it was permitted. 
(Figure 3 – 6)  
 
Figure 3 - 6. Proportion of surveyed patients with family member involved in patient 
care 
Most patients in ICU of H05 experienced major surgery since admission while there was just 
one patient experienced surgery at ICU in H08. Overall, the proportion of patients that had 
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surgery after admission was 24.8%, and this proportion in tertiary ICUs (32.1%) was higher 
than in provincial ICUs (17.5%). (Figure 3 – 7) 
 
Figure 3 - 7. Proportion of surveyed patients that underwent surgery since admission 
In total, 52.3% (1719/3287) of patients were intubated, with marked differences between the 
ICUs. This rate ranged from above 31.8% to 100% in tertiary ICUs and from 22.4% to 62.6% 
in provincial ICUs. The pooled proportion patients that were intubated was higher in tertiary 
ICUs than that in provincial ICUs. (Figure 3 – 8) 
 
Figure 3 - 8. Proportion of surveyed patients intubated  
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The proportion of patients with a central vascular catheter was widely different between 
ICUs. The pooled proportion of patients with a central vascular catheter was 28.0% 
(921/3287) overall, 40% (654/1633) in tertiary ICUs (range from 8.5% to 96.4%), and 16.1% 
(267/1654) in provincial ICUs (range from 3.7% to 32.9%).  Figure 3 – 9. 
 
Figure 3 - 9. Proportion of surveyed patients with central vascular catheter 
Patients with urinary catheter accounted for 49.2% (1616/3287) in total, 52.9% in tertiary 
ICUs (range 12.3% in H10 to 99.3% in H05), and 45.5% in provincial ICUs (range 17.6% in 
H08 to 65.8% in H09) (Figure 3 – 10). Only 8.2% of total patients experienced hemodialysis 
therapy on surveyed days. This rate ranged from 0% to 33.6% (Figure 3 - 11). 
 
Figure 3 - 10. Proportion of surveyed patients with urinary catheter 
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Figure 3 - 11. Proportion of surveyed patients having hemodialysis  
3.3.3 HAI prevalence  
Overall, 29.5% (965/3266 patients, 21 missing) had at least one HAI; 922 patients had one 
HAI, 39 patients had 2 HAIs, and 4 patients had 3 HAIs. The HAI prevalence ranged widely 
between ICUs from 5.6% to 60.9% with a median prevalence of 30.5%. Overall tertiary ICUs 
had higher HAI prevalence than provincial ICU, exception for H10, and hospital acquired 
pneumonia (HAP) was the most common HAI (79.4% [804/1012]), followed by blood stream 
infection (BSI) (4.4% [44/1012]), and surgical site infections (4.2% [42/1012]). For each 
ICU, HAP also was the most common HAI, its prevalence ranged from 19.7% to 58.0% 
patients in tertiary ICU with exception for H10 (4.0%) and from 9.8% to 34.3% patients in 
provincial ICUs (Table 3 – 1).  
3.3.4 HAI origin and its relationship to a medical device 
Most HAIs (84.5% [855/1012]) were acquired in the survey hospital: 42.5% (363/855) 
acquired prior to ICU admission and 57.5% (492/855) developed after ICU admission (Table 
3 – 2). Among 705 first HAIs developed in the current hospital, the median time from 
hospital admission to onset of HAI was 7 days (IQR: 3-15 days). HAIs developing within 30 
days from hospital admission accounted for 92.6% (653/705) of all first HAIs and the median 
time from hospital admission to onset HAI was 7 days (IQR: 3 – 12 days) (details was 
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presented in figure 3 – 12). Device-associated HAIs accounted for 643/1012 (63.5%) of 
HAIs, mainly VAP (589/643 [91.6% of device-associated HAIs]) (Table 3 - 2). 
Table 3 – 1. Proportion of HAI types in each ICU 
ICU at 
Hospital 
Pneumonia Blood 
stream 
infection 
Surgical 
site 
infection 
Gastro - 
intestinal 
infection 
Urinary 
tract 
infection 
Central 
nervous 
system 
infection 
Skin & 
soft 
tissue 
infection 
Other 
infections 
Total 
HAIs 
Total 
patients 
with HAI 
H01, n (%) 40 (19.7) 3 (1.5) 20 (9.9) 0 2 (1.0) 6 (3.0) 0 0 71 (35.0) 68 (33.5) 
H02, n (%) 60 (27.5) 4 (1.8) 4 (1.8) 8 (3.7) 2 (0.9) 4 (1.8) 2 (0.9) 3 (1.4) 87 (39.9) 84 (38.5) 
H05, n (%) 80 (58.0) 2 (1.4) 2 (1.4) 0 0 0 0 0 84 (60.9) 84 (60.9) 
H10, n (%) 23 (4.0) 0 3 (0.5) 2 (0.3) 0 4 (0.7) 7 (1.2) 1 (0.2) 40 (6.9) 40 (6.9) 
H13, n (%) 110 (39.7) 8 (2.9) 8 (2.9) 20 (7.2) 9 (3.2) 1 (0.4) 1 (0.4) 2 (0.7) 159 (57.4) 144 (50.5) 
H16, n (%) 118 (55.4) 4 (1.9) 0 5 (2.3) 3 (1.4) 0 2 (0.9) 0 132 (62.0) 126 (59.2) 
           
H04, n (%) 14 (9.8) 0 0 0 2 (1.4) 0 0 0 16 (11.2) 15 (10.5) 
H06, n (%) 36 (25.5) 7 (5.0) 0 1 (0.7) 1 (0.7) 0 0 0 45 (31.9) 43 (30.5) 
H07, n (%) 21 (14.5) 0 0 0 0 0 0 0 21 (14.5) 21 (14.5) 
H08, n (%) 39 (20.9) 1 (0.5) 0 0 0 0 0 0 40 (21.4) 40 (21.4) 
H09, n (%) 136 (34.3) 0 3 (0.8) 2 (0.5) 1 (0.3) 2 (0.5) 1 (0.3) 2 (0.5) 147 (37.0) 146 (36.8) 
H11, n (%) 75 (33.8) 0 2 (0.9) 1 (0.5) 2 (0.9) 2 (0.9) 2 (0.9) 4 (1.8) 88 (39.6) 81 (36.5) 
H12, n (%) 28 (12.6) 4 (1.8) 0 0 0 0 0 4 (1.8) 36 (16.1) 36 (16.1) 
H15, n (%) 24 (13.3) 11 (6.1) 0 1 (0.6) 7 (3.9) 0 0 3 (1.7) 46 (25.4) 41 (22.7) 
Hospitals in the first block of rows (H01, H02, …, H16) are tertiary hospitals, and in the second 
block of rows (H04, H06, …, H15) are provincial hospitals 
Table 3 - 2. Location HAI was acquired and association with medical devices. 
Type of infections Location Acquired HAI Related device Total 
No. of 
HAI, n 
(%) 
Current hospital Other 
hospital 
UNK Yes  No UNK 
In ICU Out ICU 
Pneumonia & LRTIa, n 
(%) 
389 
(48.4) 
301  
(37.4) 
60  
(7.5) 
54  
(6.7) 
589 
(73.3) 
120 
(14.9) 
95 
 (11.8) 
804 
(79.4) 
Bloodstream infection, n 
(%) 
34  
(77.3) 
8  
(18.2) 
2  
(4.5) 
0 27 
(61.4) 
11  
(25.0) 
6  
(13.6) 
44  
(4.4) 
Surgical site infection, n 
(%) 
23  
(54.8) 
11 (26.2) 6  
(14.3) 
2  
(4.8) 
NA 
 
NA 
 
NA 
 
42  
(4.2) 
Gastrointestinal 
infection, n (%) 
13  
(32.5) 
19 (47.5) 7  
(17.5) 
1 
 (2.5) 
NA 
 
NA 
 
NA 
 
40  
(4.0) 
Urinary tract infection, n 
(%) 
18  
(62.1) 
8  
(27.6) 
3  
(10.3) 
0 27 
(93.1) 
2  
(6.9) 
0 29  
(2.9) 
Central nervous system 
infection, n (%) 
5  
(26.3) 
4  
(21.1) 
8  
(42.1) 
2  
(10.5) 
NA 
 
NA 
 
NA 
 
19  
(1.9) 
Skin and soft tissue 
infection, n (%) 
2  
(13.3) 
6  
(40.0) 
1  
(6.7) 
6  
(40.0) 
NA 
 
NA 
 
NA 
 
15  
(1.5) 
Other infectionsb, n (%) 
8  
(42.1) 
6  
(31.6) 
2  
(10.5) 
3  
(15.8) 
NA 
 
NA 
 
NA 
 
19  
(1.9) 
Total, n (%) 492 (48.6) 
363 
 (35.9) 
89  
(8.8) 
68  
(6.7) 
643 
(73.3) 
133 
(15.2) 
101 
 (11.5) 
1012  
(100) 
UNK: unknown or missing data; NA: Not applicable; LRTI: low respiratory tract infection 
a Only one case of LRTI 
b Including: nine cases of systemic infection, four catheter related infections, four reproductive tract 
infections, one endocarditis and one eyes ear nose throats infection not classified.  
Note: Twenty-one patients whose infection could not be differentiated between community-acquired and 
hospital-acquired infection were excluded from calculating HAI prevalence.  
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Figure 3 – 12. Time to development of HAI in current (surveyed) hospital over 30 
days 
3.3.5 Risk factors for HAIs Acquired in ICU 
We assessed risk factors for ICU-acquired HAIs in 2,618 patients who were enrolled in the 
study for the first time and had no HAI at ICU admission. The prevalence of HAI among 
these patients at survey time was 16.2% (424/2618 patients). In a univariate analysis 
numerous factors were statistically associated with HAI. The highest risk factors associated 
with HAI were intubation (odds ratio [OR] 6.31 [95% CI 4.86-8.18]), having surgery after 
hospital admission (minor surgery OR 4.78 [95% CI 3.57-6.40], major surgery OR 3.78 [95% 
CI 2.90-4.93]), and urinary catheterization (OR 3.90 [95% CI 3.09-4.92]). (Table 3 - 3).  
Table 3 - 3. Risk factors for developing HAI in ICU 
Risk factors No. of 
patients 
(total = 
2618), n 
Patients with 
HAI (total = 
424), n (%) 
Univariate analysis Multivariate analysis 
OR (95% CI) P value OR (95% CI) P value 
Gender       
Male 1656 271 (16.4) 1.03 (0.83-1.28) 0.758 1.29 (0.98-1.69) 0.072 
Female 962 153 (15.9) Reference  Reference  
Missing  0    141  
Age group       
18 – 60 years 1344 202 (15.0) Reference  Reference  
> 60 years 1274 222 (17.4) 1.19 (0.97-1.47) 0.097 1.13 (0.86-1.48) 0.392 
Missing  0    141  
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Risk factors No. of 
patients 
(total = 
2618), n 
Patients with 
HAI (total = 
424), n (%) 
Univariate analysis Multivariate analysis 
OR (95% CI) P value OR (95% CI) P value 
Location of patients 
at admission to ICU  
      
Community and others  1352 144 (10.7) Reference  Reference  
Same hospital 655 171 (26.1) 2.96 (2.32-3.79) < 0.001 1.40 (0.97-2.00) 0.068 
Other hospital 507 109 (21.5) 2.30 (1.75-3.02) < 0.001 1.25 (0.85-1.83) 0.262 
Missing  104    141  
Reason for admission       
Medical disease 1029 120 (11.7) Reference  Reference  
Infectious disease  1106 214 (19.3) 1.82 (1.43-2.31) < 0.001 0.99 (0.71-1.38) 0.942 
Surgery 368 90 (24.5) 2.45 (1.81-3.32) < 0.001 1.05 (0.59-1.87) 0.876 
Missing  115    141  
Comorbidity       
No comorbidity 1560 250 (16.0) Reference  Reference  
Have comorbidity 972 171 (17.6) 1.12 (0.90-1.38) 0.303 0.72 (0.54-0.95) 0.021 
Missing 86    141  
Surgery after 
admission 
      
None surgery  2009 219 (10.9) Reference  Reference  
Minor surgery 252 93 (36.9) 4.78 (3.57-6.40) < 0.001 1.74 (1.15-2.63) 0.009 
Major surgery 354 112 (31.6) 3.78 (2.90-4.93) < 0.001 1.18 (0.72-1.96) 0.510 
Missing  3    141  
Intubation       
Yes 1252 346 (27.6) 6.31 (4.86-8.18) < 0.001 2.52 (1.81-3.51) < 0.001 
No 1366 78 (5.7) Reference  Reference  
Missing 0    141  
Central vascular 
catheter 
      
Yes 693 197 (28.4) 2.97 (2.39-3.68) < 0.001 1.75 (1.20-2.55) 0.004 
No 1925 227 (11.8) Reference  Reference  
Missing  0    141  
Urinary catheter       
Yes 1226 312 (25.4) 3.90 (3.09-4.92) < 0.001 2.03 (1.45-2.84) < 0.001 
No 1392 112 (8.0) Reference  Reference  
Missing  0    141  
Hemodialysis       
Yes 203 51 (25.1) 1.84 (1.31-2.57) < 0.001 0.99 (0.62-1.59) 0.981 
No 2415 373 (15.4) Reference  Reference  
Missing  0    141  
Peripheral vascular 
catheter 
      
Yes 2202 321 (14.6) 0.52 (0.40-0.67) < 0.001 1.89 (1.23-2.90) 0.004 
No 416 103 (24.8) Reference  Reference  
Missing  0    141  
Family involved 
patient care 
      
Yes 1717 190 (11.1) Reference  Reference  
No 901 234 (26.0) 2.82 (2.28-3.48) < 0.001 0.60 (0.19-1.85) 0.373 
Missing  0    141  
Each day longer 
from ICU admission 
to survey time 
      
In analysis 2513 424 (16.9) 1.08 (1.07-1.10) < 0.001 1.11 (1.09-1.12) < 0.001 
Missing 105    141  
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In multivariate logistic regression, all risk factors were included and adjusted for hospital 
sites. Seven risk factors independently associated with HAIs, which included: intubation (OR 
2.52 [95% CI 1.81 - 3.51]), urinary catheter (OR 2.03 [95% CI 1.45 - 2.84]), minor surgery 
after admission (OR 1.74 [95% CI 1.15 - 2.63]), central vascular catheter (OR 1.75 [95% CI 
1.20 - 2.55]), peripheral vascular catheter showed a protective effect in univariate analysis but 
was associated with a significant increased risk for HAIs in multivariate analysis (OR 1.89 
[95% CI 1.23 - 2.90]), and every one day longer of ICU stay (OR 1.11 [95% CI 1.09 - 1.12]), 
having comorbidity showed higher risk in univariate analysis but turn out to have some 
protection from HAI in multivariate analysis (Table 3 - 3). 
3.4 Discussion 
To date, this is the largest study on HAIs in ICUs in Vietnamese hospitals. The HAI 
prevalence in this study (29.5%, 965/3266 patients) was lower than the pooled HAI 
prevalence of 35.2% reported from other LMICs ICUs. But the individual hospital 
prevalences vary widely, from 6.9% to 60.9% in our study and from 4.4% to 88.9% in other 
LMICs [1]. This reflects the heterogeneity amongst ICUs, so comparing pooled prevalences 
need to be interpreted carefully. However, the high prevalence of HAI in our study, 
particularly at three of the ICUs (H05, H13, H16), is concerning and suggest further 
investigations and actions to prevent infections are required.  
The HAI prevalence in the current study is higher than that reported from adult ICUs in 
European hospitals using almost the same protocol (23.0%, 1750/7613 patients) [5] and in 
ICUs in Southern Europe, Turkey and Iran (23.5%, 176/749 patients) [138] and much higher 
than rate of 9.1% (156/1707) in ICUs in the United States in 2011[7]. In a period of 
surveillance in European ICUs in 2007, ICU-acquired infection was 7.0% for pneumonia, 
3.9% for BSI, and 6.8% for UTI amongst patients who stayed longer than 2 days in ICU.  In 
our study, total HAP, BSI, and UTI were 23.4%, 1.3%, and 1.2% respectively.  
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Our study showed a point prevalence of 16.2% for infections acquired in the ICU and there 
were numerous risk factors for infection. Medical device use was high in the ICUs, ranging 
from 29.3 to 73.3 days per 100 patient days for intubation, 56.2 to 87.9 days for central 
vascular catheter, and 65.8 to 89.6 days for urinary catheter [40]. Furthermore, there were few 
single rooms in the surveyed ICUs and common rooms usually contained 4 – 5 beds, ranging 
up to 30 beds (Table A – 1 in Appendix A). The recommendation from the European Society 
of Intensive Care Medicine is that number of isolation rooms per total ICU beds should range 
from 1-2 rooms per 10 ICU beds and may be up to 5 – 6 rooms per 10 ICU beds in some 
special ICUs (burnt units, infection units, transplantation units, etc.) [143]. In addition, low 
nursing staff : patient ratios (0.81 – 2.5) [142] and high bed occupancy rates [108], often over 
110%,  will have contributed to the high prevalence of HAIs acquired in the ICU [143]. These 
conditions make successful infection control very challenging. In particular, the lack of 
nursing staff for patient care allows little time for proper infection control measures [144-
146]. This is supported by the smaller amount of alcohol hand rub used compared to ICUs in 
wealthier settings: a median of 66.4 ml (IQR: 23.7–100.5 ml)/patient day (Table A – 1 
Appendix A), compared with a median of 83 ml (IQR: 64–105)/patient day in ICUs of 
Germany in 2010 [147].  
In short, effective implementation of infection control programmes to limit and control HAIs 
requires good knowledge and skills, but also requires good basic ICU infrastructure and 
enough staff to achieve strict compliance with infection control measures. These problems are 
a major challenge for LMICs, but it need to be addressed urgently due to huge burden of 
HAIs on public health and economics [1, 6, 62, 63, 148].  
Hospital-acquired pneumonia (HAP) was the most common type of HAI, as reported in other 
studies [1, 10, 138]. HAP accounted for 23.4% of total surveyed patients and 79.4% of all 
HAIs in our study, nearly double that reported (40.0% - 45.3%) in ICUs of developed 
countries [5, 137]. A large proportion of HAP (37.4%, 301/804), and also of total HAIs 
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(35.9%), were acquired in the same hospital before admission to ICU and was the cause of the 
ICU admission. In addition to high proportion of device related HAIs (Table 3 - 2), this figure 
raises the need for an effective infection control program outside ICU, particularly in 
emergency departments where invasive devices were commonly done for HAI prevention.  
Blood stream infections (BSI) accounted for 4.4% of all HAI, considerable lower than the 
reported about 18.0% in European ICUs [5]. That survey did not show the proportion of 
patients in ICUs with invasive device. However, in another study in European ICUs in 2007, 
BSI rate was 3.9% of all patients that stayed more than 2 days in ICU and with utility of 
central vascular catheter of 56.2 to 87.9 days per 100 patient days [40]. In our study, the 
proportion of patients with a central vascular catheter was 28.0%. Therefore, the lower rate of 
BSI in our study may have been due to the lower proportion of patients with central vascular 
catheter and the high HAP prevalence. There might, however, have been an underestimation 
of BSI due to underutilization of blood cultures. Only 243 blood cultures were taken from the 
3287 patients in the 24 hours preceding the survey day, which is lower than anticipated 
although we are not aware of any comparable data from other settings. 
Multivariate analysis identified intubation as an important risk factor, which combined with 
the high prevalence of HAP suggests that future interventions should target this risk factor. 
Potential interventions to assess include ventilation and sedation strategies, cuff and tracheal 
tube design, cuff pressure management [149]. Strategies like selective gut decontamination 
using polymyxins may not be appropriate in this setting with high antimicrobial resistance 
background rates with colistin as last resort drug [150] and poorly resourced infection control 
to contain any potential colistin resistance generated by the technique. Univariate analysis 
showed that the involvement of the patient’s family in patient care was a protective factor 
from HAI but in multivariate analysis this factor turned to associate with higher risk for HAI 
although it did not reach statistically significant. As ICUs had department-wide policies to 
either allow or forbid family from taking care of their admitted family member this practice 
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was highly clustered at the ICU level, the result needs to be interpreted with caution. Further 
research is needed to understand the risks for HAI regarding family members involved in 
patient care. The caution also need for comorbidity assessment. This factor is usually 
associated with higher risk for HAI but in this study it was associated with lower risk for HAI 
in multivariate analysis. This could be the heterogeneity of comorbidity which included ten 
kinds of comorbidities and within the causes of admission. 
National surveillance systems for HAI are scarce in LMIC settings yet ongoing surveillance is 
crucial to informing policymakers of the needs of the population and high quality data is 
critical to the development of potential interventions applicable at the national level. In our 
study, we did not found statistically different risk for HAI between male and female gender, 
between age > 60 years and age 18 – 60 years, patients referenced from other hospitals and 
patients came from community, patients admitted to ICU due to infection or surgery and 
patients admitted to ICU due to medical disease, patients with and without comorbidity. A 
survey of all departments in European acute hospitals found that male gender, older age, and 
surgery since admission were associated with higher risk for HAI [5]. However, another study 
on HAI in ICUs in Europe did not find a statistically significant difference in risk for HAI 
between patients admitted to ICUs due to medical and surgical reasons [40]. A survey in all 
departments in acute hospitals the United States in 2010 found that older age was associated 
with higher risk for HAI [7]. These reported differences could be due to differences in study 
populations. Our study was only conducted in ICU, while other studies involved patients in 
all departments in acute hospitals. Another factor that may explain the differences was that 
most HAIs in our study (86.7%) were device-related, whilst this proportion in the studies in 
Europe and the United States were 45.9% and 25.6%, respectively [5, 7].  
As other studies have reported [5, 7], our study found that each additional day in ICU and the 
presence of any medical device was associated with statistically significant higher risk for 
HAI. Therefore, one way to reduce HAI prevalence is to reduce the duration of ICU stays and 
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improve the use of medical devices. In particular, medical device related infections may be 
reduced by assiduous hand hygiene, improved techniques and expertise in applying the 
device, and removing the device as early as possible.  
Study limitations 
As HAIs had not previously been routinely surveyed in Vietnamese hospitals, criteria for the 
diagnosis of specific HAI may not have been fully understood, potentially leading to 
misclassification of specific HAIs. To limit this problem, we organized several workshops 
and site visits to train doctors. The enrolment of patients who were just admitted to ICU 
before 8.00 A.M. then were discharged from ICU soon after survey time could lead to 
underestimate the HAI prevalence. However, the mean ICU stays at participating ICUs 
ranged from 3.8 to 16 days (Table A – 1 in Appendix A) which means that number of these 
cases was not many and its impact on the HAI prevalence was probably not significant. HAIs 
also are a sensitive issue in Vietnam; therefore, ICU doctors may not have reported all HAIs, 
leading to an underestimation. To minimize this effect data, hospitals were anonymized using 
codes. When data were uploaded we ran data checks and returned queries to doctors that 
needed to be resolved. We therefore think that the hands-on supervision and input from the 
study team ensured that data quality was optimal.  
Conclusions 
There is a high prevalence of HAIs in Vietnamese ICUs with more than one third acquired 
before ICU admission and a predominance of hospital acquired pneumonia. This needs to be 
urgently addressed by strengthening in infection control efforts for not only ICUs but the 
other departments of hospitals. Besides these, solutions to shorten length of stay in ICU and 
limit use of invasive device are important to limit HAI in ICUs. These interventions should be 
systematically implication at national and local level. 
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Chapter 4 
Antibiotic Use and Resistance in Vietnamese Adult Intensive Care Units 
4.1 Introduction 
Antibiotic resistance results in bacteria being able to grow in the presence of antibiotics to 
which it used to be susceptible [151]. Antibiotic resistance is a global public health problem 
as it increases hospital stay, morbidity, mortality, and health expenditure. It is estimated that 
in the European Union annually antibiotic resistance leads to 25,000 deaths annually, an 
additional 2.5 million hospital days, at a cost of 1.5 billion Euros [152]. In the United States 
of America (with about 300 million citizens) antibiotic resistance results in more than 2.0 
million illnesses with more than 23,000 deaths, and overall direct societal costs of 20 billion 
US$ [153]. In Thailand (population 70 million), antibiotic resistance leads to over 3,2 million 
additional hospital days and more than 38,000 deaths, costing up to 200 million US$ directly 
per year [154].  
A systematic review by WHO in 2014 illustrates that the mortality in patients with antibiotic 
resistant infections is double to that in patients with susceptible infections [155]. The World 
Economic Forum has estimated that antibiotic resistance can decrease GDP by 0.4% to 1.6% 
[148]. A report by Jim O’ Neil states that if no effective actions on the present situation of 
antimicrobial resistance are taken, there would be 10 million deaths and a decrease of globally 
GDP 2 – 3.5% (100 trillion US$) worldwide every year. [156].  
Intensive care units (ICUs) are hotpots for antimicrobial resistance, due to abundance of risk 
factors for hospital acquired infections in combination with a high level of antibiotic use, a 
key driver of rising antibiotic resistance levels. In high income countries, the proportion of 
ICU patients prescribed antibiotics is higher than in other wards. A survey by ECDC in 947 
European acute care hospitals of 30 European nations in 2011 – 2012 showed that 56.5% 
patients in ICUs was used antimicrobials on survey day compared with that of about 41% in 
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surgical wards and 37% in medical wards [5]. A survey in the USA in 2011 with 183 
hospitals and 5860 surveyed patients showed that prevalence of antimicrobial use in ICUs 
was 57.7% while in the other wards was 48.6% [98]. Another survey in 37 Australian and 
New Zealand ICUs in 2007 showed that 71% ICU patients was on antimicrobial use on the 
surveyed days [99]. In a German study of 40 ICUs, median antibiotic use was 135.1 
DDD/100 patient days (ranging from 42.7 to 279.8) in whole period 2001 to 2004 with an 
increasing trend from 124.7 DDD/100 PD in 2001 to 138.5 DDD/100 PD in 2004 but median 
carbapenem use was not changed, 6.65 DDD/100 PD in 2001 and 6.57 DDD/100 PD in 2004 
with P. aeruginosa resistant to carbapenem from 1.71 isolates/1000 PD in period 2001- 2003 
and 1.65 isolates/1000 PD in 2004 [96]. A retrospective observational study on 2422 patients 
at a 12 beds surgical ICU in German from 2010 to 2012 with introduction of an antimicrobial 
stewardship programme combination with procalcitonin guideline for antibiotics 
discontinuation in 2011 showed a decreased antibiotic use from 100.5 DDD/100 PD in 2010 
to around 79.19 DDD/100 PD in 2012 with a decrease antibiotics cost in the ICU from 54498 
EUR to 33297 EUR (from 16.30 EUR/PD in 2010 to 9.26 EUR/PD in 2012) and no 
significant change in mortality and ICU stay, 10.4% vs 11.4% and median (IQR) of 1 (1 – 3) 
days vs 1 (1 - 4) days for 2010 vs 2012 respectively [97]. 
There is little data on antibiotic use and resistance in Vietnam. A survey at 15 hospitals across 
Vietnam in 2008, mean antibiotics consumption was 274.7 DDD/100 patient days [157]. 
Thus, whilst it is not without risk to draw comparisons between studies of different design, it 
appears that the Vietnamese hospitals as a whole were prescribing more antibiotics than the 
intensive care units in Germany. A situational analysis published in 2010 and funded by 
GARP, showed antibiotics consumption in Vietnamese hospitals accounted for 36% of whole 
hospital treatment expenditure [158]. This high antibiotic consumption obviously was a main 
factor causing high levels of antibiotic resistance in Vietnam.  Rapid increase in antibiotics 
resistance could be conceived through the rate of Streptococcus pneumoniae isolated from 
blood and cerebral spiral fluid of meningitis patients in Ho Chi Minh City resistant to 
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penicillin which increased from 8% to 56% in a short time from 1993 - 1995 period to 1999 – 
2002 period [159]. In 2001, another survey showed that Streptococcus pneumoniae resistant 
to penicillin was highest in Vietnam (71.4%) compared with average 52.4% for 11 surveyed 
Asian countries (including Vietnam) [160]. Recently, a multicenter study on pathogens of 
BSI, nosocomial pneumonia, and complicated intra-abdominal infections in Asia – Pacific in 
2010 also found that overall carbapenem resistance was highest in Vietnam 35.0% compared 
with 23.0% in common, of which carbapenem resistance among A. baumannii, P. aeruginosa, 
and Enterobacteriaceae were 89.5%, 46.7%, and 5.6% compared with 73.0%, 29.8%, and 
2.8% respectively of overall five countries [161]. That study also indicated that prevalence of 
extended spectrum beta – lactamase among Enterobacteriaceae isolated in ICUs also highest 
in Vietnam with 81.0% while the second was 58.8%, and overall was 43.8%.  
There was limited data available on antibiotic resistance and antibiotic use in Vietnamese 
ICUs. A study on pathogens of HAI at ICU, Emergency Department (ED), and Centre for 
Toxicology Control of Bach Mai hospital in 2003 showed that most common isolates were A. 
baumannii 27.3% (44/161) and P. aeruginosa 27.3% (44/162) with rate of carbapenem 
resistance was 13.6% (6/44) and 18.2% (8/44) respectively [162]. This study also found that 
K. pneumoniae and E. coli accounted for 9.9% (16/161) and 6.8% (11/161) of isolates from 
HAI, respectively, with no strain resistant to carbapenems. A study on pathogens of hospital 
acquired pneumonia at ICU of Bach Mai hospital in 2008 – 2009 found that most common 
bacteria isolated was A. baumannii 44.7% (59/132) and P. aeruginosa 17.4% (23/132) with 
carbapenem resistance was 90.7% (49/54), and 68.4% (13/19), respectively [119]. About 
antibiotic use in ICU, a survey at Bach Mai Hospital in 2006 found that antibiotics use in total 
patient at ICU, ED, and Centre for Toxicology Control was 54.3% (25/46) while in Obstetrics 
and Surgical Departments was the highest at 97.8% (45/46) and 95% (113/119) respectively; 
and lowest at internal departments at 40.3% (441/1094) [112]. A survey at three provincial 
hospitals, one district hospital, and one centre for dialysis in Hanoi city in 2006 found that 
proportion of patients on antibiotic use was 90.3% (56/62) at ICUs, highest up to 95.3% 
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(143/150) at pediatrics departments and lowest at internal department 60.1% (333/554) [114]. 
A survey at three provincial hospital in the North in 2005 showed that proportion of patients 
on antibiotic use was 61.0% (25/41) at ICUs while in surgical departments was 64.4% 
(76/118) and highest at obstetric departments of 81.6% (71/87) [115].  
Despite this disturbing picture of very high levels of resistance in the region, only limited data 
available on antibiotic use and resistance in ICUs specially, in Vietnam. These data also 
showed high levels of carbapenems resistance in HAI pathogens and proportion of patients on 
antibiotic use. However, there was almost no data on antibiotic consumption in Vietnamese 
ICUs. The magnitude of antibiotic use and resistance in ICUs in Vietnam is needed to inform 
policies and interventions. This chapter aims to describe antibiotic use and antibiotic 
resistance in ICUs of 14 hospitals across Vietnam. 
4.2 Material and Methods 
A point prevalence survey (PPS) on hospital acquired infections (HAIs) and antimicrobial use 
was done monthly on a single day at ICUs of 14 participating hospitals across Vietnam from 
October 2012 to September 2013. The hospitals included 6 tertiary and 8 provincial hospitals. 
The design of the PPS is based on the methodology developed and used by the European 
Center of Diseases Prevention and Control (ECDC) [14]. Antimicrobial use is expressed in 
days of therapy (DOT) [130, 163]. One DOT represents the use of a single antimicrobial 
agent on a given day regardless of the dosage, which is normalized to DOT/100 patient-days 
(PD). If one patient received two antimicrobial agents at a given day means that the patient 
used 2 DOT/PD or 200 DOT/100 PD. Antimicrobial consumption measured by DDD is 
different to DOTs [130]. Both metrics are used to measure antimicrobial consumption. DDD 
is used to measure exactly amount of antimicrobial consumption according to WHO 
standards, and DOT is used to evaluate relatively antimicrobial consumption and reflects 
better clinical practice. More details in methods are presented in chapter 2. 
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4.3 Results  
A total of 3287 patients (equal to 3287 patient days) were included in the final analysis with 
the median age of 61.0 years (IQR 45.0-77.0) and male patients accounted for 63.9% 
(2101/3287). Overall, 46.3% patients admitted for infectious disease, 39.1% for medical 
diseases, and 14.9% for surgical reason. Antimicrobials were used in 84.8% (2787/3287) of 
the patients on surveyed days. The HAI prevalence was 29.5% (965/3266) among surveyed 
patients with 922 patients with a single HAI episode and 43 patients with two or more HAI 
episodes. 15.6% (151/965) patients acquired their HAI during a previous hospital admission 
and 84.4% (814/965) patient acquired their HAI in the current hospital. A total of 726 
pathogens were detected in patients with HAI, representing 59.4% (573/965) of patients with 
HAI. Data from the medical and surgical ICUs of H04 were collected separately but given 
their small size which are presented as one general ICU.  
4.3.1 Antimicrobial use 
Antimicrobial use was evaluated in all enrolled patients. The pooled proportion of patients 
receiving an antimicrobial at the time of the survey was 84.8% (2787/3287) and ranged from 
60.4% to 99.8% between ICUs, with highest usage rates seen in tertiary ICUs (Figure 4 – 1). 
Interestingly nearly all patients admitted to the ICUs of H05 and H10 received an 
antimicrobial. H05 is a tertiary – surgical specialty hospital, with 91.7% ICU admissions for 
surgery with all patients intubated. H10 is a tertiary general hospital with 21.1% ICU 
admissions for surgery and 15.5% for infectious disease with 31.8% intubated patients. In 
addition, prevalence of HAI in H05 ICU was 60.9% while in H10 ICU was 6.9%. These 
factors could not explain why nearly 100% of patients received antibiotics in both ICUs. The 
lowest consumption was seen in H07 and H12. These hospitals were general provincial 
hospitals. 60.7% admissions to the ICU of H07 was for surgery and infectious diseases while 
that was 36.8% of the admissions to the ICU of H12. Prevalence of intubation and HAI in 
ICU of H07 was 55.9% and 14.5% while these in ICU of H12 was 22.4% and 16.1%, 
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respectively (Table A - 2 in Appendix A). These differences can not explain for the similar 
proportions of antibiotic use in these ICUs. The majority of patients was prescribed two 
antimicrobials (n=1343; 40.8%), followed by one microbial in 733 patients (22.3%), three in 
552 patients (16.8%), and four in 159 patients (4.8%). Regarding antimicrobial combinations, 
the most common double combinations were: 3rd generation cephalosporins with 
fluoroquinolones (19.1%), carbapenems with fluoroquinolones (10.8%), and 3rd generation 
cephalosporins with aminoglycosides (7.8%). Combinations of three antimicrobials were: 3rd 
generation cephalosporins with fluoroquinolones and glycopeptides (13.6%), 3rd generation 
cephalosporins with fluoroquinolones and imidazole derivatives (6.0%). More details on 
antimicrobial combination and frequent use are presented in Table A - 3 and Table A - 4 in 
Appendix A. 
 
 
Figure 4 – 1. Proportion of surveyed patients using antimicrobials on surveyed days 
On average, antimicrobial consumption was 173.7 DOT/100 PD, varying from 206.0 
DOT/100 PD at tertiary ICUs and 141.9 in provincial ICUs. Consumption of antimicrobials 
ranged from the lowest 85.2 DOT/100 PD at ICU in H12 hospital to highest 274.7 DOT/100 
PD at ICU in H10 hospital. The low antibiotic consumption at ICU of H12 may be explained 
by the low proportion of admissions due to surgery and infectious diseases (36.8%) and low 
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invasive procedure (22.4% intubated patients). However, it is difficult to explain the high 
antibiotic consumption at ICU of H10 because of low proportion of intubated patients 
(31.8%), central vascular catheter access (8.5%), HAI (6.9%), and admission due to surgery 
(21.1%) and infectious diseases (15.5%) (Table A - 2 in Appendix A). Antibiotic indications 
may provide more insights (see below). The three most common used antimicrobials were 
3rd-generation cephalosporins, fluoroquinolones, and carbapenems, accounting for more than 
50% of total DOT of all used antimicrobials. In total, consumption of 3rd-generation 
cephalosporins was 34.3 DOT/100 PD, fluoroquinolones 32.9 DOT/100 PD, and 
carbapenems 23.9 DOT/100 PD. More details are presented in Figure 4 - 2.  
 
Figure 4 - 2. Antimicrobial consumption by class for each ICU 
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Analysing antimicrobial use by proportions: antimicrobials for systemic use (ATC group J01) 
accounted for 97.9% (5590/5711) of the total antimicrobials used. Of which, third generation 
cephalosporins, fluoroquinolones, and carbapenems were used most commonly - accounting 
for 20.1% (1126/5590), 19.4% (1082/5590), and 14.1% (786/5590), respectively. Among 
antibiotics used for HAI treatment, the most frequently used agents were carbapenems 
(22.9%; 432/1890), fluoroquinolones (16.0%; 302/1890), and 3rd generation cephalosporins 
(15.5%; 293/1890). Polymyxins (parenteral colistin) accounted for 3.3% (186/5590) of total 
use but was the fifth most frequently used agent for HAIs, reflecting the impact of drug 
resistance on choice of antimicrobials. (Figure. 4 - 3). 
 
 
Figure 4 - 3. Antimicrobials used by types of indication 
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The type of infection was known for 76.2% (4348/5707) antimicrobial agents used. The most 
predominant infection was pneumonia, accounting for 63.1%, followed by intraabdominal 
sepsis (Table 4 – 1).  
Table 4 - 1. Types of infections for which antimicrobials were administered 
No.   Infection sites indicated antimicrobials Frequency Percentage  
1.  Pneumonia 2857 63.1% 
2.  Intraabdominal sepsis  391 8.6% 
3.  Cellulitis, wound, deep soft tissue, not involving bone 338 7.5% 
4.  Infections of the central nervous system 251 5.5% 
5.  Gastrointestinal infections (e.g. salmonellosis, antibiotic 
associated diarrhoea) 154 3.4% 
6.  Clinical sepsis (suspected bloodstream infection without lab 
confirmation/ results are not available, no blood cultures 
collected or negative blood culture), excluding FN 146 3.2% 
7.  Laboratory confirmed bacteraemia 85 1.9% 
8.  Acute bronchitis or exacerbations of chronic bronchitis 69 1.5% 
9.  Symptomatic lower urinary tract infection (e.g. cystitis) 55 1.2% 
10.  Symptomatic upper urinary tract infection (e.g. pyelonephritis) 52 1.1% 
11.  Systemic inflammatory response with no clear anatomic site 36 0.8% 
12.  Infections of ear, nose, throat, larynx and mouth 29 0.6% 
13.  Obstetric or gynaecological infections, STD in women 24 0.5% 
14.  Asymptomatic bacteriuria 17 0.4% 
15.  Cardiovascular infections: endocarditis, vascular graft 15 0.3% 
16.  Febrile neutropaenia or other form of manifestation of infection 
in immunocompromised host (e.g. HIV, chemotherapy etc) 
with no clear anatomical site 6 0.1% 
 Total  4525 100% 
 
Of the infectious indications, 41.8% (2386/5711) were community-acquired infections and 
33.9% (1937/5711) HAIs.  Non-infectious reasons for prescribing antibiotics were: 
prophylaxis (498/5711) and other (e.g. erythromycin for stimulating gastric kinetic, 38/5711) 
indications accounted for 9.4% (536/5711) and unknown indication accounted for 14.9% 
(852/5711). Prophylaxis and other indications was near 0% for the ICUs of H01, H08, and 
H15, likely explained by the fact that there was almost no admission to these ICUs for 
surgery.  The high proportion (30.5%) of antibiotics use for prophylaxis in ICU of H07 
hospitals may be due to similarly rate of ICU admission for surgical reason (35.2%). 
Antibiotic indication for community acquired infections ranged from 12.6% in ICU of H05 
hospital to 71.1% in ICU of H08 hospital. These rates are relatively similar to the proportions 
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of ICU admission due to infection in these ICUs, 5.5% and 75.3% respectively. In most ICUs 
proportion of unknown indication for antibiotic use was generally under 5%, except for ICU 
of H11 (11.0%) and H10 (46.0%). Unknown indication here implies that there was no 
obvious convincing reason for antibiotic use. These high levels may be due to lack of 
antibiotic stewardship and guidelines on infection diagnosis and antibiotic use. More details 
are provided in Figure 4 - 4.  
 
Figure 4 - 4. Proportion of antimicrobial indication types by the ICUs 
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Table 4 - 2. Microorganisms associated with HAIs 
  
Microorganisms 
Pathogens isolated from hospital acquired infections 
All HAIs Pneumonia  Blood stream 
infections  
Surgical site 
infections 
Urinary tract 
infections 
n (%) n (%) n (%) n (%) n (%) 
Gram-negative bacteria 611 (84.2) 516 (87.9) 28 (63.6) 25 (73.5) 15 (60.0) 
Acinetobacter spp. 223 (30.7) 197 (33.6) 10 (22.7) 2 (5.9) 5 (20.0) 
Pseudomonas aeruginosa 100 (13.8) 92 (15.7) 2 (4.5) 3 (8.8)  0 
Klebsiella pneumoniae 84 (11.6) 68 (11.6) 5 (11.4) 8 (23.5) 1 (4.0) 
Escherichia coli 39 (5.4) 20 (3.4) 6 (13.6) 4 (11.8) 3 (12.0) 
Klebsiella spp. 54 (7.4) 44 (7.4) 2 (4.5) 3 (8.8) 1 (4.0) 
Providencia spp. 28 (3.9) 25 (4.3) 0 2 (5.9) 0 
Achromobacter spp. 18 (2.5) 17 (2.9) 0 1 (2.9) 0 
Stenotrophomonas 
maltophilia 
6 (0.8) 6 (1.0) 0 0 0 
Gram-negative bacilli others 55 (7.6) 43 (7.3) 3 (6.8) 2 (5.9) 5 (20.0) 
Gram-negative cocci other 4 (0.6) 4 (0.7) 0 0 0 
Gram-positive bacteria 104 (14.3) 65 (11.1) 15 (34.1) 9 (26.5) 7 (28.0) 
Staphylococcus aureus 39 (5.4) 28 (4.8) 6 (13.6) 3 (8.8) 0 
Staphylococcus spp. 19 (2.6) 11 (1.9) 6 (13.6) 0 1 (4.0) 
Streptococcus spp. 11 (1.5) 9 (1.5) 0 1 (2.9) 0 
Enterococcus spp. 29 (4.0) 11 (1.9) 3 (6.8) 5 (14.7) 6 (24.0) 
Gram-positive bacilli other 6 (0.8) 6 (1.0) 0 0 0 
Fungi 11 (1.5) 6 (1.0) 1 (2.3) 0 3 (12.0) 
Candida spp. 10 (1.4) 5 (0.8) 1 (2.3) 0 3 (12.0) 
Other fungi 1 (0.1) 1 (0.2) 0 0 0 
Total isolates 726 (100) 587 (100) 44 (100) 34 (100) 25 (100) 
 
4.3.2.2 Antimicrobial resistance of HAI pathogens 
Among 726 isolates, susceptibility was available for 705 isolates (97.1%). Antimicrobial 
resistance was common in these isolates. Resistance to carbapenem accounted for 86.8% 
Acinetobacter spp., 55.7% P. aeruginosa, and 14.9% K. pneumoniae. Resistance to 3rd 
generation cephalosporin accounted for 67.3% of all Enterobacteriaceae isolated. More than 
75% of the S. aureus isolates were methicillin resistant and up to 57.7% of the Enterococcus 
spp. were resistant to glycopeptides. More details about aetiology for all HAI and some 
specific HAIs are presented in Table 4 – 3. 
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Table 4 - 3. Antimicrobial susceptibilities of HAI associated microbes 
Pathogens for HAI originated in 
surveyed hospitals 
Antimicrobials resistance Total, n = 
705 (%) 
Enterobacteriaceae C3-S, Car-S C3-R, Car-S C3-R, Car-R UNK 235 (33.3) 
Klebsiella pneumoniae, n (%) 21 (28.4) 42 (56.8) 11 (14.9) 7 81 (11.5) 
Escherichia coli, n (%) 15 (40.5) 20 (54.1) 2 (5.4) 2 39 (5.5) 
Klebsiella spp., n (%) 17 (30.1) 33 (62.3) 3 (5.7) 0 53 (7.5) 
Providencia spp., n (%) 11 (40.7) 15 (55.6) 1 (3.7) 0 27 (3.8) 
Other Enterobacteriaceae, n (%) 9 (28.1) 19 (59.4) 4 (12.5) 3 35 (5.0) 
Gram-negative bacilli Car-S Car-R  UNK 362 (51.3) 
Acinetobacter spp., n (%) 28 (13.2) 184 (86.8)  10 222 (31.5) 
Pseudomonas aeruginosa, n (%) 39 (44.3) 49 (55.7)  10 98 (13.9) 
Other Gram-negative bacilli, n (%) NA NA   42 (6.0) 
Staphylococcus spp. Oxa-S Oxa-R  UNK 56 (7.9) 
Staphylococcus aureus, n (%) 9 (24.3) 28 (75.7)  2 39 (5.5) 
Staphylococcus spp., n (%) 7 (63.6) 4 (36.4)  6 17 (2.4) 
Enterococcus spp. Glyco-S Glyco-R  UNK 29 (4.1) 
Enterococcus spp., n (%) 11 (42.3) 15 (57.7)  3 29 (4.1) 
Other microorganisms     23 (3.3) 
Streptococcus spp., n (%)     8 (1.1) 
Other bacteria, n (%)     10 (1.4) 
Candida spp., n (%)     5 (0.7) 
Total isolates     705 (100) 
C3-R: resistant to 3rd generation cephalosporins, C3-S: susceptible to 3rd generation cephalosporins, 
Car-R: resistant to carbapenems, Car-S: susceptible to carbapenems, Glyco-R: resistant to 
glycopeptides, Glyco-S: susceptible to glycopeptides, Oxa-S: susceptible to oxacillin, Oxa-R: 
resistant to oxacillin, UNK: unknown, NA: not assess. 
 
Pathogen of specific HAI 
Pathogens with susceptibility data isolated from patients with hospital-acquired pneumonia 
(HAP) were: A. baumannii 26.5%, P. aeruginosa 15.7%, and K. pneumoniae 11.2% with 
carbapenem resistance levels of 89.7%, 55.6%, and 15.3%, respectively. Among 
Enterobacteriaceae other than K. pneumoniae, 3rd generation cephalosporin resistance ranged 
from 60.0% to 72% and carbapenem resistance ranged from 3.8% to 11.1% of isolates. 
Methicillin resistant S. aureus accounted for 76.9% (20/26) of S. aureus isolated.  Most 
common pathogens for hospital acquired blood stream infections were gram negative bacilli 
(65.8%). 7/8 of A. baumannii was resistant to carbapenem, 3/6 E. coli and 3/5 K. pneumoniae 
were resistant to 3rd generation cephalosporins, and 5/6 S. aureus resistant to methicillin. The 
majority of pathogens from SSI and UTI were also gram negative bacilli, 73.5% and 68.2% 
respectively, and 44.4% Enterobacteriaceae resistant to 3rd in both SSI and UTI. All (2/2) A. 
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baumannii isolated in SSI were susceptible to carbapenems but all (5/5) A. baumannii for UTI 
were resistant to carbapenems.  
Pathogen of HAI originated from surveyed hospitals 
Antimicrobial resistance of pathogens for HAIs originated from surveyed hospitals are 
presented in Table A – 5 in Appendix A. Proportion of antimicrobial resistance was high 
similar to total pathogens for HAI. In tertiary ICUs, carbapenem resistance was 94.1% to 
100% in A. baumannii, 33.3% to 100% in P. aeruginosa, and 0% to 33.0% in K. pneumoniae.  
In provincial ICUs, carbapenem resistance ranged from 0.0% to 83.3% in A. baumannii, 0.0% 
to 83.3% in P. aeruginosa, and 0.0% to 50.0% in K. pneumoniae. Nearly 100% of A. 
baumannii resistant to carbapenems was seen at ICUs using more than 140 DOT/100 PD. 
Association between total antimicrobial use and some main antibiotic resistance for each ICU 
were presented in Figure 4 – 5. 
 
Figure 4 – 5. Total antimicrobial use and main antibiotic resistance at ICUs 
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Among 241 patients with a carbapenem resistant strain, 30 patients were given monotherapy 
(11 with polymyxins, 19 with other antibiotics), 117 patients were given combination therapy 
with polymyxins, and 94 patients were given combination therapy without polymyxins. 
53.1% (128/241) patients with carbapenem resistant infections were given polymyxins. 
Among 117 patients with combination therapy including polymyxins, 79 patients were treated 
with two antibiotics, 35 patients with three antibiotics, and three patients with four antibiotics. 
Most common antibiotic combinations with polymyxins were: carbapenems (53.8%; 63/117), 
cefoperazone (20.5%; 24/117), and piperacillin & enzyme inhibitor (6.8%; 8/117). Among 94 
patients who were not treated with polymyxins, 63 patients were given two antibiotics and 31 
patients given three or more antibiotics. The most common antibiotics in these combinations 
were carbapenems 57.4% (54/94), vancomycin 28.7% (27/94), and levofloxacin 25.5% 
(24/94). Overall there were many different treatment strategies for carbapenem resistant 
infections, likely due to the lack of a national guideline for these infections. More details were 
presented in Table A - 6 in Appendix A.  
4.4 Discussion  
4.4.1 Antimicrobial use 
There were two levels of ICUs (tertiary and provincial ICUs) and three types of ICUs (H05 is 
surgical, H01 and H15 is infectious, and the others are mixed ICUs) in our study. This PPS 
illustrates that a high proportion of ICU patients receive antimicrobials (84.8%), ranging from 
60.4% to 99.8% per individual ICUs, and that the rate at tertiary ICUs (90.3%) was higher 
than at provincial ICUs (79.3%) (Figure 4 – 1). The overall 84.8% of the ICU patients on 
antimicrobials in this study is also higher than the 56.5% in European ICUs [5] and the 
reported  maximum of 77.3% at surgical ICUs in the United States in 2011 [98]. 
Looking for explanations for this finding, ICUs with the highest proportion of patients on 
antimicrobial use were a mixed ICU (99.8% at H10) and a surgical ICU (97.1% at H05). 
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Interestingly, not specialized ICUs on infectious diseases (76.4% at H01 and 69.8% at H15) 
had the highest rates, though this would be expected. Furthermore, the lowest proportion of 
patients prescribed antimicrobials amongst the tertiary hospitals was in one of the ICUs 
specializing in infection (H01) and an ICU of a provincial hospital specializing in infection 
(H15) was the third lowest among provincial ICUs. These findings suggest that it is not the 
nature of the admissions to the ICUs that is causing the high rate of antibiotic use. Possibly, 
the fact that hospitals specialized in infectious diseases have a better understanding of treating 
infections, may explain the low use in these ICUs.  This phenomenon was more clearly seen 
when seeing data on antimicrobial use by DOT/100 PD (Figure 4 – 2). Overall, antimicrobial 
use at Vietnam ICUs in the current study was 173.7 DOT/100 PD. Antimicrobial use at H10 
ICU was the highest (274.7 DOT/100 PD) and was about double that of H01 ICU (143.8 
DOT/100 PD) and triple that of H15 ICU (98.9 DOT/100 PD), the two infectious disease 
speciality ICUs. This could mean that antimicrobial use at these two specialized ICUs were 
more strictly than the other ICUs so that there was less unnecessary use of antimicrobials than 
the other ICUs. Of note both of these sites have had a longstanding relationship with Oxford 
University, which may also have influenced prescribing behavior, though many of the large 
hospitals also have established a longstanding relationship with overseas institutions. Data on 
indications for antimicrobial use (Figure 4 – 3) showed almost no other indications for 
antimicrobial use except for infection treatment (community and hospital acquired infections) 
at these two ICUs while at the other ICUs, with the exception of H08, indications for 
prophylaxis and unknown reason ranged from under 10% to more than 50%. Other reason for 
this finding could be that other ICUs are surgical and mixed ICUs, where possibly more 
appropriate than is the case for two ICUs specialized in infectious diseases. However, the 
considerable proportion of antimicrobial use with unknown reason occurring in the other 
ICUs, suggest that the use of antimicrobials at these ICUs was less restricted than at two 
infection ICUs. These data suggest that involvement of specialists in infectious diseases 
participate in ICU work could lead to a decrease in antimicrobial use in ICUs and should be 
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investigated further. At present, Vietnamese ICUs have no regularly consultations from 
specialists in infectious diseases, or regular input from microbiologists.  
Antimicrobial use measured by DOT/100 PD also shows that the Vietnamese rates are 
significantly higher in ICUs from developed countries. In our study, pooled antimicrobial 
consumption of 173.7 DOT/100 PD is higher than that of 136.8 DOT/100 PD in ICU in a 
single center study in the United States in 2010 [164] and than that in German ICUs in 2012 
with ~80 DDD/100 PD [97]. This could be explained by a higher infectious disease burden in 
Vietnam ICUs: 46.3% of patients were admitted to ICU for an infectious disease in addition 
with 12.9% (424/3287) patients acquired HAI after ICU admission [chapter 3]). In the United 
States, only 17.2% of elderly patients admitted to ICU in 2010 was due to an infectious 
disease [165]. The high burden of infectious diseases in Vietnamese ICUs is a combination of 
poor infection control practices leading to high rates of HAI (Chapter 3) and the general 
burden of tropical infectious diseases in community [166]. As a result, infectious diseases are 
on the fifth position in Vietnam on the disease burden ranking after diseases on respiratory, 
circulatory, digestive, and obstetric problems [101]. Besides the high burden of infectious 
diseases, there are also high rates of patients on antimicrobials, both appropriate and 
inappropriate. A significant proportion of antimicrobial use in Vietnam is due to unknown 
reason, 14.9% in overall and up to 46.0% in an ICU (Figure 4 – 3). These situations require 
urgently a systematic antimicrobial stewardship for Vietnam ICUs and also improve hygiene 
in the hospital and in the community. 
Usually, antimicrobial use would decrease over time because of improvement in infection 
control practice, increased awareness on antimicrobial resistance, and more accurate diagnosis 
of infectious diseases. However, antimicrobial consumption at ICUs in the current study was 
higher than reported in a previous study in ICUs of three hospital in the North Vietnam in 
2007, which ranged from 76 to 99.9 DDD/100 PD with average of 81.1 DDD/100 PD [146]. 
This difference could be due to ICU selection for these studies and also difference in study 
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methods to measure antimicrobial use. Antimicrobial consumption in the current study is 
significantly lower than that for whole hospital of 274.7 DDD/100 PD in average of 15 
hospitals, ranging from about 130 at H15 to 466 DDD/100 at H08 among non-pediatrics 
hospitals in 2008 [157]. This is striking as ICUs in general have the highest antimicrobial 
consumption in a hospital. This needs to be investigated further to find out underlining 
reasons for future interventions to achieve accurate antimicrobial use. 
Pneumonia is a common indication for antimicrobial use, accounting for 63.1% of total 
antimicrobials used for infection treatment. While in acute hospitals in European, respiratory 
tract infections only accounted for 32.8% of total antimicrobial use [5]. This reflect high 
burden of respiratory infection in ICUs in Vietnam, which should be prioritized in developing 
antibiotic stewardship and infection control measures. 
The proportion of carbapenem use in the current study for treatment of HAI is much higher 
than that used for HAIs in European hospitals: 22.9% versus 9.4% respectively [5]. Although 
the European data is for HAI treatment in whole European hospitals (not only ICU), it still 
reveals the high carbapenems use in Vietnamese ICUs, a last resort for infection treatment. 
Carbapenem use in our study by 23.9 DOT/100 PD (Figure 4 – 2) is a slightly higher than that 
of 19.6 DOT/100 PD in one ICUs in the United States in 2010 [164]. Reasons for high 
carbapenem use could be: the high rate of bacteria resistant to antimicrobials, high disease 
severity of ICU patients, inadequate and accurate facilities for diagnosis of bacterial 
infections, and inadequate antimicrobial stewardship. All these aspects should be addressed to 
reserve this last resort as well as other antimicrobials. 
4.4.2 Pathogens for HAIs 
In our study, Gram-negative bacteria were the most common isolated pathogens from patients 
with HAI. This is similar to studies in low and middle income countries [10, 138, 144]. 
Another study in South Korea and India showed that S. aureus, a Gram-positive bacterium,  
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accounted for a considerable proportion of pathogens for HAI in ICUs, 34.9% and 25.0% 
respectively [52]. However, in our study S. aureus accounted for just 4.8%, while Gram 
negative bacteria (Acinetobacter spp., P. aeruginosa, and K. pneumonia) were major 
pathogens for all HAIs accounting for 56.1% (Table 4 - 2) with high proportions of 
carbapenem resistance (Table 4 - 3). In the current study, Acinetobacter spp. was the most 
common isolate (30.7%) for HAI and higher compared to 19.2% in other ICUs in Asia, and 
3.7% in North America [167]. A. baumannii and P. aeruginosa accounted for 44.5% of total 
isolates for HAIs. This proportion is considerable higher than that of 34.1% in Turkey in 2007 
– 2008 [168] and 34.6% in a previous study at three ICUs in Vietnam in 2007 [146]. 
Carbapenem resistance among A. baumannii and P. aeruginosa increased compared to 69.1% 
and 44.4% sequentially in previous study in Vietnam ICUs in 2007 [146]. The high 
prevalence of carbapenem resistance could be caused by a part from the high prevalence of 
antibiotic use which leads to selection for antibiotic resistant bacteria. And these figure could 
be due to selection bias from the design of point prevalence survey; patients with long stay are 
over represented and may be surveyed during the second or even later episode of HAI.  
Consequently, high prevalence of carbapenem resistance leads to an increased colistin use 
[140] and subsequent emergence and spread of colistin resistance.  
The high rates of MRSA and glycopeptide resistant enterococci are also a major concern. 
However, the burden of Gram-positive infections as a cause of HAI is relatively low as 
compared to Gram-negative infections. High level of resistant to last resort of antimicrobials 
could be consequence from poor infection control practice and high antimicrobial 
consumption. Antimicrobial resistance also leads to a high consumption of last resort 
antimicrobials. Antimicrobial stewardship programmes and the deployment of alternatives to 
carbapenems may help to slow the development of further resistance to the remaining active 
antibiotics [169] and need to be evaluated in this context. Additionally, suitable infection 
control measures must be complied and monitored strictly. However, to achieve effectivity of 
these interventions all basic facilities and resources for doing these must be supplied, such as 
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infrastructure of ICU, facilities for infection diagnosis, care and infection control, adequate 
human resource achieving requirement of working in ICU. 
In conclusion 
High antimicrobial consumption, with about one third for HAIs treatment, and around 15% of 
antimicrobial use for unknown reason illustrate the urgent need for antimicrobial stewardship 
programmes and also infection control programmes in Vietnamese ICUs. The majority of 
infections in ICUs was pneumonia, which should be prioritized in future control strategies.  
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Chapter 5 
Risk factors for ventilator-associated pneumonia and ventilator-
associated respiratory infections in Vietnamese intensive care units 
5.1 Introduction  
Ventilator associated pneumonia (VAP) is one of the ventilator associated respiratory 
infections (VARI) which occurs in a significant proportion of ventilated patients in ICUs. 
These infections are reported to have important consequences, including prolonged 
ventilation time, length of ICU and hospital stay, hospital cost, and increased mortality [46, 
48, 51, 67, 170-172]. As a result, there have been many efforts to reduce the occurrence of 
these infections [173-175]. Despite these efforts, reported VAP prevalence rates are often 
high. An international study across 56 ICUs in 11 countries in 2012 showed an overall VAP 
prevalence of 15.6% with an incidence of 13.6 episodes/1000 ventilation days. Prevalence for 
the USA was reported as 13.5%, with incidence of 12.1 episodes/1000 ventilation days. In 
Europe prevalence was higher at 19.4% and incidence of 15.0 episodes/1000 ventilation days. 
Latin America and Asia Pacific had similar incidence to USA of 13.6 episodes/1000 
ventilation days and prevalence of 13.8% and 16.0% respectively  [42].  However there is 
considerable variation in reported figures particularly in the United States where other studies 
reported lower VAP incidences: 4.4 episodes/1000 ventilation days in a specialist burns ICU, 
1.0 episodes/ 1000 ventilation days in a major medical teaching hospital ICU, 1.6 
episodes/1000 ventilation days in a  mixed medical/surgical teaching hospital ICU, and 2.2 
episodes/ 1000 ventilation days in a surgical teaching hospital ICU [176]. 
In low and lower middle income countries, few data are available. A systemic review of HAI 
in developing countries between 2006 and 2008 reported VAP to be the most frequent HAI in 
critical care units, with an incidence of 22.9 episodes/1000 ventilation days, nearly eight folds 
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higher than in the USA. They also noted that high-quality studies tended to report higher 
rates. [10].  
In Vietnam, there is no national surveillance system for HAI,  but studies on HAI in ICUs 
have shown that the point prevalence of HAI in ICUs ranged from 19.3% to 31.3% [110, 112, 
114-117] and that VAP incidence ranged from 17.4% to 56.6% [118, 119, 121] and VAP 
incidence density ranged from 11.7 episodes to 61.3 episodes per 1000 ventilation days [116, 
118, 119]. Surveillance on hospital-acquired infections (HAI) in intensive care units of 14 
tertiary and provincial hospitals across Vietnam in 2013, conducted as part of this thesis, 
showed that the prevalence of HAI was 29.5%, of which hospital-acquired pneumonia 
accounted for approximately 80% (chapter 3) [120].  
These sparse data suggest that the burden of VAP is relatively high in intensive care units in 
Vietnam. However, more systematic high quality data is needed to inform policy makers and 
doctors to enable optimal prevention and management of this issue. This chapter describes the 
results of a study that systemically assessed the incidence and risk factors of VARI, including 
VAP and other ventilator-associated respiratory infections, at three referral hospitals in Hanoi 
and Ho Chi Minh City, Vietnam. 
5.2 Methods 
A prospective, observational study of the clinical epidemiology and etiology of VAP was 
performed from November 2013 to May 2015 on the Intensive Care Units of the National 
Hospital for Tropical Diseases (NHTD) and from July 2014 to May 2015 on the Intensive 
Care Units of Bach Mai Hospital (BMH), both in Hanoi, and from October 2014 to 
November 2015 on the Intensive Care Units of Hospital for Tropical Diseases (HTD) in Ho 
Chi Minh City, Vietnam.  The detailed methods are presented in chapter 2. 
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5.3 Results 
5.3.1 Characteristics of study sites 
The National Hospital for Tropical Diseases (NHTD) is a teaching hospital for infectious 
diseases with 280 beds located in Hanoi. NHTD provides in-hospital care for more than 7300 
patients annually. The ICU has 21 beds (18 ventilated beds) in 2 single rooms and 5 common 
room (distance between beds is about 60 cm in common room), 7 doctors and 28 nurses in 
total, and provides medical services for about 500 ICU patients per year with mean ICU stay 
of about 9 days. Bach Mai Hospital (BMH) is the largest hospital in Hanoi with 1900 beds, 
provides in-hospital care for more than 114,000 patients annually.  BMH ICU has 38 beds 
(based on 30 beds of origin design, so that the distance between beds is also about 60 cm), 
managed by total 13 doctors and 55 nurses, and provides medical services for around 1,300 
ICU patients per year with mean ICU stay of around 10 days. The last study site is the ICU in 
Hospital for Tropical Diseases (HTD) in Ho Chi Minh city. There are 550 beds in this 
hospital for about 42000 inpatients annually. HTD ICU has 23 beds with 8 doctors and 48 
nurses serving 1500 ICU patients per year with mean ICU stay of about 16 days. Like NHTD, 
HTD serves as an infectious disease referral centre and only admits patients where the 
predominant problem is perceived to be infection. All sites provided advanced respiratory 
support, haemodynamic support and renal support. Extracorporeal membrane oxygenation 
(ECMO) was available in one site at the time of this study (BMH), though was not commonly 
used. In these ICUs, alcohol hand rub is available at the bedside, and sterile technique and 
maximized barrier precaution are prerequisite for all invasive procedures. Tracheostomy is 
performed on ward by ICU staff in most cases. Antibiotic guidelines are available and 
antibiotic use is routinely evaluated at these ICUs, however in contrast with Western units 
there is no microbiologist visiting the ICUs or de-escalation in commonly practice. 
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5.3.2 Common characteristics of patients 
In total there were 453 patients enrolled in the study from November 2013 to November 
2015. Three tetanus patients were excluded when their clinical research forms and medical 
records were reviewed as it was clear they had been admitted with suspected VAP. One 
patient withdrew from the study and 75 other patients were excluded from analysis due to: 
duration of ventilation of less than 48 hours (n = 69) and treatment with ECMO during the 
study period (n=6). Thus 374 patients were eligible for analysis, of which 161 (43.1%) were 
from NHTD, 61 (16.3%) from BMH, and 152 (40.6%) from HTD. Among 374 patients in 
analysis, 232 (62.0%) patients had medical insurance and 142 (38.0%) patients did not. This 
means that the sample size of 600 was not reached, due to unanticipated low recruitment rate 
and lack of funding to extend the study period. 
5.3.2.1 Demographics  
Among the 374 patients in final analysis, male gender was predominant with 267 patients 
accounting for 71.4% (267/374). Patients’ age ranged widely from 16 years to 94 years with a 
median (IQR) of 52 (38 – 64) years (Table 5-1, Figure 5-1). There was a total of 18 patients 
admitted to ICU after surgery, of whom 10 had undergone emergency operations and 8 
underwent elective operations. APACHE II scores (available for 341 patients at enrolment) 
ranged from 0 to 31 points with median (IQR) of 10 (6 – 15) points, and 330 patients had 
SOFA score ranging from 0 to 17 points with median (IQR) of 4 (2 – 7) points. Old age 
(defined as the proportion aged over 60 years) and gender were not significantly different 
between three study sites. Differences in SOFA and APACHE II score of patients were 
statistically significant between NHTD and BMH in comparison with HTD but not 
statistically significant between NHTD and BMH. (Table 5 - 1). 
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Figure 5 – 1. Age distribution of enrolled patients 
5.3.2.2 Comorbidities 
There were 144 (38.5%) patients with a total of 200 comorbidities, of whom, 98 patients had 
one comorbidity, 42 patients had two comorbidities, and 6 patients had three comorbidities. 
The proportion of patients with comorbidities was significantly different between three study 
sites. The highest proportion of comorbidities were reported in patients admitted to Bach Mai 
hospital (73.8%), followed by NHTD (46.3%), and HTD (16.4%) (Table 5 – 1). The most 
common comorbidities were alcoholism (28%), diabetes mellitus 18%, and chronic 
pulmonary diseases (12%) (Figure 5 - 2). 
 
Figure 5 - 2. Proportion and type of comorbidities in study patients 
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Table 5 - 1. Patient characteristics by study site 
Demographics  Total  
(n=374) 
NHTD 
(n=161) 
BMH  
(n=61) 
HTD  
(n=152) 
P value1 P value2 P value3 
APACHE II score, 
median (IQR), 
mean ± SD 
10 (6 – 15), 
10.9 ± 6.0 
 11 (7 – 15), 
11.5 ± 6.1 
 13 (9.3 - 17), 
13.2 ± 5.3 
 8 (5 – 12), 
9.2 ± 5.8 
0.058a 0.001a <0.0005a 
SOFA score, 
median (IQR), 
mean ± SD 
 4 (2 – 7), 
5.1 ± 3.9 
 5 (3 – 9), 
6.3 ± 4.0 
 5.5 (3 – 7.3), 
5.9 ± 3.7 
 3 (1 – 5), 
3.7 ± 3.6 
0.754a <0.0005a <0.0005a 
Age, median 
(IQR), mean ± SD 
52 (38-64), 
51.8 ± 18.1 
 52 (42-62), 
52.0 ± 16.6 
 56 (42-67.5), 
55.1 ± 18.0 
50 (34-65.8), 
50.4 ± 19.5 
0.223a 0.354a 0.090a 
Ages > 60 years, n 
(%) 
119 (31.8) 47 (29.2) 23 (37.7) 49 (32.2) 0.258b 0.624b 0.522b 
Male gender, n (%) 267 (71.4) 116 (72.0) 42 (68.9) 109 (71.7) 0.623b 1.000b 0.739b 
Comorbidity, n (%) 144 (38.5) 74 (46.3) 45 (73.8) 25 (16.4) < 0.0005b < 0.0005b < 0.0005b 
Alcoholism, n (%) 56 (15.0) 42 (25.6) 13 (20.6) 1 (0.7) 0.492b < 0.0005b < 0.0005b 
Diabetes mellitus, 
n (%) 
35 (9.4) 14 (8.3) 14 (22.2)  7 (4.6) 0.007b 0.178b < 0.0005b 
Chronic pulmonary 
diseases, n (%) 
23 (6.1) 7 (4.2) 13 (20.6) 3 (2.0) < 0.0005b 0.338b < 0.0005b 
Immune 
deficiencyc, n (%) 
15 (4.0) 11 (6.5) 1 (1.6) 3 (2.0) 0.187b 0.053b 1.000b 
Cirrhosis, n (%) 11 (2.9) 10 (6.0) 0 1 (0.7) 0.065b 0.011b 1.000b 
1 NHTD and BMH, 2 NHTD and HTD, and 3 BMH and HTD; a Mann Whitney U test, b Fisher’s Exact 
test; c Including long term steroid use, chemotherapy, AIDS  
 
5.3.2.3 Medical factors before and at ICU admission 
In this study the majority (75.1%) of patients were transferred from other hospitals to the 
study sites. Proportions of transferred patients were statistically significant different between 
the three study sites. Transfer was particularly common at NHTD (88.8% of patients) and 
HTD (77%) as compared with BMH (34.4%). Most commonly patients first presented to 
provincial hospitals (46.3%), less commonly tertiary hospitals (15.8%). Twelve percent of 
patients were intubated before admission to the study sites, this was statistically significant 
higher at NHTD (21.7%) and BMH (11.5%) in comparison with at HTD (2.0%). Patients 
with a previous hospital admission or antibiotic use within 90 days before this illness 
accounted for 11.0% and 6.7% of all patients, respectively. 86.4% of patients already received 
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antibiotics on ICU admission: highest at NHTD (92.5%) and lowest at HTD (78.9%). (Table 
5 - 2). 
Table 5 - 2. Medical factors before and at ICU admission by study site 
Interventions Total  
(n = 374) 
NHTD  
(n = 161) 
BMH  
(n = 61) 
HTD  
(n = 152) 
P value1 P value2 P value3 
Inpatient in last 90 days, n 
(%) 
41  
(11.0) 
24  
(14.9) 
10  
(16.4) 
7  
(4.6) 
0.835 0.002 0.009 
Antibiotic use in past 90 days, 
n (%) 
25  
(6.7) 
12  
(7.5) 
8  
(13.1) 
5  
(3.3) 
0.197 0.135 0.011 
Hospital transfer for this 
illness, n (%) 
281 
(75.1) 
143  
(88.8) 
21  
(34.4) 
117  
(77.0) 
< 0.0005 0.006 < 0.0005 
Previous 
hospital type, 
n (%) 
Tertiary 59  
(15.8) 
51 
(31.7) 
2  
(3.3) 
6  
(3.9) 
   
Province 173  
(46.3) 
72  
(44.7) 
15  
(24.6) 
86  
(56.6) 
   
District 49  
(13.1) 
20  
(12.4) 
4  
(6.6) 
25  
(16.4) 
   
Intubated before admission to 
study site, n (%) 
45  
(12.0) 
35  
(21.7) 
7  
(11.5) 
3  
(2.0) 
0.088 < 0.0005 0.007 
Antibiotic use on ICU 
admissiona, n (%) 
323  
(86.4) 
149  
(92.5) 
54  
(88.5) 
120 
(78.9) 
0.420 0.001 0.119 
1 NHTD and BMH, 2 NHTD and HTD, and 3 BMH and HTD (Fisher’s Exact Test). 
a Excludes anti-tuberculous and anti-viral medication 
5.3.2.4 Admission diagnosis 
In this study, more than 90% of patients were admitted for an infectious disease. The most 
common reasons for admission were: tetanus (132 patients, 35.3%), pneumonia (73 patients, 
19.5%), central nervous system (CNS) infection (60 patients, 16.0%), septic shock (28 
patients, 7.5%), and sepsis (27 patients, 7.2%). The proportion of these diagnoses were 
different between the three study sites. Common diseases at NHTD were: pneumonia 
(29.8%), tetanus (22.4%), CNS infections (21.1%) and septic shock (16.1%). In BMH these 
were: pneumonia (29.5%), acute pancreatitis (16.4%), exacerbations of COPD and CNS non-
infections (both 13.1%). At HTD common diagnoses were: tetanus (63.2%), CNS infections 
(16.4%), and sepsis (7.2%). Pneumonia was common at NHTD and BMH, accounting for 
about 30% of patients, while it was just 4.6% at HTD. (Table 5 - 3). 
 92 
Table 5 - 3. Admission diagnosis by study site 
Admission diagnosis Total, n (%) NHTD, n (%) BMH, n (%) HTD, n (%) 
Tetanus 132 (35.3) 36 (22.4) 0  96 (63.2) 
Pneumonia 73 (19.5) 48 (29.8) 18 (29.5) 7 (4.6) 
CNS infections 60 (16.0) 34 (21.1) 1 (1.6) 25 (16.4) 
Septic shock 28 (7.5) 26 (16.1) 2 (3.3) 0 
Sepsis 27 (7.2) 12 (7.5) 4 (6.6) 11 (7.2) 
CNS non-infections 14 (3.7) 4 (2.5) 8 (13.1) 2 (1.3) 
Acute pancreatitis 10 (2.7) 0 10 (16.4) 0  
COPD 9 (2.4) 0 8 (13.1) 1 (0.7) 
Dengue  9 (2.4) 0 0 9 (5.9) 
Other illnesses 12 (3.2) 1 (0.6) 10 (16.4) 1 (0.7) 
Total  374 (100.0) 161 (100.0) 61 (100.0) 152 (100.0) 
CNS non-infections: 4 post brain operation, 3 coma/diabetes mellitus, 3 brain hemorrhage, 2 hepatic 
comas, 1 epilepsy, 1 spiral cord compression. 
Other illnesses: 3 myocardiac infarction, 2 acute renal failures, and 1 post cardiac valve replacement 
operation, 1 hepatic abscess, 1 malaria, and 1 unknown original fever, 1 after cardiac arrest, 1 
pulmonary artery thrombosis, 1 chest trauma with atelectasis.  
 
5.3.2.5 Characteristics of patients according to admission diagnosis 
The median APACHE II score at ICU admission ranged from 6 to 16 points between 
admission diagnoses. Low medians were seen in tetanus patients (6 points) and acute 
pancreatitis (9 points), the median of the other diagnoses were 12 points or higher with the 
highest was seen in COPD (16 points).  The median age ranged widely from 27 years in 
dengue patients to 66 years in COPD patients. Male gender accounted for more than 50% in 
most diagnoses, except in dengue where this was lower: 33.3%. The proportion of patients 
with a comorbidity ranged from 9.1% in tetanus up to 90% in acute pancreatitis.  Proportion 
of patients transferred from other hospitals to the study sites were widely different from 
22.2% in COPD to 92.9% in septic shock.  Antibiotic use was different between admission 
diagnosis: from 55.6% in dengue up to 100% in acute pancreatitis. For most admission 
diagnoses under one third of patients had tracheostomy during ICU stay with exception of 
tetanus and CNS infections, where the proportion having tracheostomy was 100% and 61.0% 
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respectively. A high proportion of patients used sedatives, ranged from 75.0% in CNS 
infections to 100% in septic shock, acute pancreatitis, and tetanus.  Neuromuscular paralysis 
was used in 86.4% of tetanus patients but under a quarter of patients with the other diagnoses.  
Steroid was used most commonly in CNS infections (68.3%), followed by pneumonia 
(54.8%), and septic shock (53.6%). The proportion of patients that used vasopressors ranged 
from 11.1% in COPD to 96.4% in septic shock. The median time patients spent on the 
ventilator ranged from 5 days in dengue up to 14 days in CNS infections, with the highest of 
17 days in tetanus. (Table 5 – 4). 
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Table 5 - 4. Participants’ characteristics and treatment according to admission diagnosis 
Admission 
diagnosis 
APACHE 
II, median 
(IQR) 
Age, 
median 
(IQR) 
Male 
gender, 
n (%) 
Co-
morbidity n 
(%) 
Hospital 
Transfer, 
n (%) 
Antibiotic 
on ICU 
admission, n 
(%) 
Trache-
ostomy, n 
(%) 
Sedative, 
n (%) 
Neuro-
muscular 
paralysis, n 
(%) 
Steroid, n 
(%) 
Vaso-
pressor, n 
(%) 
Ventilation 
days, median 
(IQR) 
Tetanus,  
n = 132 
6 
(3 – 8) 
52 
(41 – 67.5) 
103 
(78.0) 
12 
(9.1) 
107 
(81.1) 
121 
(91.7) 
132 
(100) 
132 
(100) 
114 
(86.4) 
6 
(4.5) 
17 
(12.9) 
17.5 
(13 – 24) 
Pneumonia,  
n = 73 
12 
(8 – 17) 
57 
(42 – 73.5) 
51 
(69.9) 
47 
(64.4) 
52 
(71.2) 
65 
(89.0) 
25 
(34.2) 
68 
(93.2) 
16 
(21.9) 
40 
(54.8) 
35 
(47.9) 
9 
(6 – 15.5) 
CNS infections, 
n = 60 
12 
(10 – 16) 
47.5 
(30.5– 56.8) 
42 
(70.0) 
18 
(30.0) 
52 
(86.7) 
44 
(73.3) 
37 
(61.7) 
45 
(75.0) 
6 
(10.0) 
41 
(68.3) 
14 
(23.3) 
14 
(7.3 – 33) 
Septic shock, 
n=28 
14 
(10.8 – 19) 
51.5 
(46 – 61.8) 
21 
(75.0) 
22 
(78.6) 
26 
(92.9) 
26 
(92.9) 
8 
(28.6) 
28 
(100.0) 
7 
(25.0) 
15 
(53.6) 
27 
(96.4) 
11.5 
(7 – 16) 
Sepsis,  
n = 27 
14 
(10 – 17) 
50 
(35 – 66) 
16 
(59.3) 
12 
(46.2) 
22 
(81.5) 
23 
(85.2) 
4 
(14.8) 
24 
(92.3) 
6 
(23.1) 
12 
(46.2) 
19 
(73.1) 
6 
(5 – 9) 
CNS non-
infections, 
 n= 14 
14 
(11.8– 19.8) 
57 
(25.8 – 65) 
8 
(57.1) 
9 
(64.3) 
7 
(50.0) 
10 
(71.4) 
4 
(28.6) 
13 
(92.9) 
1 
(7.1) 
4 
(28.6) 
3 
(21.4) 
6 
(4.8 – 9.8) 
Acute 
pancreatitis,  
n = 10 
9 
(5.8 – 12.3) 
49 
(40.5– 66.3) 
9 
(90) 
9 
(90.0) 
3 
(30.0) 
10 
(100) 
1 
(10.0) 
10 
(100) 
0 0 3 
(30.0) 
6 
(4.8 – 9.8) 
COPD,  
n = 9 
16 
(15 – 17) 
66 
(50 – 75.5) 
8 
(88.9) 
8 
(88.9) 
2 
(22.2) 
8 
(88.9) 
2 
(22.2) 
8 
(88.9) 
1 
(11.1) 
3 
(33.3) 
1 
(11.1) 
6 
(4.5 – 15) 
Dengue, 
 n = 9 
14 
(9.5 – 16) 
27 
(19.5– 34.5) 
3 
(33.3) 
1 
(11.1) 
6 
(66.7) 
5 
(55.6) 
0 8 
(88.9) 
1 
(11.1) 
3 
(33.3) 
7 
(77.8) 
5 
(4 - 10 
Other illnesses,  
n = 12 
11 
(10 – 16.5) 
54 
(39 – 63.8) 
6 
(50.0) 
6 
(50.0) 
4 
(33.3) 
11 
(91.7) 
0 10 
(83.3) 
0 3 
(25.0) 
4 
(33.3) 
7 
(4 – 9.3) 
Total, 
 n = 374 
10 
(6 – 15) 
52 
(38 – 64) 
267 
(71.4) 
144 
(38.7) 
281 
(75.1) 
323 
(86.4) 
213 
(57.0) 
346 
(93.0) 
152 
(40.9) 
127 
(34.1) 
130 
(34.9) 
12 
(6 – 22) 
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Tetanus patients accounted for almost one third of study patients and high requirement for 
neuromuscular blocking-agent paralysis. Therefore, analysis was carried out separately. All 
factors except for age and proportion transferred from other hospitals outlined earlier 
(demographic characteristics, comorbidities and factors before ICU admission) were 
statistically different between tetanus and non-tetanus patients (Table 5 – 5, Table 5 – 6, and 
Table 5 – 7). Though given the large number of factors tested, the significance of some of the 
observed variation such as in sex, immune deficiency and transfer from another hospital, 
should be considered with caution. Nevertheless due to the very distinct differences in 
pathology and treatment between tetanus patients and other patients analyses have been 
performed separately and as a whole group. 
Table 5 – 5. Demographic characteristics of tetanus and non-tetanus patients 
Risk factors Non-tetanus, n = 242 Tetanus, n = 132 Pa value 
SOFA, median (IQR), 
mean ± SD 
6 (4 – 9),  
6.8 ± 3.8 
2 (1 – 3),  
2 ± 1.5 
< 0.0005b 
APACHE II, median 
(IQR), mean ± SD 
13 (10 – 17),  
13.4 ± 5.3 
6 (3 – 8),  
6.3 ± 4.2 
< 0.0005b 
Age (years), median 
(IQR), mean ± SD 
51 (37 – 63.3),  
50.7 ± 18.0 
52 (41 – 67.5),  
53.9 ± 18.1 
0.202b 
Age (years) > 60 75 (31.0%) 44 (33.3%) 0.644 
<= 60  167 (69.0%) 88 (66.7%)  
Gender Male  164 (67.8%) 103 (78.0%) 0.042 
Female  78 (32.2%) 29 (22.0%)  
Comorbidity Yes 132 (55.0%) 12 (9.1%) < 0.0005 
No 108 (45.0%) 120 (90.9%)  
Alcoholic 
addiction 
Yes 54 (22.3%) 2 (1.5%) < 0.0005 
No 188 (77.7%) 130 (98.5%)  
Diabetes 
mellitus 
Yes 34 (14.0%) 1 (0.8%) < 0.0005 
No 208 (86.0%) 131 (99.2%)  
Chronic lung 
disease 
Yes 21 (8.7%) 2 (1.5%) 0.006 
No 220 (91.3%) 130 (98.5%)  
Immunity 
deficiency 
Yes 14 (5.8%) 1 (0.8%) 0.024 
No 228 (94.2%) 131 (99.2%)  
Cirrhosis Yes 11 (4.5%) 0 0.010 
No 231 (95.5%) 132  
a Fisher’s Exact Test unless otherwise stated, b Mann Whitney and Median Test. Missing: Non-tetanus 
SOFA 26, APACHE II 23; tetanus SOFA 18, APACHE II 10. 
 96 
Table 5 – 6. Medical factors before and at ICU admission of tetanus and non-tetanus 
patients 
Factors Non-tetanus, n = 242 Tetanus, n = 132 P valuea 
Inpatient in past 90 
days 
Yes 36 (14.9%) 5 (3.8%) 0.001 
No 206 (85.1%) 127 (96.2%)  
Antibiotic use in 
past 90 days 
Yes 22 (9.1%) 3 (2.3%) 0.015 
No 220 (90.9%) 129 (97.7%)  
Transfer from 
another hospital 
Yes  174 (71.9%) 107 (81.1%) 0.060 
No 68 (28.1%) 25 (18.9%)  
Intubation before 
admission 
Yes 40 (16.5%) 5 (3.8%) < 0.0005 
No 202 (83.5%) 127 (96.2%)  
AB in this illness on 
ICU admission 
Yes 202 (83.5%) 121 (91.7%) 0.028 
No 40 (16.5%) 11 (8.3%)  
a Fisher’s Exact Test 
Table 5 – 7. Treatment for tetanus and non-tetanus patients 
Treatment Non-tetanus, n = 242 Tetanus, n = 132 Pa value 
Sedatives Yes 214 (89.2%) 132 (100%) < 0.0005 
No 26 (10.8%) 0  
Neuromuscular paralysis Yes 38 (15.8%) 114 (86.4%) < 0.0005 
No 202 (84.2%) 18 (13.6%)  
Proton pump inhibitor Yes 206 (86.2%) 51 (38.6%) < 0.0005 
No 33 (13.8%) 81 (61.4%)  
Insulin Yes 83 (34.6%) 12 (9.1%) < 0.0005 
No 157 (65.4%) 120 (90.9%)  
Steroids Yes 121 (50.4%) 6 (4.5%) < 0.0005 
No 119 (49.4%) 126 (95.5%)  
Vasopressor  Yes 113 (47.1%) 17 (12.9%) < 0.0005 
No 127 (52.9%) 115 (87.1%)  
Hemodialysis Yes 50 (20.7%) 9 (6.8%) < 0.0005 
No 191 (79.3%) 123 (93.2%)  
Transfusion Yes 76 (31.8%) 9 (6.9%) < 0.0005 
No 163 (68.2%) 122 (93.1%)  
Tracheostomy Yes 81 (33.9%) 132 (100%) < 0.0005 
No 158 (66.1%) 0  
Thoracentesis Yes 26 (11.0%) 0 < 0.0005 
No 210 (89.0%) 132 (100%)  
Days on ventilator, median (IQR), 
mean ± SD 
8.5 (5 – 16),  
14.3 ± 15.7 
17.5 (13 – 24),  
20.2 ± 14.0 
< 0.0005b 
Days in ICU, median (IQR), mean 
± SD 
14 (9 – 27),  
21.5 ± 20.2 
26 (20 – 35),  
29.1 ± 16.0 
< 0.0005b 
a Fisher’s Exact Test unless otherwise stated, b Mann Whitney and Median Test 
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5.3.3 Ventilator-associated pneumonia (VAP) and ventilator-associated respiratory 
infections (VARI) 
5.3.3.1 VAP and VARI incidence 
In the study period, a total of 37/374 (9.9%) patients developed VAP. The VAP incidence in 
the 28 day follow up of the study period at NHTD, BMH, and HTD were 7.5%, 13.1%, and 
11.2% respectively. Time from beginning of ventilation to developing VAP ranged from 3 to 
26 days with a median (IQR) time of 10 (5.5 – 12) days (Table 5 - 8, Table 5 - 9). There were 
two patients with VAT presentation who then developed VAP after one and two weeks, both 
patients were treated with colistin and an anti-Pseudomonal carbapenem initially. 
Besides these VAP episodes, there were 55 other ventilator-associated respiratory infections 
(VARI), which included ventilator-associated pneumonia not fulfilling VAP criteria and 
ventilator-associated tracheobronchitis [See Chapter 2 section 2.3.4]. In total, there were 92 
VARI patients making the VARI incidence of 24.6% (92/374) in the study time follow up. 
There was no significantly difference in rates between study sites. (Table 5 – 8). 
The incidence density of VAP and VARI was 7.6 and 21.4 episodes per 1000 ventilation days 
respectively (Table 5 - 8). The incidence density of VAP per 1000 ventilation days was the 
highest at BMH (15.8 episodes) then HTD (8.1 episodes), and lowest at NHTD (5.2 
episodes). The incidence density was statistically significant between NHTD and BMH (p = 
0.036), though in the light of the other findings and the number of tests performed this may 
still be a chance finding. There was no statistically significant difference in VARI incidence 
density between the three sites. (Table 5 - 8). 
In total, mean (95% CI) and median (IQR) time for developing VARI from beginning of 
ventilation was 10.4 (9.2 – 11.6) days and 10 (6 – 14) days, respectively. Median time from 
beginning of ventilation to develop VAP and VARI was 10 days and 9 days, respectively, and 
this difference was not statistically significant (p = 0.752) (Table 5 - 9). 
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Table 5 - 8. Incidence & incidence density of VAP and VARI by Study Site 
VARI events Total 
(n=374) 
NHTD 
(n=161) 
BMH 
(n=61) 
HTD  
(n=152) 
P  
value1 
P  
value2 
P  
value3 
VAP, n (%) 37  
(9.9%) 
12  
(7.5%) 
8  
(13.1%) 
17  
(11.2%) 
0.197 0.330 0.814 
Other VARI, n (%) 55  
(14.7%) 
27  
(16.0%) 
5  
(8.2%) 
23  
(15.1%) 
0.183 0.826 0.290 
Total VARI, n (%) 92  
(24.6%) 
39  
(24.2%) 
13  
(21.3%) 
40  
(26.3%) 
0.725 0.698 0.488 
VAP incidence 
(episodes/1000 VD) 
7.6  
(37/4893) 
5.2  
(12/2286) 
15.8  
(8/507) 
8.1  
(17/2100) 
0.036 0.330 0.190 
VARI incidence 
(episodes/1000 VD) 
21.4  
(92/4304) 
19.4  
(39/2009) 
28.3  
(13/460) 
21.8  
(40/1835) 
0.311 0.683 0.503 
1 NHTD and BMH, 2 NHTD and HTD, and 3 BMH and HTD (All Fisher’s Exact Test).  
VD: ventilation days. 
Table 5 - 9. Time from initiation of ventilation to development of VAP or VARI 
Ventilator-associated 
events 
Ventilation time to evolving VAP/VARI (days) 
Mean (95% CI) Median (IQR)  Min – max 
VAP (n = 37) 10.0 (8.3 – 11.7) 10.0 (5.5 – 12.0)a 3.0 – 26.0 
VARI excluding VAP 
(n = 55) 
10.7 (9.0 – 12.4) 9 (6.0 – 15.0)a 2.0 - 27.0 
Total VARI (n = 92) 10.4 (9.2 – 11.6) 10 (6.0 -14.0) 2.0 – 27.0 
a p = 0.752, Mann Whitney U Test 
5.3.3.2. Risk factors for VARI 
Patient characteristics 
Due to the limited number of VAP cases and the shared aetiological pathway [37], risk factors 
for VARI as a whole rather than VAP were examined. Only the difference in the APACHE II 
score was statistically significant between patients with and without VARI (p = 0.022). (Table 
5 - 10). 
Table 5 - 10. Severity score, age and ventilation days at risk and VARI status 
Risk Factors  Non-VARI VARI P 
valuea  N Median (IQR) N Median (IQR) 
SOFA score 247 4 (3 – 7) 83 3 (2 – 6) 0.078 
APACHE II score 255 11 (7 -15) 86 8.5 (5 – 14) 0.022 
Age (years) 282 53 (39.8 – 65) 92 48 (36 – 61.8) 0.218 
Ventilation days at risk 282 9 (6 – 16) 92 10 (6 – 14) 0.470 
a Mann Whitney test 
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There were no differences in demographic factors between patients with and without VARI. 
(Table 5 - 11). 
Table 5 - 11. Impact of demographics and comorbidities on VARI 
Characteristics Total Non-VARI VARI patients P valuea 
N (%) n (%) OR (95% CI)  
Age (years) > 60 119 95 (79.8) 24 (20.2) 0.70 (0.41 – 1.18) 0.175 
<= 60  255 187 (73.3) 68 (26.7) Reference   
Gender Male  267 197 (73.8) 70 (26.2) 1.37 (0.80 – 2.36) 0.252 
Female  107 85 (79.4) 22 (20.6) Reference  
Comorbidity Yes 144 118 (81.9) 26 (18.1) 0.68 (0.38 – 1.19) 0.173 
No 228 162 (71.1)  66 (28.9) Reference  
Alcoholic 
addiction 
Yes 56 43 (76.8) 13 (23.2) 0.92 (0.47 – 1.79) 0.794 
No 318 239 (75.2) 79 (24.8) Reference  
Diabetes mellitus Yes 35 28 (80.0) 7 (20.0) 0.75 (0.32 – 1.77) 0.508 
No 339 254 (74.9) 84 (25.1) Reference  
Chronic lung 
disease 
Yes 23 20 (87.0) 3 (13.0) 0.44 (0.13 – 1.52) 0.193 
No 350 261 (74.6) 89 (25.4) Reference  
Study sites HTD 152 112 (73.7) 40 (26.3) 1.12 (0.67 – 1.86) 0.670 
BMH 61 48 (78.7) 13 (21.3) 0.85 (0.42 – 1.73) 0.648 
NHTD 161 122 (75.8) 39 (24.2) Reference  
a Univariate logistic regression 
Medical factors before and on ICU admission 
Antibiotic use and hospital admission in the previous 90 days, transfer from another hospital, 
and intubation prior to admission to study ICU, and antibiotic use on ICU admission were 
also investigated for VARI risk. None of these factors was associated with a statistically 
significant difference in VARI incidence. (Table 5 - 12). 
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Table 5 - 12. Effects of medical factors before and on ICU admission on VARI 
Risk factors  Total,  
n 
No VARI, 
n (%) 
VARI, n 
(%) 
OR (95% CI) P valuea 
Inpatient in 
previous 90 days 
Yes 41 34 (82.9) 7 (17.1) 0.60 (0.26 – 1.41) 0.240 
No 333 248 (74.5) 85 (25.5) Reference  
Antibiotic use in 90 
days 
Yes 25 21 (84.0) 4 (16.0) 0.57 (0.19 – 1.69) 0.307 
No 349 261 (74.8) 88 (25.2) Reference  
Transfer from 
another hospital 
Yes  281 212 (75.4) 69 (24.6) 0.99 (0.58 – 1.71) 0.973 
No 93 70 (75.3) 23 (24.7) Reference  
Type of previous 
hospital 
Tertiary 59 44 (74.6) 15 (25.4) 1.05 (0.44 – 2.52) 0.911 
Province 173 130 (75.1) 43 (24.9) 1.02 (0.49 – 2.13) 0.958 
District 49 37 (75.5) 12 (24.5) Reference  
Intubation before 
admission 
Yes 45 35 (77.8) 10 (22.2) 0.86 (0.41 – 1.81) 0.693 
No 329 247 (75.1) 82 (24.9) Reference  
Antibiotic use on 
ICU admission 
Yes 323 245 (75.9) 78 (24.1) 0.84 (0.43 – 1.64) 0.611 
No 51 37 (72.5) 14 (27.5) Reference  
a Univariate logistic regression 
 
Admission diagnosis and VARI incidence  
Risks for VARI were statistically significant different between admission diagnoses. Patients 
with septic shock, tetanus, and acute pancreatitis patients had statistically higher risk of VARI 
than pneumonia patients with odds ratio of 4.47, 5.39, and 6.29 respectively. (Table 5 - 13) 
Table 5 - 13. Admission diagnosis and VARI 
Diagnosis Total, n No VARI, 
 n (%) 
VARI,  
n (%) 
OR (95% CI) P valuea 
Septic shock 28 19 (67.9) 9 (32.1) 4.47 (1.47 – 13.58) 0.008 
Tetanus 132 84 (63.6) 48 (36.4) 5.39 (2.29 – 12.68) < 0.0005 
Acute pancreatitis 10 6 (60.0) 4 (40.0) 6.29 (1.42 – 27.77) 0.015 
Chronic obstructive 
pulmonary diseases 
9 6 (66.7) 3 (33.3) 4.71 (0.96 – 23.12) 0.056 
CNS infections 60 49 (81.7) 11 (18.3) 2.12 (0.77 – 5.85) 0.149 
Other illnesses 12 9 (75.0) 3 (25.0) 3.14 (0.69 – 14.39) 0.140 
Sepsis 27 25 (92.6) 2 (7.4) 0.75 (0.15 – 3.88) 0.736 
CNS non-infections 14 12 (85.7) 2 (14.3) 1.57 (0.29 – 8.50) 0.600 
Dengue 9 6 (66.7) 3 (33.3) 4.71 (0.96 – 23.12) 0.056 
Pneumonia 73 66 (90.4) 7 (9.6) Reference   
Total patients, n (%) 374 282 (75.4) 92 (24.6)   
a Univariate logistic regression  
CNS non-infections: 4 post brain operation, 3 coma/diabetes mellitus, 3 brain hemorrhage, 2 hepatic 
comas, 1 epilepsy, 1 spiral cord compression. Other illnesses: 3 myocardiac infarction, 2 acute renal 
failures, and 1 post cardiac valve replacement operation, 1 hepatic abscess, 1 malaria, and 1 unknown 
original fever, 1 after cardiac arrest, 1 pulmonary artery thrombosis, 1 chest trauma with atelectasis. 
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Treatment and VARI incidence 
Patients using steroids, had a lower incidence of VARI with an odds ratio of 0.58 (95% CI 
0.34 – 0.98; p = 0.042).  Other treatments associated with a significant higher incidence of 
VARI were: neuromuscular paralysis (odds ratio 2,9; 95% CI 1.78-4.72) and tracheostomy 
(odds ratio 1.74; 95% CI1.08 – 2.82) (Table 5 - 14). These differences in risk were thought to 
be possibly due to difference in primary diagnosis and therefore further analysis was 
conducted, comparing risk factors in tetanus and non-tetanus patients (section 5.3.3.3). 
Table 5 - 14. Treatments prescribed and VARI 
Treatment Total, 
n 
No VARI, 
n (%) 
VARI, 
n (%) 
OR (95% CI) P valuea 
Sedatives Yes 346 257 (74.3) 89 (25.7) 4.16 (0.96 – 17.94) 0.056 
No 26 24 (92.3) 2 (7.7) Reference  
Neuromuscular 
paralysis 
Yes 152 97 (63.8) 55 (36.2) 2.90 (1.78 – 4.72) < 0.0005 
No 220 184 (83.6) 36 (16.4) Reference  
Proton pump 
inhibitors 
Yes 257 196 (76.3) 61 (23.7) 0.87 (0.53 – 1.45) 0.594 
No 114 84 (73.7) 30 (26.3) Reference  
Insulin Yes 95 73 (76.8) 22 (23.2) 0.91 (0.53 – 1.57) 0.732 
No 277 208 (75.1) 69 (24.9) Reference  
Steroids Yes 127 104 (81.9) 23 (18.1) 0.58 (0.34 – 0.98) 0.042 
No 245 177 (72.2) 68 (27.8) Reference  
Vasopressor  Yes 130 95 (73.1) 35 (26.9) 1.22 (0.75 – 2.00) 0.419 
No 242 186 (76.9) 56 (23.1) Reference  
Hemodialysis Yes 59 42 (71.2) 17 (28.8) 1.29 (0.69 – 2.40) 0.421 
No 314 239 (76.1) 75 (23.9) Reference  
Transfusion Yes 85 63 (74.1) 22 (25.9) 1.11 (0.64 – 1.94) 0.703 
No 285 217 (76.1) 68 (23.9) Reference  
Tracheostomyb Yes 189 133 (70.4) 56 (29.6) 1.74 (1.08 – 2.82) 0.023 
No 185 149 (80.5) 36 (19.5) Reference  
Thoracentesis Yes 26 17 (65.4) 9 (34.6) 1.70 (0.73 – 3.96) 0.219 
No 341 260 (76.2) 81 (23.8) Reference  
a Univariate logistic regression 
b Tracheostomy considered as a risk factor for VARI only if performed at least 2 days before VARI 
developed.  
 
5.3.3.3 Risk factor for VAP/VARI in non-tetanus and tetanus patients 
In this study, tetanus patients were the largest number (132 patients), accounting for more 
than one third of the study population (35.3%) and nearly double the number of pneumonia 
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patients (73 patients), the second largest number of patients divided by admission diagnosis. 
Severe tetanus patients are commonly considerably different to patients with other admission 
diagnoses in terms of the time on mechanical ventilation, lower age and less comorbidities 
(Table 5-4). Patients require supportive treatment and uniquely long periods of muscle 
relaxant and high sedation compared to other patient groups. In addition the underlying 
disease process is often seen as an isolated dysfunction of the musculoskeletal system rather 
than a multisystem disorder such as sepsis.  Because of these differences between tetanus 
patients and the other patients, tetanus and non-tetanus patients were separately analysised to 
find risk factors for VARI. 
VARI incidence between non-tetanus and tetanus patients 
VAP incidence in tetanus patients (10.5%) was higher as compared to non-tetanus patients 
(9.5%), with incidence density of VAP per 1000 ventilation days at risk in tetanus patients of 
6.4 episodes versus 8.5 episodes in non-tetanus patients (p = 0.499, Table 5 - 15). In contrast, 
other VARI (without VAP) and total VARI incidence, and incidence density in tetanus 
patients were higher than in non-tetanus patients. In univariate logistic regression, tetanus 
patients had increased risk of VARI with an OR of 2.53 (95% CI 1.56 – 4.09) compared to 
non-tetanus patients (p < 0.0005) (Table 5 - 15).  
SOFA, APACHE II score and ventilation days at risk in non-tetanus and tetanus 
patients 
There was no significant difference in age, SOFA score and APACHE II score between 
VARI and non-VARI patients in both tetanus and non-tetanus group. In non-tetanus patients, 
the median ventilation days at risk (days on ventilator while patients in current ICU without 
VARI) in VARI patients (10.5 days) was longer than that (7 days) in non-VARI patients, but 
this difference did not reach statistical significance (p=0.089). Whereas, in tetanus group the 
median ventilation days at risk in VARI patients (8.5 days) was statistically significantly 
different from that in non-VARI patients (15 days, p < 0.001).  (Table 5 - 16) 
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Impact of Demographics on VARI in non-tetanus and tetanus patients 
There was no significant difference in VARI incidence between gender, age group, or having 
a comorbidity when analysed by non-tetanus and tetanus groups. In the non-tetanus group, the 
VARI incidence was not significantly different between the study sites. In the tetanus group, 
VARI incidence at HTD (31.2%) was lower than at NHTD (50%) with OR (95% CI) 0.46 
(0.21 – 0.995) and p = 0.048. (Table 5 - 17). 
Medical factors before and on ICU admission 
Patients with history of hospital admission and antibiotic use in past 90 days, transfer from 
other hospital to the study sites, type of transfer hospitals, intubation before admission, and 
antibiotics use at ICU admission had no significant differences in VARI incidence in 
comparison with patients without these in both non-tetanus and tetanus group. (Table 5 - 18). 
Treatment and VARI incidence in non-tetanus and tetanus patients 
In non-tetanus patients, thoracocentesis was the only factor significantly associated with 
increased risk for VARI with odds ratio of 2.74 (95% CI 1.13 – 6.66). In tetanus patients, only 
vasopressor use was significantly associated with a higher VARI incidence compared to those 
not using vasopressors, (odds ratio 2.90, 95% CI 1.02 – 8.20). The statistically significant 
effect of steroid use and tracheostomy for VARI incidence overall were not seen when in both 
non-tetanus and tetanus patients separately. (Table 5 - 19) It should be noted that only 6 
patients with tetanus were treated with steroids. 
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Table 5 - 15. VAP/VARI incidence and incidence density among non-tetanus and tetanus patients at each site 
VARI Non-Tetanus Tetanus P value1 
NHTD  
(n = 125) 
BMH  
(n = 61) 
HTD  
(n = 56) 
Total 
(n = 242) 
NHTD  
(n = 36) 
BMH  
(n = 0) 
HTD  
(n = 96) 
Total 
(n = 132) 
VAP, n (%) 9 (7.2%) 8 (13.1%) 6 (10.7%) 23 (9.5%) 3 (8.3%)  11 (11.5%) 14 (10.6%) 0.894 
Other VARI, n (%) 12 (9.6%) 5 (8.2%) 4 (7.1%) 21 (8.7%) 15 (41.7%)  19 (19.8%) 34 (25.8%) < 0.0005 
Total VARIa, n (%) 21 (16.8%) 13 (21.3%) 10 (17.9%) 44 (18.2%)a 18 (50%)  30 (31.2%) 48 (36.4%)a 0.0016 
VAP incidence (episodes/1000 VD) 5.6  15.8 9.8  8.5  4.3  7.4 6.4 0.4999 
VARI incidence (episodes/1000 VD) 13.9  28.3  18.2  17.5 35.9   23.3 26.9 0.0433 
1 comparison tetanus and non-tetanus patients in total (Fisher’s Exact Test). a OR (95% CI) of total VARI incidence in tetanus and non-tetanus was 2.53 (1.56 – 4.09)  
  p < 0.0005 (univariate logistic regression). VD: ventilation days. 
Table 5 - 16. SOFA, APACHE II score, ventilation day at risk and VARI status 
Risk factors Non-Tetanus Tetanus 
No VARI VARI P valuea No VARI VARI P valuea 
N Median (IQR),  N Median (IQR),  
 
N Median (IQR),  
 
N Median (IQR),  
 
Age (years) 198 52 (37 – 64),  
 
44 48 (32 – 62.3),  
 
0.259 84 54 (41.5 – 68),  
 
48 49 (41 – 61.8),  
 
0.333 
SOFA score 176 6 (3 – 9),  
 
40 6.5 (5 – 11),  
 
0.136 71  2 (1 – 3),  
 
43 2 (1 – 3),  
 
0.998 
APACHE II score 177 13 (10 – 17),  
 
42 13 (10 – 17.3),  
 
0.484 78 7 (3 – 9),  
 
44 5 (2.3 – 7.8),  
 
0.089 
Ventilation days at riskc 198 7.5 (5 – 13),   44 
10.5 (6 – 14)b,  
 0.092 84 
15 (10 – 21.3),  
 48 
8.5 (6 – 14.5)b,  
 < 0.0005 
a Mann Whitney U Test, b Ventilation days at risk for VARI between tetanus and non-tetanus patients was not statistically significant difference with p = 0.445a, c days on 
ventilator while patients in current ICU without VARI. 
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Table 5 - 17. Comparison of demographics in patients with and without VARI by tetanus status 
Characteristics Non-tetanus  Tetanus  
Risk factors Total, n  No VARI,  
n (%) 
VARI,  
n (%) 
OR (95% CI) P valuea Total, n  No VARI,  
n (%) 
VARI,  
n (%) 
OR (95% CI) P valuea 
Age (years) > 60 75 64 (85.3) 11 (14.7) 0.70 (0.33 – 1.47) 0.344 44 31 (70.5) 13 (29.5) 0.64 (0.29 – 1.40) 0.251 
<= 60  167 134 (80.2) 33 (19.8) Reference  88 53 (60.2) 35 (39.8) Reference  
Gender Male  164 135 (82.3) 29 (17.7) 0.90 (0.45 – 1.80) 0.771 103 62 (60.2) 41 (39.8) 2.08 (0.81 – 5.31) 0.126 
Female  78 63 (80.8) 15 (19.2) Reference  29 22 (75.9) 7 (24.1) Reference  
Comorbidity Yes 132 109 (82.6) 23 (17.4) 0.87 (0.45 – 1.68) 0.688 12 9 (75.0) 3 (25.0) 0.56 (0.14 – 2.16) 0.396 
 No 108 87 (80.6) 21 (19.4) Reference  120 75 (62.5) 45 (37.5) Reference  
Alcoholic 
addiction 
Yes 54 42 (77.8) 12 (22.2) 1.39 (0.66 – 2.94) 0.384 2 1 (50.0) 1 (50.0) 1.77 (0.11 – 28.89) 0.690 
No 188 156 (83.0) 32 (17.0) Reference  130 83 (63.8) 47 (36.2) Reference  
Diabetes 
mellitus 
Yes 34 27 (79.4) 7 (20.6) 1.20 (0.49 – 2.96) 0.695 1 1 (100.0) 0 0.000 1.000 
No 208 171 (82.2) 37 (17.8) Reference  131 83 (63.4) 48 (36.6) Reference  
Chronic lung 
disease 
Yes 21 18 (85.7) 3 (14.3) 0.73 (0.21 – 2.59) 0.623 2 2 (100.0) 0 0.000 0.999 
No 220 179 (81.4) 41 (18.6) Reference  130 82 (63.1) 48 (36.9) Reference  
Study sites HTD 56 46 (82.1) 10 (17.9) 1.08 (0.47 – 2.47) 0.821 96 66 (68.8) 30 (31.2) 0.46 (0.21 – 0.995) 0.048 
BMH 61 48 (78.7) 13 (21.3) 1.34 (0.62 – 2.90) 0.456 0     
NHTD 125 104 (83.2) 21 (16.8) Reference  36 18 (50.0) 18 (50.0) Reference  
a Univariate logistic regression 
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Table 5 - 18. Univariate analysis of relationship between interventions before ICU admission and VARI 
Risk factors Non-Tetanus Tetanus 
Total 
(n) 
No VARI, n 
(%) 
VARI n 
(%) 
OR  
(95% CI) 
P 
valuea 
Total 
(n) 
No VARI, n 
(%) 
VARI, n  
(%) 
OR  
(95% CI) 
P 
valuea 
Inpatient 90 days 
prior 
Yes 36 31 (86.1) 5 (13.9) 0.69 (0.25 – 1.89) 0.471 5 3 (60.0) 2 (40.0) 1.17 (0.19 – 7.28) 0.863 
No 206 167 (81.1) 39 (18.9) Reference  127 81 (63.8) 46 (36.2) Reference  
Antibiotic use in 
90 days 
Yes 22 19 (86.4) 3 (13.6) 0.69 (0.20 – 2.44) 0.564 3 2 (66.6) 1 (33.3) 0.87 (0.08 – 9.88) 0.912 
No 220 179 (81.4) 41 (18.6) Reference  129 82 (63.6) 47 (36.4) Reference  
Transfer from 
another hospital 
Yes  174 143 (82.2) 31 (17.8) 0.92 (0.45 – 1.88) 0.813 107 69 (64.5) 38 (35.5) 0.83 (0.34 – 2.02) 0.779 
No 68 55 (80.9) 13 (19.1) Reference  25 15 (60.0) 10 (40.0) Reference  
Referral hospital 
type 
Tertiary 53 41 (77.4) 12 (22.6) 1.23 (0.38 – 3.95) 0.729 6 3 (50.0) 3 (50.0) 2.29 (0.37 – 14.25) 0.376 
Province 96  81 (84.4) 15 (15.6) 0.78 (0.25 – 2.38) 0.660 77 49 (63.6) 28 (36.4) 1.31 (0.48 – 3.56) 0.601 
District 26 21 (80.8) 5 (19.2) Reference   23 16 (69.6) 7 (30.4) Reference  
Intubation before 
admission 
Yes 40 31 (77.5) 9 (22.5) 1.39 (0.61 – 3.17) 0.440 5 4 (80.0) 1 (20.0) 0.43 (0.05 – 3.92) 0.451 
No 202 167 (82.7) 35 (17.3) Reference  127 80 (63.0) 47 (37.0) Reference  
AB in this illness 
on ICU 
admission 
Yes 202 167 (82.7) 35 (17.3) 0.72 (0.32 – 1.65) 0.440 121 78 (64.5) 43 (35.5) 0.66 (0.19 – 2.30) 0.515 
No 40 31 (77.5) 9 (22.5) Reference  11 6 (54.5) 5 (45.5) Reference  
a Univariate logistic regression 
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Table 5 - 19. Treatments prescribed and VARI in non-tetanus and tetanus patients 
 Non-Tetanus Tetanus 
Treatment Total, 
n 
No VARI, 
n (%) 
VARI, 
 n (%) 
OR (95% CI) P valuea Total, n No VARI, 
n (%) 
VARI, 
 n (%) 
OR (95% CI) P 
valuea 
Sedatives Yes 214 173 (80.8) 41 (19.2) 2.84 (0.65 – 12.52) 0.167 132 84 (63.6) 48 (36.4)   
No 26 24 (92.3) 2 (7.7) Reference  0 0 0   
Neuromuscular 
paralysis 
Yes 38 27 (71.1) 11 (28.9) 2.16 (0.98 – 4.80) 0.057 114 70 (61.4) 44 (38.6) 2.20 (0.68 – 7.11) 0.188 
No 202 170 (84.2) 32 (15.8) Reference  18 14 (77.8) 4 (22.2) Reference  
Proton pump 
inhibitor 
Yes 206 167 (81.1) 39 (18.9) 1.69 (0.56 – 5.10) 0.349 51 29 (56.9) 22 (43.1) 1.61 (0.78 – 3.31) 0.201 
No 33 29 (87.9) 4 (12.1) Reference  81 55 (67.9) 26 (31.1) Reference  
Insulin Yes 83 65 (78.3) 18 (21.7) 1.46 (0.75 – 2.87) 0.270 12 8 (66.7) 4 (33.3) 0.86 (0.25 – 3.03) 0.819 
No 157 132 (84.1) 25 (15.9) Reference  120 76 (63.3) 44 (36.7) Reference  
Steroids Yes 121 100 (82.6) 21 (17.4) 0.93 (0.48 – 1.79) 0.819 6 4 (66.7) 2 (33.3) 0.87 (0.15 – 4.93) 0.875 
No 119 97 (81.5) 22 (18.5) Reference  126 80 (63.5) 46 (36.5) Reference  
Vasopressor  Yes 113 88 (77.9) 25 (22.1) 1.72 (0.88 – 3.36) 0.111 17 7 (41.2) 10 (58.8) 2.90 (1.02 – 8.20) 0.045 
No 127 109 (85.8) 18 (14.2) Reference  115 77 (67.0) 38 (33.0) Reference  
Hemodialysis Yes 50 38 (76.0) 12 (24.0) 1.57 (0.74 – 3.33) 0.240 9 4 (44.4) 5 (55.6) 2.33 (0.59 – 9.12) 0.226 
No 191 159 (83.2) 32 (16.8) Reference  123 80 (65.0) 43 (35.0) Reference  
Transfusion Yes 76 60 (78.9) 16 (21.1) 1.34 (0.67 – 2.68) 0.401 9 3 (33.3) 6 (66.7) 3.95 (0.94 – 16.61) 0.061 
No 163 136 (83.4) 27 (16.6) Reference  122 81 (66.4) 41 (33.6) Reference  
Tracheostomy Yes 57 49 (86.0) 8 (14.0) 0.68 (0.29 – 1.55) 0.355 132 84 (63.6) 48 (36.4)   
No 185 149 (80.5) 36 (19.5) Reference  0 0 0   
Thoracentesis Yes 26 17 (65.4) 9 (34.6) 2.74 (1.13 – 6.66) 0.026 0 0 0   
No 210 176 (83.8) 34 (16.2) Reference  132 84 (63.6) 48 (36.4)   
 a Univariate logistic regression 
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5.4 Discussion 
This study is the largest study on VAP/VARI in Vietnam, including a general ICU in the 
largest hospital in Hanoi (BMH) and two ICUs in teaching referral hospitals in Hanoi and Ho 
Chi Minh city specializing in infectious diseases. The results of this study supply the data to 
depict a more detailed picture of VAP/VARI in Vietnamese ICUs and play an important part 
in planning strategies to limit and manage VAP/VARI as well as other HAI in ICUs in 
Vietnam. 
5.4.1 VAP and VARI incidence 
Although incidence density is believed to be a better marker of VAP occurrence (correcting 
for different days at risk), both incidence and incidence density are reported here to be 
comparable with other studies. In current study, VAP incidence was 9.9% and incidence 
density was 7.6 episodes per 1000 ventilation days (Table 5 – 8), these are considerably lower 
than those reported from some previous studies in Vietnamese ICUs. The author, with 
colleagues, has previously reported VAP incidence of 17.4% and VAP incidence density of 
11.7 episodes/1000 ventilation days at NHTD in 2012 [118]. Truong Anh Thu et al. surveyed 
at Bach Mai Hospital in 2008 – 2009, reporting VAP incidence of 18.9% and VAP incidence 
density of 27.4 episodes/1000 ventilation days [119]. Recently, a report by Tran Huu Thong 
et al from a trial to evaluate the efficacy of subglottic tracheal tube suction in comparison with 
standards tracheal tubes to prevent VAP at Bach Mai Hospital in 2009 – 2013 showed a high 
VAP incidence, 56.6% and 39.0% in patients intubated with traditional tracheal tube and 
subglottic tracheal tube respectively [121].  
The VAP incidence density in this study is also substantially lower than pooled VAP density 
of other developing countries, 22.9 episodes/1000 ventilation days in a systematic review by 
Allegranzi et al in 2011 [10] or 17.2 episodes/1000 ventilation days in an international 
multicentre study by Rosenthal et al in 2012 [175]. The incidence in this study is even lower 
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than that in some developed countries, 7.9 episodes/1000 ventilation days as in a report of 
WHO in 2011 [1].  
This difference could be explained largely by the VAP criteria used in these studies. All the 
other studies used different VAP diagnosis criteria (most of them were CDC criteria for 
diagnosis VAP in 2008 [2008 CDC criteria] [13]) to that used in this study which is CDC 
criteria for VAP in 2013 (2013 CDC criteria) [23]. The main difference is that the 2013 
criteria require firstly a deterioration in respiratory status after a period of improvement or 
stability. This initial criterion in the 2013 CDC criteria is intended to identify VAP patients 
with poor respiratory function, through their need for increased ventilation support (FiO2 and 
PEEP) to achieve adequate oxygenation. Thus deterioration in lung function resulting from 
lung infection requires an increase in FiO2 or PEEP to achieve adequate oxygenation. 
However, in mechanically ventilated patients with normal premorbid lung function, as seen in 
many patients with encephalitis and tetanus, it is likely that substantial damage to the lung is 
required to decrease oxygenation to a level at which there is a need to increase FiO2 or PEEP 
to secure adequate oxygenation. In this situation, treating physicians usually recognize the 
presence of VAP through infectious symptoms and more subtle decline in lung function, for 
example patients presenting with fever, increased sputum, decrease in respiratory function 
demonstrated by a decline in PaO2/FiO2 ratio. Another reason for potential low sensitivity of 
the 2013 CDC criteria for recognition of VAP in resource poor settings is the restricted ability 
to closely monitor arterial oxygen partial pressure and thus tailor ventilator settings to this. 
For example it is common for Vietnamese physicians have to set FiO2 to around 40% to be 
sure of adequate oxygenation in as patients who are only monitored with pulse oximetry. 
Furthermore old ventilators with inaccurate flow and pressure metres are also set 
conservatively to ensure patient safety in a setting with limited monitoring capacity and low 
nurse : patient ratios.  Consequently, in patients with normal lung function if VAP were to 
develop, it would take a large reduction in PaO2 to bring oxygen saturations to a level that 
would need a change in FiO2 or PEEP and meet the 2013 CDC criteria. In clinical practice, 
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physicians commonly recognize this situation early and carry out diagnostic procedures and 
give empiric antibiotic treatment. In our series, VARI incidence and incidence density were 
similar to reported rates of VAP, and therefore it is possible that many of these patients would 
have met CDC criteria if given Western levels of monitoring and equipment to allow more 
careful ventilator adjustment. This point was further supported by the finding that the median 
(IQR) ventilation time in ICU to developed VAP and VARI were almost the same 10 days 
(Table 5 - 9). In conclusion, it seems likely that many patients that would have been 
diagnosed with VAP using the older CDC criteria are not recognized by the 2013 CDC 
criteria. In our study there were 41 patients among 55 ‘other VARI’ patients who were 
diagnosed with pneumonia by the treating physician. All these patients were treated under 
name other VARI and none of them progressed to VAP. We did not design to collect chest x-
ray data for this phenomenon so we could not determine these patients developed pneumonia 
or VAT. 
Low sensitivity of the 2013 CDC criteria to identify VAP has been found by other studies.  
Wallace et al found that there was a discrepancy in identify VAP among different systems. 
VAP incidence (episodes/1000 ventilation days) by CPIS (36.3), HELICS (22.2), 2008 CDC 
criteria (15.2), and clinical diagnosis (15.2) was much higher VAP incidence found by 2013 
CDC criteria (1.1) [177]. Ego et al. used six different systems for VAP identify among 91 
patients also found that VAP incidence identified by 2013 CDC criteria (9.9%) was 
considerable low than CPIS (41.8%) and 2008 CDC criteria (23.1%) [178]. Waltrick et al. 
used parallel CPIS and 2013 CDC criteria to identify VAP in a prospective observational 
study at two general ICUs from August 2013 to June 2014 [179].  In this study, there were 
168 patients ventilated for > 48 hours in the study period, of which 38 patients were 
diagnosed VAP by CPIS and 14 patients diagnosed by novel CDC 2013, all these 14 patients 
included in 38 VAP patients diagnosed by CPIS. Chang et al. used the 2013 CDC criteria 
retrospectively to identify VAP among 165 conventionally diagnosed VAP patients from 
April 2010 to February 2014 in five ICUs of regional teaching hospitals in Taiwan [180]. This 
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study found that just 12.1% (20/165) and 1.2% (2/165) of patients diagnosed VAP by the 
conventional VAP criteria (combination of clinical, radiology, and microbiology criteria) 
were diagnosed as possible and probable VAP by 2013 CDC criteria, respectively. Summary 
main results of these studies are presented in Table 5 – 20.  
Table 5 - 20. Summary of results from studies describing differences in VAP incidence 
depending on criteria used 
Author CPIS CDC/NSHN 
PNU1 
(2008) 
ACCP New 
CDC/NHSN 
(probable 
VAP) 
HELICS Johanson 
Criteria 
Clinical 
VAP 
Ego et al. [178], %  
(n) 
41.8  
(38) 
23.1  
(21) 
17.6 
(16) 
9.9  
(9) 
11.0  
(10) 
4.4  
(4) 
 
Wallace et al. [177], 
episodes/1000 VD 
36.3  15.2  1.1 22.2  15.2 
Waltrick et al. [179], 
% (episodes/1000 
VD) 
22.6  
(13.1) 
  8.3  
(5.2) 
   
VD: ventilation days 
Another reason for this low incidence could be that there was genuinely lower incidence of 
VAP in our study sites, for example due to infection control improvement in the study 
hospitals over time. At all study sites over this period the research focus and aim of the 
hospital management has been to reduce HAI, with VAP being a particular target. Increased 
knowledge amongst hospital staff and improved awareness of prevention measures may have 
had a significant effect.  In addition daily following patients for VAP and discussion of CDC 
criteria may have reduced antibiotic prescription and clinical diagnoses of VAP/ VARI. Two 
previous studies in one of the study site hospitals (BMH) showed a decreased incidence over 
time, from 34.7 episodes/ 1000 ventilator days in 2002 - 2003 to 27.4 episodes in 2008 - 2009 
[116, 119]. Although there was a report showed that VAP incidence density in NHTD in 2012 
was 11.7 episodes/1000 ventilation days [118], a decrease of about 4 episodes/1000 
ventilation days from 11.7 episodes to 7.6 episodes/1000 ventilation days in one year is hard 
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to believe because in two previous studies it just decrease 7.3 episodes over 5 year period. 
This supports more for above hypothesis that new CDC criteria for VAP diagnosis could be 
less sensitive and miss some VAP cases comparing with old CDC criteria. 
5.4.2 Risk factors for VARI  
In current study there were significant differences in VARI incidence and incidence density 
between patients with different admission diagnoses. Septic shock, tetanus, and acute 
pancreatitis patients had statistically higher risk for VARI than pneumonia patients (Table 5 – 
13). This study also found that neuromuscular paralysis use, steroid, and tracheostomy were 
associated with VARI incidence. However, it is unusual and out of keeping with published 
studies [3, 181] that steroid use showed protective effect on VARI incidence, whilst 
tracheostomy resulted in a higher risk for VARI (Table 5 – 14). A further unusual finding was 
that APACHE II score in VARI patients was statistically lower than non-VARI patient (Table 
5 – 10). Whereas Vincent et al. found that patients with higher severity level and 
immunosuppression had higher rate of infection than patients without these [167]. These 
counter-intuitive findings were suspected to relate to the high proportion of tetanus patients in 
our study population. Severe tetanus usually needs ventilation for a long time, about 3 weeks 
or more on ventilation with further support leading to 4 – 6 weeks in ICU overall. 
Subsequently risk factors were analyzed separately for tetanus patients and the rest (non-
tetanus patients). 
There was statistically significant higher risk of VARI in tetanus patients than in non-tetanus 
patients (Table 5 – 15, Figure 5 – 3). Higher VARI incidence in tetanus patients could be 
explained by two main things. Firstly, severe tetanus patients take a long time on ventilation, 
commonly three to four weeks, this is considerable longer than other diseases (Table 5 – 4). 
This obviously puts tetanus patients at higher risk for VARI than other diseases. Whilst 
incidence density attempts to correct for the time on ventilation, it seems plausible that risk 
increases with duration of ventilation as bacteria are able to colonize further into the airway. 
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Data on second episodes of VAP/ VARI were not collected and it is possible that incidence 
density may be even higher in tetanus patients as they are more likely to have multiple 
episodes than those who are ventilated for shorter periods.  
Treatment of tetanus involves routine tracheostomy and muscle relaxant use in those who are 
ventilated therefore it is not surprising that these are also associated with high incidence of 
VARI. It is possible that it is these treatments increase the risk of VARI in themselves – 
tracheostomy by providing a shorter access for pathogens to the lower respiratory tract and 
muscle relaxants/sedatives due to the impaired cough sputum clearance. As tetanus patients 
who are ventilated all receive these interventions and we did not collect data about the 
temporal relationship of these interventions to VARI, it is not possible from our data to 
ascertain whether tetanus itself or its treatment is most linked to VARI. The use of 
vasopressors in tetanus was significantly related to VARI but their use is indicative of severe 
disease with longer periods of mechanical ventilation and therefore it is not likely to be a 
causative factor. Severity level by SOFA and APACHE II scores at ICU admission does not 
reflect the severity status of tetanus patients because tetanus patients are commonly admitted 
to ICUs in the early stage of disease, which then progresses to maximum severity in about 
two weeks before gradually improving [182]. That is why although tetanus patients had 
statistically lower severity by SOFA and APACHE II score but still had higher VARI 
incidence than non-tetanus patients (Table 5 – 5). 
In non-tetanus patients only thoracentesis was associated with higher risk for VARI (Table 
19). The increased VARI risk associated with thoracentesis may relate to the underlying 
diseases and its severity or physical factors such as difficulty in turning patients and lung 
atelectasis related to the thoracostomy tube. This result is similar with finding by Oldfield et 
al that increase in chest tube days was independently associated with higher risk for hospital 
acquired infection which including VAP [183]. Besides this factor there was no other factors 
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significantly associated with high VARI incidence (Table 5 – 17, Table 5 – 18, and Table 5 – 
19).  
In the contrast with the results when the whole patient group was analysed, subgroup analysis 
by tetanus status (tetanus and non-tetanus) found no significant association between steroid 
use, tracheostomy or neuromuscular paralysis and VARI incidence. However, stratification 
by tetanus did not result in any alteration of the direction of (non-significant) association in 
either group. The association between neuromuscular paralysis and VARI is biologically 
plausible and in keeping with the literature [181], the loss of significance for this variable in 
subgroup analysis likely relates to reduction in sample size.  For steroid use and tracheostomy 
there may be other variables confounding the relationship with VARI. The relatively small 
sample size and heterogeneity of the patients made further analysis to explore this impossible. 
However when tetanus and non-tetanus patients are viewed, VARI incidence was not 
statistically significant difference in those with and without steroid therapy and it is likely that 
this figure is due to the smaller sample sizes of the subgroups and less heterogeneity of non-
tetanus subgroup.  
5.4.3 Patient characteristics 
In the present study the median age of participants was lower than the median age of ICU 
patients across Vietnam of 61 years, according to the results of a survey at adult ICUs of 14 
hospitals across Vietnam, including the three study sites, in 2012 – 2013 [120], and lower 
than the median age of 61.1 years in European ICUs in 2007 [40] and 60.4 years in Wales in 
2012 [184]. This difference may be due to bias in recruiting patients as this study did not 
routinely recruit all patients admitted to the ICU. However other descriptions of ICU 
populations from developing countries have shown similar differences in case-mix with 
younger patients predominating [81].  
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The proportion of males in this study was 71.4%, which is higher than commonly seen in ICU 
patients in other studies (ranging from 55.3% to 63.9%) [40, 120, 121, 184]. This male 
preponderance may reflect the fact that most patients in this study were admitted to ICU due 
to infectious diseases, sex differences in the manifestation of infectious diseases are 
recognized, yet poorly understood [185], and a previous study at ICU of NHTD also showed 
a higher male proportion of 69.5% [118].  
Severity of patients in this study was lower as compared to other ICU based studies. Mean 
and median APACHE II score in this study were 10.9 and 10 points respectively. Whereas 
mean APACHE II score of ICU patients in the study of Tran Huu Thong et al at Bach Mai 
Hospital in 2009 – 2013 was 19.4 points. Ary Serpa Neto et al. reported a mean APACHE II 
score of 18.2 points in a mixed 41 bed ICU in Brazil from 2012 to 2013 [186]. A report by 
Richard Pugh et al. showed a mean APACHE II score of 16.5 points in 113 patients ventilated 
for 48 hours or more in ICUs of Wales in 2014 [184]. The low APACHE II score in our study 
may be explained partly by the low age of our patient population (median age of 52 years) 
and the relative high proportion of patients who had tetanus, a group with little to no 
comorbidities: just 9% of tetanus cases had a comorbidity. Furthermore in countries such as 
Vietnam patients who may normally be admitted to normal wards in high-income settings are 
often admitted to ICU due to limited monitoring capacity in other departments. 
Underlying disease like diabetes put individuals at risk for developing diseases, or more 
severe disease, and due to multiple medications are challenging to treat with poor outcome as 
a result. Comorbidities are common in patients admitted to ICUs. The overall proportion of 
patients with a comorbidity was 38.5% in our study. However, this proportion was 
significantly different between the three study sites (Table 5 – 1). The proportion of 
comorbidities in our study was similar to 37.1% in an earlier Vietnamese ICU based study 
[120]. In that study, the most common comorbidity was stroke sequelae 10.9% (343/3151), 
followed by diabetes mellitus 9.8% (310/3151), and alcoholism in fifth place with 4.5% 
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(141/3151). While, alcoholism was the most common comorbidity in our study, accounting 
for 15% of all participants and diabetes mellitus still in second place with 9.4%. Again the 
preponderance of infectious disease as a cause of ICU admission may account for this, as 
alcoholism and diabetes mellitus can increase susceptibility to infections. Johannes Frank et 
al. found that alcoholism led to extend a hypo-inflammatory of innate immunity mediated 
through lipopolysaccharide, this condition increased risk for infection  [187]. Dao TT et al 
carried out a survey in reported that people who consumed moderate to heavy alcohol weekly 
had an increased risk for Klebsiella pneumoniae carriage with OR (95% CI) 1.7 (1.04 – 2.8) 
[188]. Other reasons for the high proportion of alcoholism is that alcohol consumption is 
common in Vietnam. Kim Bao Giang et al found that 65.5% men and 5.3% women 
interviewed consumed alcohol in previous week [189]. Van Bui T. et al also found that about 
60% Vietnamese men consumed alcohol in a last week and 40% of men were described as 
‘harmful drinkers’ [190]. Although diabetes mellitus prevalence was estimated just around 
5.4% of population in 2012, it had doubled from 2.7% in 2002 [191]; it accounted for nearly 
10% of patients in our study. Both alcoholism and diabetes mellitus patients in our study had 
higher VARI incidence although these differences did not reach statistical significance.  
Medical interventions that patients had before admission can have important effects on 
patients’ disease progress. If patients were in another hospital before means that patients 
either progressed or did not recover requiring them to be transferred to the participating ICUs. 
Though the intention of medical interventions is to improve the health of a patient, they can 
also put patients at risk. For example, invasive interventions could put patients at risk for 
hospital acquired infections and antibiotic use could put patients at risk of having disease 
caused by resistant bacteria. In our study, 75.1% of participants were transferred from another 
hospital. This means that only 24.9% of ICU patients in this study came directly from 
community, about  half of that in European ICUs, where studies have shown that 50.5% of 
ICU patients came from community [40]. This difference may be due to our study being 
carried out at tertiary hospitals whereas European surveillance was carried out on all ICUs in 
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their network. The high proportion of referred patients also suggests that the three study sites 
were highly specialized ICUs. Particularly, the high proportion of patients referred from other 
tertiary hospitals to the ICU of NHTD which accounted for 31.7% of total participants at this 
site. The proportion of patients intubated at another hospital ranged largely between the study 
sites (Table 5 – 2). This rate could represent the severity of transferred patients to these study 
sites and may impact on hospital acquired infection at these study sites. Most patients (86.4%) 
were given antibiotics on ICU admission, underlining the high burden of infectious diseases 
in these study sites. This rate was similar to the rate of 84.8% ICU patients used antibiotics in 
previous point prevalence survey in ICUs across Vietnam suggesting that this burden is 
shared more widely [120]. However this may also be an important factor in the reduced 
overall VAP incidence we have found in this study compared to others: as most patients 
received antibiotics this may have slowed development of subsequent VARI. Antibiotics will 
be examined in further detail in the following chapter. 
In conclusion  
This is the largest prospective study on VAP and VARI in Vietnamese ICUs and found that 
VAP incidence density was 7.6 episodes per 1000 ventilator days according to 2013 CDC 
criteria for VAP but VARI incidence density was 21.4 episodes per 1000 ventilator days. The 
large discrepancy between the two suggests that 2013 CDC criteria for VAP did not 
satisfactorily identify patients treated clinically for respiratory infections in the ICU. Risk 
factors for VARI are mostly dependent on admission diagnosis, the highest risk factors for 
VARI were diagnosis of tetanus, septic shock and acute pancreatitis. Particularly, tetanus 
patients had low SOFA and APACHE II score although they had higher risk for VARI than 
the other diagnoses. This may be due to inherent differences in the diseases itself or 
differences in treatment. Studies which include diseases with a protracted requirement for 
ventilation, such as tetanus should be evaluated more carefully due to the special clinical 
characteristics and treatments involved.  
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 Chapter 6  
Etiology and impact of ventilator-associated pneumonia  
and ventilator-associated respiratory infection 
6.1. Introduction 
6.1.1 Impact of ventilator-associated respiratory infections 
Ventilator-associated respiratory infections (VARI - a term used to include ventilator 
associated pneumonia and ventilator associated tracheobronchitis) are the most common 
infections in intensive care units, with important consequences for patients and healthcare 
systems.  
Although ventilator associated pneumonia (VAP) is associated with increased ICU and 
hospital stays, hospital cost, and morbidity, the association between VAP and mortality is 
unclear [46, 48, 51, 67, 170-172]. Although many studies have previously reported higher 
mortality in patients with VAP, these have usually been retrospective observational studies. 
More recent studies which have attempted to match control groups and calculate attributable 
mortality due to VAP. The results from these studies have indicated the relationship may not 
be so clear. Jordi Rello et al.  conducted a retrospective matched cohort study using a large 
United States inpatient database on patients admitted to an ICU between January 1998 and 
June 1999 and on mechanical ventilation for > 24 hours. Among 9080 eligible patients, 842 
(9.3%) had VAP (defined as a hospital acquired pneumonia diagnosis occurring following 
intubation for 24 hours or more). These VAP patients were matched with 2243 control 
patients without VAP. VAP patients had statistically significant longer duration of 
mechanical ventilation (14.3 vs 4.7 days), ICU stay (11.7 vs 5.6 days), and hospital stay (25.5 
vs 14.0 days), (all with p < 0.001) [67]. Mean hospital cost per VAP patient was more than 
40,000 US$ higher in patients with VAP than without (p < 0.001). However, hospital 
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mortality was not different between VAP patients and control subjects (30.5% vs 30.4% 
respectively, p = 0.713). Another study using a large United States inpatients database of 
patients ventilated for at least 2 days and discharged between 1st October 2008 and 31st 
December 2009 found 88,689 eligible patients, of whom 2383 (2.5%) had VAP with an 
incidence density of 1.27 per 1000 ventilation days [170]. In a matched cohort, they were able 
to match 2,144 VAP patients with 2144 without VAP, showing also that VAP patients had 
longer mean time on ventilation (21.8 vs 10.3 days), ICU stay (20.5 vs 11.6 days), and 
hospital stay (32.6 vs 19.5 days, all p < 0.0001). Mean difference in hospitalization cost of 
patients with and without VAP was 39,828 US$ (p < 0.0001). This study also found that 
hospital mortality of VAP patients was lower than patients without VAP, 22.5% vs 29.4% 
respectively, p < 0.001. Melsen et al. performed a systematic review of observational studies 
on VAP and mortality used PubMed, Web of Science, and Embase from its inception through 
February 2007 and found no evidence of attributable mortality for VAP in trauma and ARDS 
patients [171].  Observational studies on the sequelae of VAP will inevitably be subject to 
multiple biases and confounding. As risk of VAP will increased with the number of days on 
the ventilator, patients that develop VAP will likely have longer ventilation times to the point 
of diagnosis. This is likely to be associated with factors associated with mortality, even after 
matching (residual confounding), particularly given the highly heterogenous populations in 
intensive care. Recognising these limitations, Melsen et al. went on to perform an individual 
patient meta-analysis of patients enrolled in randomized controlled trials of VAP prevention 
studies. By analyzing the mortality effect of these preventive measures in 6284 patients from 
24 randomized trials they were able to calculate an overall attributable mortality of 13%.  
However of note they found that this attributable mortality varied markedly across patient 
types, with no attributable mortality in medical and trauma patients, but very high attributable 
mortality in surgical patients (69%), further there was no increased risk in those with 
APACHE II scores < 20 points or in those with very high scores (APACHE II score > 30 
points) [68].  
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The impact of ventilator associated tracheobronchitis (VAT) on outcomes is less clear, due to 
a lack of precision and consensus in diagnostic criteria and limited research studies. A case 
control study with participants matched for time on ventilator at VAT onset in addition to five 
other parameters such as APACHE II score, found that VAT was associated with a doubling 
of ventilation time and ICU stay, but not with mortality [71]. An early randomized controlled 
trial of antibiotic therapy for VAT was stopped because of an increased mortality in the 
control group (no antibiotics) [95]. It is notable that the most common comorbidity in this 
study was COPD (present in 40% of the intervention arm and 47% of the control arm). A 
meta-analysis of 17 VAT studies published before 2008 found that VAT was not associated 
with mortality, nor was treatment of VAT associated with a reduction in mortality, though 
only 3 trials including that described by Nseir above, addressed the association of treatment 
with mortality outcome [43]. In a prospective observational study published since the meta-
analysis outlined above, 14% of patients who developed VAT went on to develop VAP, the 
only risk factor for developing VAP was inappropriate antibiotic use [192].  
In summary previous research would suggest that VAP has an impact on mortality in some 
situations, whilst the same appears not to be true of VAT. Both appear to result in prolonged 
length of ICU stay and ventilation time. 
6.1.2 Etiology of ventilator-associated respiratory infections 
As discussed earlier, VAP and VAT are believed to have a similar pathogenesis. The overlap 
in their defining criteria results in a similar microbiological etiology and thus they can be 
considered together.  Most studies have focused on VAP. 
The bacterial etiology of VAP and their susceptibility to antibiotics is different between 
settings. In general, Gram negative bacilli are the predominant pathogens of VAP and the 
most common pathogens are Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella 
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pneumoniae, Escherichia coli, and Staphylococcus aureus [40, 51, 168, 193, 194]. In 
developing countries, the predominant bacteria causing VAP tend to be P. aeruginosa, K. 
pneumoniae, and A. baumannii, with S. aureus and other Gram positive bacteria accounting 
for a smaller proportion [48, 51, 172, 194, 195]. In developed countries, S. aureus and P. 
aeruginosa are more common, while A. baumannii accounts for a modest proportion [40, 49, 
50]. Pathogens of VARI are commonly multidrug resistant bacteria leading to difficulty in 
treatment. Rosenthal et al. conducted a prospective cohort surveillance on device-associated 
healthcare-acquired infections in 503 ICUs in 43 countries from 2007 – 2012. The study 
showed that MRSA accounted for 62.0% of S. aureus isolates associated with VAP, and that 
carbapenem resistance occurred in 77.1% of A. baumannii, 42.8% P. aeruginosa, 17.2% K. 
pneumoniae, and 7.5% E. coli in these cases [45]. Chung et al focused on Asian sites, with 
prospective data from 73 hospitals in 10 Asian countries (including Thailand, Philippines, but 
not Vietnam) collected between 2008 and 2009. Bacteria were isolated from 977 cases of 
VAP, the most common being Acinetobacter species, Pseudomonas aeruginosa and 
Klebsiella pneumoniae. Carbapenem resistance was again very high in Acinetobacter species 
(up to 86.7% in cases from Malaysia), with lower rates in Pseudomonas aeruginosa (up to 
56.9% in China) and Klebsiella pneumoniae (up to 4% in China) [196].  
In Vietnam, there are limited data in international publications on VAP and its associated 
bacterial etiology. An 11-year retrospective study at the Hospital for Tropical Diseases in Ho 
Chi Minh City from 2000 to 2010 described the bacterial pathogens associated with VAP, 
defined as pneumonia developing after more than two days of ventilation that is ongoing or 
has been weaned off the day before the pneumonia diagnosis. The study reported that the 
most common pathogens were Acinetobacter spp (30.4%, 206 isolates), P. aeruginosa 
(26.4%, 186 isolates), K. pneumoniae (17%, 118 isolates), Staphylococcus spp. (8.3%, 53 
isolates), and Streptococcus pneumoniae (3.1%, 24 isolates) [197].  The investigators found 
that the proportion of A. baumannii resistant to carbapenems increased rapidly from 12.5% in 
2007 to 41.7% in 2008 then nearly 90% in 2009 and 2010. Another study from the same 
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centre from 2011 – 2012 reported that Acinetobacter spp. accounted for 94/195 (48.2%) 
bacteria isolated from suspected VAP through tracheal aspiration, 74 of which were A. 
baumannii with > 80% were resistant to at least three different antibiotics classes, including 
carbapenems, fluoroquinolones, and cephalosporins [198]. One study on antibiotic 
susceptibility of 904 A. baumannii strains and 529 P. aeruginosa strains isolated from 
hospital-acquired pneumonia or VAP at five hospitals in Vietnam (two in Hanoi and three in 
Ho Chi Minh City) from 2012 to 2014 found that about 90% of A. baumannii were resistant 
to carbapenems and this resistance pattern had changed a little from 88.6% in 2012 to 95.0% 
in 2013 then down to 89.4% in 2014. While, the proportion of P. aeruginosa resistant to 
carbapenems rose from about 30% in 2012 to 66.5% in 2014 [199]. 
The frequency of VAP caused by antibiotic resistant bacteria makes treatment challenging. 
Although VAP impact on mortality is still controversial, inappropriate or delays in 
appropriate antibiotic therapy for VAP could result in a considerable increase of mortality and 
comorbidity [51, 200]. Most VAP management guidelines recommend empirical antibiotics 
to cover common potential pathogens and selected according to local antibiotic resistance 
patterns [77, 83, 90, 91]. 
The aims of this study were to systematically analyse the associated microorganisms, 
antibiotics treatment and outcome of VAP and VARI in Vietnam. These data would provide 
evidence for interventions to limit and control VAP as well as ventilator-associated 
respiratory infections and provide important local data concerning their empiric treatment. 
6.2 Methods 
A prospective observational study was conducted at three study sites, ICU at National 
Hospital for Tropical Diseases and Bach Mai Hospital in Hanoi, and ICU at Hospital for 
Tropical Disease in Ho Chi Minh city. More details of the design and conduct of this study 
are presented in chapter 2. 
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6.3. Results  
There were 453 patients enrolled in the study from November 2013 to November 2015. Of 
whom, 79 patients were excluded due to early weaning from mechanical ventilation (69 
patients), treatment with ECMO (6 patients), and suspected VAP at enrolment (3 patients), 
and one patients withdraw from the study. Therefore 374 patients were eligible for analysis, 
of which 161 (43.1%) were from NHTD, 61 (16.3%) from BMH, and 152 (40.6%) from 
HTD. 
6.3.1. Etiology of ventilator-associated pneumonia and ventilator-associated 
respiratory infection 
There were 37 patients met the definition for VAP, of whom 32 had bacteria isolated from 
respiratory specimens. A further 55 patients met the definition for other VARI, of whom 41 
had possible causative bacteria cultured (table 6-1). In total there were 111 bacterial isolates 
from 73 patients with VARI (32 VAP and 41 other VARI). 90% of the bacteria were Gram 
negative. The most frequent isolates were Acinetobacter baumannii (32 strains, 28.8%), 
Klebsiella pneumoniae (26 strains, 23.4%), and Pseudomonas aeruginosa (24 strains, 21.6%). 
These three bacteria accounted for approximately three quarters of all bacterial isolates. 
Among Gram positive bacteria Staphylococcus aureus was the commonest isolate (10 strains; 
9% of total), followed by Streptococcus pneumoniae (3 strains; 2.7% of total). (Table 6 – 1). 
Antibiotic resistant bacteria were common. Carbapenem resistance was present in 84.4% 
(27/32) of A. baumannii, 45.8% (11/24) P. aeruginosa, and 23.1% (6/26) K. pneumoniae 
(Figure 6 – 1). All of the Chryseobacterium meningosepticum and Escherichia coli isolates 
were resistant to carbapenems. All Haemophilus influenzae, Haemophilus haemolyticus, and 
Proteus mirabilis were susceptible to 3rd generation cephalosporins, and all Stenotrophomonas 
maltophilia were susceptible to sulfamethoxazole and levofloxacin. Among 10 strains of S. 
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aureus, methicillin resistant Staphylococcus aureus (MRSA) accounted for 50% (5/10 
isolates). Streptococcus pneumoniae and Streptococcus mitis all were susceptible to penicillin.  
Table 6 – 1. Bacterial species cultured from respiratory specimens in those with 
ventilator-associated respiratory infections (VARI) 
Species VAP, 
 n (%) 
Other VARI, 
n (%) 
Total,  
n (%) 
Gram negative bacteria 40 (83.3%) 56 (88.9%) 96 (86.5%) 
Acinetobacter baumannii 17 (35.4) 15 (23.8) 32 (28.8) 
Klebsiella pneumoniae 9 (18.8) 17 (27.0) 26 (23.4) 
Pseudomonas aeruginosa 8 (16.7) 16 (25.4) 24 (21.6) 
Haemophilus influenzae 2 (4.2) 3 (4.8) 5 (4.5) 
Chryseobacterium meningosepticum 2 (4.2) 1 (1.6) 3 (2.7) 
Stenotrophomonas maltophilia 0 3 (4.8) 3 (2.7) 
Escherichia coli 1 (2.1) 0 1 (0.9) 
Haemophilus haemolyticus 0 1 (1.6) 1 (0.9) 
Proteus mirabilis 1 (2.1) 0 1 (0.9) 
Gram positive bacteria 8 (16.7%) 6 (9.5%) 14 (12.6%) 
Staphylococcus aureus 7 (14.6) 3 (4.8) 10 (9.0) 
Streptococcus pneumoniae 0 3 (4.8) 3 (2.7) 
Streptococcus mitis 1 (2.1) 0 1 (0.9) 
Fungi  0 1 (1.6%) 1 (0.9%) 
Candida albicans 0 1 (1.6) 1 (0.9) 
Total species 48 63 111 
 
 
Figure 6 – 1. Carbapenem resistance in common VARI isolates 
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6.3.2 Impact of VARI 
6.3.2.1 General impact of VARI 
In total, median (IQR) ventilation time, ICU stay, and cost for ICU stay in all study patients 
were 12 (6 - 22) days, 20 (12 – 30) days, and 3,005 (1,607 – 5,581) US$. Among 364 patients 
with known 28-day study outcome status, 62 patients (17.0%) died. There were statistically 
significant differences between patient with VARI (included VAP) and patients without 
VARI with respect to ICU stay, ventilation time, and ICU cost. Median (IQR) ventilation 
time of VARI patients was 21.5 (IQR 15 - 29) compared to 9 (IQR 6 - 19) in those without 
VARI. Similarly ICU stay was longer in those with VARI: 27.0 days (IQR 21 – 37) compared 
to 16 days (IQR 10 – 28) (p < 0.0001)). Median days of therapy (DOT) of antibiotics use per 
patient were highest in patients with VAP (35 DOT/patient), then in patients with other VARI 
(28 DOT/patient), and lowest in patients without VARI (17 DOT/patient). Also there was a 
difference in antibiotic use by DOT/patient between patients with VARI and patients without 
VARI, p < 0.0001. ICU cost of patients with VARI were significantly higher in patients 
without VARI: median (IQR) costs were 4723 (2753 – 7795) US$ and 2534 (1291 – 4435) 
US$ respectively (p < 0.0001). However, there were no statistically significant differences in 
mortality between patients with and without VARI and without VARI. (Table 6 - 2) 
In comparing VAP patients with other VARI patients, there were no statistically significant 
differences in ventilation time, ICU stay, and ICU cost, but mortality was higher in patients 
with VAP than patients with other VARI: 27.8% and 7.4% respectively with p = 0.021. In 
comparison with patients without VARI, patients with VAP had significant higher in ICU 
stay, ventilation days, and antibiotics use; although 28-days mortality in patients with VAP 
(27.8%) was higher than that in patients without VARI (17.5%), the difference was not 
statistically significant, p = 0.170. (Table 6 – 2) 
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Table 6 - 2. VARI impact on ventilation days, ICU stay, antibiotic use, ICU cost, and 
mortality 
Impact factors Patients with VARI  Patients 
without VARI 
(n=282) 
Total patients  
(n= 374) 
P1 value 
VAP (n=37) Other VARI 
(n=55) 
Total VARI 
(n=92) 
ICU stay  
Median (IQR), 
(days) 
25  
(18.5 – 37) 
27  
(25 – 38) 
27  
(21 – 37) 
16  
(10 – 28) 
20  
(12 – 30) 
< 0.0005a 
Ventilation days, 
Median (IQR), 
(days) 
21  
(13 – 28) 
22  
(17 – 30) 
21.5  
(15 – 29) 
9  
(6 – 16) 
12  
(6 – 22) 
< 0.0005a 
Antibiotics use, 
Median (IQR), 
(DOT/patient)  
35  
(20 – 54.5) 
28  
(18 – 39) 
29.5  
(19 – 45.8) 
17  
(10 – 26) 
20  
(12 – 30) 
< 0.0005a 
ICU costc,  
Median (IQR), 
(US$) 
7213  
(2828 - 9044) 
4196  
(2726 - 7193) 
4723  
(2753 - 7795) 
2534  
(1291 - 4435) 
3005  
(1607 - 5581) 
< 0.0005a 
28-day Mortality, 
n (%) 
10/36 (27.8) 4/54 (7.4) 14/90 (15.6) 48/274 (17.5) 62/364 (17.0) 0.748b 
1 Between patients with VARI and patients without VARI. a Mann Whitney U test, b Fisher Exact Test. 
c 1 US $ = 21246 VND, exchange rate by 30th December 2014. 
Comparison between VAP vs other VARI on ICU stay p = 0.220, ventilation days p= 0.423, ICU cost 
p= 0.140, antibiotics use p = 0.106 (Mann Whitney U test), on mortality p =0.0215 (Fisher Exact 
Test).  
Comparison between VAP vs no VARI on ICU stay, ventilation days, and antibiotics us all p < 0.0005 
(Mann Whitney U test), on mortality p = 0.170 Missing mortality (Fisher Exact Test). 10 cases: 2 in 
VARI and 8 in non-VARI. 
 
6.3.2.2 Impacts of VARI on ICU stay and ventilation days per admission diagnosis 
In all patients, median (IQR) ICU stay was longest in those with CNS infection (29 days (16 – 
48.5)), followed by those with tetanus (26 days (20 – 35)), pneumonia (14 days (8 – 23)), 
sepsis and septic shock (13 days (8 – 23)), and the other diagnoses (11 days (7.8 – 15.3)). 
With the exception of patients with CNS infections, the median ICU stays of patients with 
VARI were significantly longer than in patients without VARI. (Table 6 – 3). 
Median ventilation time of patients with VARI were about two to three times longer than 
these of patients without VARI in all five admission diagnosis categories (Table 6 – 4). 
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Table 6 -  3. VARI and length of ICU stay (in days) by admission diagnosis 
Diagnosis  All patients Patients without VARI Patients with VARI Pa value 
N Median (IQR) N Median (IQR) N Median (IQR) 
Pneumonia 73 14 (8 – 23) 66 14 (8 – 21) 7 23 (18 – 33) 0.021 
Sepsis & 
shock 
55 13 (8 – 23) 44 11.5 (7 – 15) 11 26 (16 – 49) 0.001 
Tetanus  132 26 (20 – 35) 84 23 (17 – 30) 48 29.5 (25 – 37.8) < 0.0005 
CNS 
infection 
60 29 (16 – 48.5) 49 30 (15.5 – 47) 11 26 (21 – 60) 0.417 
The others 54 11 (7.8 – 15.3) 39 10 (7 – 13) 15 19 (14 – 26) < 0.0005 
a Mann Whitney U test comparing patients with and without VARI 
Table 6 - 4. VARI and days on mechanical ventilation by admission diagnosis 
Diagnosis  Total patients Patients without VARI Patients with VARI Pa value 
N Median (IQR) N Median (IQR) N Median (IQR) 
Pneumonia 73 9 (6 – 15.5) 66 8 (5.8 – 14) 7 20 (14 – 28) 0.006 
Sepsis & shock 55 8 (6 – 13) 44 6.5 (5 – 9.8) 11 22 (15 – 34) < 0.0005 
Tetanus  132 17.5 (13 – 24) 84 15 (10 – 21.3) 48 23 (18.3 – 29) < 0.0005 
CNS infection 60 14 (7.3 – 33) 49 11 (6.5 – 29) 11 26 (14 – 42) 0.043 
Others 54 6 (4 – 9.3) 39 5 (4 – 7) 15 12 (7 – 25) < 0.0005 
a Mann Whitney U test comparing patients with and without VARI 
 
6.3.2.3 Impact of VARI on systemic antibiotics use 
Total systemic antibiotics consumption 
In total, there were 657 antibiotics courses for community acquired infections, 353 courses for 
hospital acquired infections, 97 courses for ventilator associated pneumonia, and 24 courses 
for prophylaxis. Median duration courses were 7.0 days (IQR 3.5 – 9.5) for community 
infection, 7.0 days (IQR 4.0 – 12.0) for hospital acquired infection, 8.0 days (IQR 5.0 – 11.0) 
for VAP, 4.0 days (IQR 3.0 – 8.0) for prophylaxis. Overall, antibiotic consumption in ICU in 
the study follow up period was 117.2 DOT/100 patient days, of which 49.2 DOT (42.0%, 
49.2/117.2) was for hospital acquired infections (9.4% for VAP and 32.6% for other HAI) 
and 66.1 DOT (56.4%, 66.1/117.2) for community acquired infections. The five most 
common antibiotics used were carbapenems (32.3%), fluoroquinolones (16.0%), imidazole 
derivatives (10.5%), colistin (9.6%), and combinations of penicillins included beta-lactamase 
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inhibitors (7.0%). These antibiotics accounted for 75.4% of total DOT/100 patient days. Most 
polymyxins and over two thirds of penicillin/beta-lactamase inhibitor combinations were used 
for HAI, whilst the indication for carbapenem use was more evenly spread across community 
and hospital acquired infection. Interestingly, 8.8% of colistin was used for community 
acquired infections including 6 cases: 1 septic shock, 2 pneumonia, 2 COPD, 1 pancreatitis at 
ICU of BMH. More details were presented in Table 6 – 5. 
Table 6 - 5. Antibiotic consumption by indication (DOT/100 PD) 
Type of antibiotics CAI HAI Prophylaxis Total, (%)  
Carbapenems, (%) 19.9 (52.5) 17.7 (46.7) 0.3 (0.8) 37.9 (32.3) 
Fluoroquinolones, (%) 14.2 (75.9) 4.2 (22.5) 0.4 (2.1) 18.7 (16.0) 
Imidazole derivatives, (%) 12.0 (96.7) 0.1 (0.8) 0.2 (1.6) 12.3 (10.5) 
Polymyxins (Colistin), (%) 1.0 (8.8) 10.3 (91.2) 0.0 11.3 (9.6) 
Combinations of penicillins included 
beta-lactamase inhibitors, (%) 2.4 (29.3) 5.5 (67.1) 0.4 (4.9) 8.2 (7.0) 
Third-generation cephalosporins, (%) 4.7 (63.5) 2.4 (32.4) 0.3 (4.1) 7.4 (6.3) 
Glycopeptide antibacterials, (%) 3.0 (43.5) 3.7 (53.6) 0.3 (4.3) 6.9 (5.9) 
Other antibacterialsa , (%) 1.9 (47.5) 2.1 (52.5) 0.0  4.0 (3.4) 
Other aminoglycosides, (%) 1.0 (37.0) 1.7 (63.0) 0.0 2.7 (2.3) 
Beta-lactamase sensitive penicillins, (%) 2.3 (100) 0.0 0.0 2.3 (2.0) 
Penicillins with extended spectrum, (%) 1.1 (84.6) 0.2 (15.4) 0.0 1.3 (1.1) 
Beta-lactamase resistant penicillins, (%) 0.6 (54.5) 0.5 (45.5) 0.0 1.1 (0.9) 
Macrolides, (%) 0.6 (85.7) 0.1 (14.3) 0.0 0.7 (0.6) 
Tetracyclines, (%) 0.5 (83.3) 0.1 (16.7) 0.0 0.6 (0.5) 
Combinations of sulfonamides and 
trimethoprim, incl. derivatives, (%) 0.3 (50) 0.3 (50) 0.0 0.6 (0.5) 
Lincosamides, (%) 0.5 (100) 0.0 0.0 0.5 (0.4) 
Fourth-generation cephalosporins, (%) 0.2 (66.7) 0.1 (33.3) 0.0 0.3 (0.3) 
Nitrofuran derivatives, (%) 0.0 0.3 (100) 0.0 0.3 (0.3) 
Amphenicols, (%) 0.1 (50) 0.1 (50) 0.0 0.2 (0.2) 
Total AB use, (%) 66.1 (56.4) 49.2 (42.0) 1.9 (1.6) 117.2 (100) 
CAI: community acquired infections, HAI: hospital acquired infections. 
 a Other antibacterials: fosfomycin and linezolid. 
Impact of VARI and admission diagnosis on antibiotics consumption 
Median (IQR) DOT per patient with VARI was two to three times higher than that per patient 
without VARI in each group of admission diagnosis and these differences were statistically 
significant exception for CNS infection (p = 0.289). Highest antibiotics consumption was in 
pneumonia and septic & shock patients with VARI where median (IQR) DOT were 61 (30 – 
86) days and 58 (42 – 93) days, respectively. Overall, median (IQR) DOT/patients with VARI 
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was 29.5 (19.0 – 45.8) days while in patients without VARI it was 17 (10 – 26) days (p < 
0.0005). (Table 6 – 6a). 
Table 6 -  6a. Antibiotic use in DOT/patient by VARI status and admission diagnosis 
Diagnosis  Total patients Patients without VARI Patients with VARI Pa value 
No. 
of pts 
Antibiotics use in 
DOT/patient, 
Median (IQR) 
No. of 
pts 
Antibiotics use in 
DOT/patient, 
Median (IQR)  
No. of 
pts 
Antibiotics use in 
DOT/patient, 
Median (IQR) 
Pneumonia 73 25 (17 - 38.5) 66 23.5 (16 - 32.8)  7 61 (30 - 86)  0.005 
Sepsis & 
shock 
55 26 (15 - 43) 44 22 (13.3 - 28.8) 11 58 (42 - 93) < 0.0005 
Tetanus  132 18 (10 - 28.7) 84 13.5 (8.3 - 20) 48 27 (18.3 - 35) < 0.0005 
CNS 
infection 
60 16 (7 - 28) 49 15 (7 - 28) 11 18 (15 - 31) 0.289 
The others 54 19 (12.8 - 28.3)  39 17 (10 - 22) 15 32 (20 - 44) < 0.0005 
Total 374 20 (12 – 30) 282 17 (10 - 26) 92 29.5 (19 - 45.8)  < 0.0005 
a Mann Whitney U Test comparing patients with and without VARI 
I calculated day of therapy/patient day in ICU in the study follow up by dividing total DOT 
for number of ICU days for each patient. Overall, median (IQR) DOT/PD was 1.13 (0.80 – 
1.97) in patients with VARI and 1.05 (0.61 – 1.86) in patients without VARI (p = 0.171). 
Median (IQR) DOT/PD in patient with and without VARI in subgroup of admission 
diagnosis respectively was 2.68 (2.00 – 3.00) vs 1.77 (1.21 – 2.21) in pneumonia, 2.46 (2.00 – 
2.72) vs 1.83 (1.07 – 2.15) in sepsis & septic shock, and 0.99 (0.72 – 1.21) vs 0.60 (0.41 – 
0.90) in tetanus (p < 0.05 for all). (Table 6 – 6b). 
Table 6 – 6b. Antibiotic use in DOT/PD by VARI status and admission diagnosis 
Diagnosis  Total patients Patients without VARI Patients with VARI Pa value 
N Antibiotics use in 
DOT/PD, median 
(IQR) 
N Antibiotics use in 
DOT/PD, median 
(IQR) 
N Antibiotics use in 
DOT/PD, median 
(IQR) 
Pneumonia 73 1.88 (1.25 – 2.44) 66 1.77 (1.21 – 2.21) 7 2.68 (2.00 – 3.00) 0.038 
Sepsis & 
shock 
55 1.96 (1.42 – 2.33) 44 1.83 (1.07 – 2.15) 11 2.46 (2.00 – 2.72) 0.003 
Tetanus  132 0.72 (0.49 – 1.00) 84 0.60 (0.41 – 0.90) 48 0.99 (0.72 – 1.21) < 0.0005 
CNS 
infection 
60 0.82 (0.39 – 1.18) 49 0.82 (0.38 – 1.25) 11 0.82 (0.56 – 1.14) 0.535 
The others 54 1.68 (1.18 – 2.00) 39 1.67 (1.20 – 2.00) 15 1.75 (1.07 – 2.00) 0.900 
Total 374 1.10 (0.66 – 1.87) 282 1.05 (0.61 – 1.86) 92 1.13 (0.80 – 1.97) 0.171 
a Mann Whitney U Test 
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Systemic antibiotics use at the study sites by VARI status and indications 
The total antibiotic use was 117.2 DOT/100 PD in ICUs. Antibiotic use was highest at Bach 
Mai Hospital ICU (BMH) with 210.1 DOT/100 PD, then at National Hospital for Tropical 
Diseases ICU (NHTD) with 139.6 DOT/100 PD, and lowest at Ho Chi Minh Hospital for 
Tropical Diseases ICU (HTD) with 72.6 DOT/100 PD. There was a small difference in the 
antibiotic consumption between patients with and without VARI. Figure 6 – 2. 
Looking at the antibiotics prescribed for hospital acquired infection (HAI), there was a large 
difference between patients with and without VARI, 82 vs 34.1 DOT/100 PD, corresponding 
to 62.3% and 30.9% of total antibiotics consumption in DOT/100 PD respectively. These 
proportions were similar at all 3 study sites. The Proportion of antibiotic use for HAI in 
patients with VARI was much higher than that in patients without VARI, 60.8% (92.5/152.2) 
vs 28.5% (38/133.7) at NHTD, 66.3% (145.8/219.9) vs 30.3% (62.1/205.1) at BMH, and 
61.9% (54.4/87.9) vs 36.0% (23.7/65.7) at HTD. Figure 6 – 2. 
 
 
Figure 6 – 2. Indications for systemic antibiotic use by VARI status at three sites 
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The greatest use of carbapenems and colistin was at BMH with 75.7 and 41.3 DOT/100 PD 
respectively, accounting for 55.7% (117/210.1) of total DOT/100 PD. These two types were 
used higher in patient with VARI than in patients without VARI. Only at BMH was colistin 
used for community acquired infection. More details were presented in Figure 6 – 3. 
 
Figure 6 – 3. Carbapenem and colistin consumption and indication at the study sites 
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Sepsis & 
shock 
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infection 
60 3389 (1548 – 6261) 49 2929 (1425 – 6235) 11 4144 (2832 – 6974) 0.298 
The others 54 3298 (1795 – 6207) 39 2994 (1579 – 4577) 15 7193 (2629 – 7810) 0.002 
a Mann Whitney U test 
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6.3.2.4 VARI impact on ICU cost 
The highest median cost for ICU stay was incurred by sepsis and septic shock patients (3473 
US$), followed by CNS infections (3389 US$), the other diagnoses (3298 US$), pneumonia 
(3250 US$), and lowest in tetanus patients (2170 US$). Except for those admitted with CNS 
infections, the median ICU cost of patients with VARI was approximately double that of 
patients without VARI. (Table 6 – 7). 
6.3.2.5 VARI impact on 28-day mortality 
During the 28 day study period, there were 10 (2.7%) patients who were lost to follow up (all 
10 in the non-tetanus group). 364 patients completed follow-up of which 302 (83.0%) patients 
were alive, and 62 (17.0%) patients died (45 patients died in the study hospital, 12 after 
transfer to another hospital, and 5 at home).  At discharge, 71 (19.0%) patients died, 6 (1.6%) 
were classified as missing (due to transferring to other departments), and 297 (79.4%) patients 
were alive.  
In total, the 28 day mortality in patients with VAP was 27.8% (10/27), in patients with other 
VARI (not VAP) was 7.4% (4/54), and in patients without VARI was 17.5% (48/274). In the 
non-tetanus group mortality was 26.3% (61/232); in those with VAP mortality was 45.5% 
(10/22), whereas in patients without VARI it was 25.3% (48/190), and in patients with other 
VARI mortality was 15.0% (3/20). Among non-tetanus patients, patients developing VAP 
had a higher odds ratio for death compared with patients who never developed VARI, odds 
ratio 2.47 (95% CI 1.00 – 6.07, p = 0.05). Interestingly mortality in patients with other VARI 
was lower than that in patients never developed VARI [odds ratios 0.38 (0.13 – 1.09) in total 
patients and 0.52 (0.15 -  1.86) for non-tetanus patients], although these differences were not 
statistically significant. In tetanus patients, there was only one death making mortality was 
just 0.8% (Table 6 – 8). Among 22 non-tetanus patients with VAP, mortality was 50% (8/16) 
in patients with carbapenem resistant isolates, 40% (2/5) in patients without any isolate, and 
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none in one patient isolated MSSA. There was no mortality among 14 tetanus patients with 
VAP (including 5 patients with carbapenem resistant isolates). 
Table 6 - 8. Impact of VAP and VARI on 28-day mortality 
VARI status Total patients Non-tetanus patients Tetanus patients 
Alive Death Odds ratio 
(95% CI) 
Pa 
value 
Alive Death Odds ratio 
(95% CI) 
Pa 
value 
Alive Death 
VAP,  
n (%) 
26  
(72.2) 
10 
(27.8) 
1.81  
(0.82 - 4.00) 
0.142 12 
(54.5) 
10 
(45.5) 
2.47  
(1.00 – 6.07) 
0.050 14 
(100) 
0 
Other VARI, 
n (%) 
50  
(92.6) 
4  
(7.4) 
0.38  
(0.13 – 1.09) 
0.072 17 
(85.0) 
3 
(15.0) 
0.52  
(0.15 – 1.86) 
0.316 33 
(97.1) 
1 
(2.9) 
Non-VARI, 
n (%) 
226  
(82.5) 
48 
(17.5) 
Reference  142 
(74.7) 
48 
(25.3) 
Reference  84 
(100) 
0 
Total,  
n (%)  
302  
(83.0) 
62 
(17.0) 
  171 
(73.7) 
61 
(26.3) 
  131 
(99.2) 
1 
(0.8) 
Mortality in VAP higher than in other VARI with odds ratios (95% CI) 4.81 (1.37 – 16.83), p = 0.014; 
in non-tetanus odds ratios (95% CI) 4.72 (1.07 – 20.89), p = 0.041 (univariate logistic regression). 
 a Univariate logistic regression 
 
VARI impacts on mortality by admission diagnosis  
In total, 28-day mortality was highest in patients with sepsis and septic shock (34.5%), 
followed by those with pneumonia (29.6%), other diagnoses (28.3%), CNS infections 
(13.3%), and tetanus (0.8%). In pneumonia and sepsis/septic shock patients, mortality in 
patients with VARI was higher than patients without VARI (57.1% vs 26.6% and 45.5% vs 
31.8% respectively). In CNS infections and the other diagnoses, mortality in patients with 
VARI was lower than patients without VARI, 9.1% vs 14.3% and 23.1% vs 30.3% 
respectively. However, none of these differences were statistically significant. (Table 6 – 9).  
Table 6 - 9. VARI and 28 study day mortality by admission diagnosis 
Admission 
diagnosis 
Mortality in VARI patients, % Mortality in 
patients without 
VARI, % 
Mortality in 
total patients, 
% 
P1a 
value 
P2a 
value 
VAP Other VARI All VARI 
Pneumonia 57.1 (4/7) 0 (0/0) 57.1 (4/7) 26.6 (17/64) 29.6 (21/71) 0.184 0.184 
Sepsis & shock 50.0 (3/6) 40.0 (2/5) 45.5 (5/11) 31.8 (14/44) 34.5 (19/55) 0.485 0.396 
Tetanus  0 (0/14) 2.9 (1/34) 2.1 (1/48) 0 (0/84) 0.8 (1/132) 0.364  
CNS infection 0 (0/1) 10.0 (1/10) 9.1 (1/11) 14.3 (7/49) 13.3 (8/60) 1.00 1.0 
The others 37.5 (3/8) 0 (0/5) 23.1 (3/13) 30.3 (10/33) 28.3 (13/46) 0.729 0.692 
a Fisher’s Exact test, 1 between VARI & without VARI, 2 between VAP & without VARI. Missing 10 
cases: 2 cases in pneumonia patients and 8 cases in others admission diagnosis. 
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VARI impacts on mortality by VARI empiric treatment  
Mortality in patients with VAP or VARI receiving adequate empiric treatments (pathogens 
isolated from respiratory specimen at the beginning of empiric treatment was susceptible to at 
least one of antibiotic agents used) was higher than patients received inadequate empiric 
treatment, odds ratios (95% CI) 1.09 (0.17 – 7.06) and 1.98 (0.39 – 10.08) respectively. 
However, these differences were not statistically significant. (Table 6 – 10).  
Table 6 - 10. Empiric VAP and VARI treatment and 28 study day mortality 
Patients with Empiric treatment  Alive Death  OR (95% CI) Pa value 
VAP Adequate, n (%)  16 (76.2) 5 (23.8) 1.09 (0.17 – 7.06) 0.925 
Inadequate, n (%) 7 (77.8) 2 (22.2) Reference   
VARI 
(included 
VAP) 
Adequate, n (%)  41 (82.0) 9 (18.0) 1.98 (0.39 – 10.08) 0.413 
Inadequate, n (%) 18 (90.0) 2 (10.0) Reference   
a Univariate logistic regression. 
Among 54 patients with other VARI, 29 cases had adequate treatment (4 died), 11 cases had 
inadequate treatment (0 died), and 14 unknown adequacy of treatment (0 died).  
 
VARI impact on 28-day mortality adjusted for age gender and APACHE II score 
In multivariate analysis, VARI had no statistically significant impact on mortality, although 
VAP had higher risk for death compared to patients without VARI (odds ratio 1.93 (95% CI 
0.73 – 5.11)). APACHE II score had statistically significant higher risk for death with odds 
ratios 1.07 (95% CI 1.01 – 1.15; p=0.034) for each one-point score increase. In comparison 
with CNS infection, only tetanus patients had lower risk for death with odds ratios 0.06 (95% 
CI 0.01 – 0.59); p = 0.015). Other admission diagnosis categories had higher risk for death 
but did not reach statistical significance. (Table 6 – 11). 
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Table 6 – 11. Impact of VARI on mortality adjusted for severity and admission 
diagnosis 
Risk factors Odds ratio (95% CI) Pa value 
Age (year) 1.02 (0.998 – 1.04) 0.074 
Male gender 0.97 (0.49 – 1.91) 0.918 
VARI status VAP 1.93 (0.73 – 5.11) 0.184 
Other VARI 0.62 (0.16 – 2.37) 0.482 
Non VARI Reference  
Diagnosis Sepsis & septic shock 2.46 (0.87 – 6.92) 0.089 
Pneumonia 1.75 (0.62 – 4.91) 0.291 
Other illnesses 1.99 (0.68 – 5.82) 0.210 
CNS infections Reference  
Tetanus 0.06 (0.01 – 0.59) 0.015 
Severity  APACHE II (points) 1.07 (1.01 – 1.15) 0.034 
a Multivariate logistic regression 
6.4 Discussion 
In this multicenter observational study for about two year (2013 – 2015), there were total 374 
patients in final analysis, of which 37 patients developed VAP and 55 patients developed 
other VARI. Gram negative bacteria accounted for nearly 90% of total pathogens isolated 
from VARI patients, with predominance of A. baumannii, K. pneumoniae, and P. aeruginosa 
and their high proportion of carbapenems resistance. Patients with VARI had significant 
higher in amount of ICU stay, ventilation days, antibiotics use, and ICU cost than those in 
patients without VARI. 
6.4.1 Etiology  
Our study found that Gram negative bacteria were the predominant pathogens associated with 
VARI (86.5%) and the most common species were A. baumannii, K. pneumoniae, P. 
aeruginosa, and S. aureus (Table 6 – 1). Carbapenem resistance was highest in A. baumannii 
(84.4%), then P. aeruginosa (45.8%), and K. pneumoniae (23.1%) (Figure 6 – 1), and all C. 
meningosepticum and E. coli isolated. MRSA accounted for 50% S. aureus (5/10 isolates). 
These findings are in line with other studies. Ling et al. in a systematic review on hospital 
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acquired infection in Southeast Asia found that common pathogens of VAP were 
Acinetobacter spp., Pseudomonas spp., and Klebsiella spp. (data from 2 studies in Malaysia, 
one in Singapore, and two in Thailand, published from 2001 to 2011) [172]. Arabi et al. in a 
systematic review on VAP in adult in developing countries (papers published from 1966 to 
2007) found that Gram negative bacilli were the most important VAP pathogens, ranging 
from 41% to 92%, and most common isolates were P. aeruginosa and Acinetobacter spp 
[48]. Inchai et al. conducted a retrospective study on 621 patients with VAP according to 
2005 ATS/IDSA criteria in medical ICU of Chiang Mai university hospital from January 
2005 to December 2011 [51]. They found that four most common pathogens of VAP were A. 
baumannii (54.3%, 337/621), with 65.3% carbapenem resistant and 3.6% resistant to all 
antibiotics; P. aeruginosa (35.2% (191/621)); MRSA (15.1% (94/621)); and K. pneumoniae 
(10.8% (67/621)). A study in adult ICU of King Abdulaziz Medical City in Saudi Arabia 
from 2004 - 2009 also found that most common pathogens for VAP were Acinetobacter spp. 
and P. aeruginosa with high proportion of carbapenems resistance, 70.8% and 30.6% 
respectively [194]. These evidences support that most common pathogen of VAP was Gram 
negative bacilli with predominance of A. baumannii, P. aeruginosa, K. pneumoniae, and S. 
aureus and high rate of carbapenem resistance and MRSA. These pathogens should be 
addressed in infection control program for prevention and limitation VAP incidence. 
6.4.2 Impact of VARI 
In our study, patients with VARI had statistically about double times higher in ICU stay, 
ventilation time, antibiotics use, and ICU cost these factors compared with patients without 
VARI (Table 6 – 2). Other studies on VAP also found that patient with VAP had two to three 
times higher in ventilation time, ICU stay, and hospital cost compared with patients without 
VAP [67, 170]. However, there was not statistically different in these parameters between 
VAP patients and other VARI patients in our study. And I did not find any comparison 
between VAP and other VARI like this. Nseir et al. conducted a retrospective case control 
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study on ventilated patients with immunocompetent, non-trauma, and without chronic 
respiratory failure found that patients with VAT (one type of VARI) had median duration in 
ICU stay and ventilation days about double of those in patients without VAT, 24 vs 12 days 
and 17 vs 8 days, respectively [71]. Impacts of other VARI could perhaps be explained by an 
increased sputum secretion due to VARI as excessive sputum secretion is one cause of 
difficulty when weaning from mechanical ventilation [201]. With more sputum, these patients 
were difficult to wean from ventilator because they rapidly became fatigue on spontaneous 
breathing and that lead to need longer ventilation support until VARI was treated to until 
having normal or less sputum secretion that patients could compensate for it. This means that 
burden of other VARI is also important as VAP on these aspects and should be set as a target 
of infection control practice.  
6.4.2.1 Impact on ventilation time and ICU stay 
Due to the wide difference between admission diagnoses on ICU stay, subgroup analysis was 
performed based on admission diagnoses for more homogeneity. 
Exception for CNS infections, ICU stay and ventilation time of patients with VARI were 
higher than patients without VARI in all admission diagnosis categories. This finding is 
consistent with the majority of published literature  [67, 170, 202-204]. Overall, absolute 
ventilation time and ICU stay between patients with VARI (VAP) and without VARI in our 
study were longer than those in other studies which may be due to differences in case-mix or 
differences in weaning practice or different criteria for discharge from ICU. Kollef et al. 
reported that mean ventilation time and ICU stay between patients with and without VAP 
were 21.8 vs 10.3 day and 20.5 vs 11.6 days, respectively, p < 0.0001 [170]. Rello et al. 
reported these in patients with VAP and without were 14.3 vs 4.7 days and 11.7 vs 5.6 days 
[67]. Erbay et al. conducted a retrospective case control study in Turkey from January 1st 
2000 to December 31st 2002 found that median ICU stay in patients with VAP and without 
were 8.0 vs 2.5 days with p < 0.0001 [204]. Mathai et al. by prospective observational study 
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on 250 adult patients ventilated for > 48 hours in North of India found that median ICU stay 
in patients with and without VAP were 13 vs 6 days, p < 0.001 [46].  
6.4.2.2 Systemic antibiotics use and VARI 
Total systemic antibiotics use 
In total, systemic antibiotic use was 117.2 DOT/100 patient days and 94.1% was used for 
infection treatment with 42.0% for hospital acquired infections and 52.1% for community 
acquired infections: the remaining 5.9% antibiotics use was for prophylaxis (Table 6 – 5). 
Antibiotic consumption in European ICUs in 2007 were 131.8 DOT/100 ICU days with 
76.3% was for anti-infection use, 22% for prophylaxis, and 1.7% for selective digestive 
decontamination [40]. Antibiotics consumption by DOT/100 PD in our study was less than in 
European ICUs despite the majority of patients being admitted with infectious diseases is 
surprising. However our case-mix includes patients with relatively long ICU stays, and thus 
may have led to decreased antibiotic consumption measured by DOT/100 PD as they 
remained in ICU after the original antibiotic course was finished. Mean ICU stay in our study 
was 24.2 days (Table 6 – 2), while that in European ICUs was just 10.2 days. 
The proportion of carbapenems (32.3%) and polymyxin (9.6%) in total DOT of antibiotics 
use in our study was much higher than these in European ICUs, 18.6% and 2.0% respectively 
[40].  This could be due to high level of antibiotic resistance or the different antibiotic 
prescription habits of physicians in our study sites. Most common pathogen of VARI were A. 
baumannii, P. aeruginosa, and K. pneumoniae with high level of carbapenems resistance, 
84.4%, 45.8%, and 23.1%, respectively (Table 6 – 1 & Figure 6 – 1). 
VARI status and total systemic antibiotics use 
Antibiotic use by median DOT/patient and DOT/PD in patients with VARI were statistically 
higher than those in patients without VARI for all patients and subgroups with specific 
diagnosis categories of pneumonia, sepsis and septic shock, and tetanus except for CNS 
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infections and other diagnostic categories (Table 6 – 6a and Table 6 - 6b). This exception 
could be due to heterogeneity of patients with CNS infection and other diagnosis. For 
example, acute bacterial CNS infections commonly require ventilation for a short time and 
usually receive antibiotics for two to three weeks, while viral encephalitis patients are usually 
not given antibiotics but require ventilation and ICU for longer periods, so these patients have 
a higher risk for hospital acquired infections including VARI, although are using less 
antibiotics. Therefore, antibiotics use should be evaluated among patients with more 
homogeneity.   
VARI status and systemic antibiotics use at the study sites 
Antibiotics use by DOT/100 PD were wide different between the study sites. Antibiotics use 
at BMH (210.1) was about 1.5 times higher than that at NHTD (139.6) and triple higher than 
that at HTD (72.6 DOT/100 PD). The high antibiotics use at BMH could be explained a part 
by differences in case-mix and duration of patient stay. In patients with VARI 62.3% of 
antibiotics used were for HAI (similar in all study sites) while in patients without VARI this 
proportion was 30.9% (ranged 28.5% to 36.0% between study sites). This means that besides 
VARI, other HAIs remain common causes for antibiotic prescription within the ICU. (Figure 
6 – 2).  
6.4.2.3 VARI impact on hospital costs 
Our study found that ICU cost of patients with VARI was statistically higher than that of 
patients without VARI, median ICU cost of VARI patients was about double of patients 
without VARI, 4723 vs 2534 US$ respectively (Table 6 – 2). In each admission diagnosis 
category, VARI patients had ICU cost statistically higher than patients without VARI, 
exception for patients with CNS infections (Table 6 – 7). Although CNS infection patient 
with VARI had higher ICU cost than CNS infection patients without VARI, the difference did 
not reach statistically significant. This may be that CNS infections was more heterogeneity of 
 140 
illnesses with short and long time need to treat, or relatively small number of CNS infections 
patients with VARI,  
Rello et al. found that in the United State mean hospital cost for patients with VAP was 
statistically higher than patients without VAP, 104983 vs 63689 US$ respectively, in 1998 - 
1999 [67]. Kollef et al found that in the United State hospital cost for patients with VAP was 
99598 US$ and patients without VAP was 59770 US$ in 2009 with p < 0.0001 [170]. Machai 
et al. conducted a prospective study on patients ventilated > 48 hours at adult tertiary ICU in 
North of India in 2010 – 2011 found that median hospital cost for patients with VAP and 
without was 6350.9 and 2598.8 US$ respectively, p < 0.0001 [70]. Erbay et al. conducted a 
retrospective study in a anaesthesiology ICU in Pamukkale university hospital, Turkey, in 
2000 to 2002 reported that hospital cost for patient with and without VAP were 2839.3 and 
653.4 US$ respectively, p < 0.0001 [204]. This evidences shows that cost for patients with 
VAP/VARI is often two times to four times higher than cost for ICU patients without 
VAP/VARI. Given the incidence of VARI of 25% reported in my study (chapter 5), VARI 
represents a significant economic burden in Vietnam. Prevention of VARI would result in 
significant cost savings.  
6.4.2.4 VARI impacts on mortality in 28 study days 
The 28-day mortality of patients with VAP (27.8%) was higher than patients without any 
VARI (17.5%), but did not reach statistical significance (Table 6 – 8). The mortality rate was 
lower than that reported in some other studies from the United States, Europe, to neighboring 
countries of Vietnam [47, 51, 67, 205]. Many previous studies have used different criteria to 
define VAP than our study and this may be a cause for the difference.  
Furthermore low mortality in current study could be explained by a large number of tetanus 
patients. A high proportion of tetanus patients (36.4%, 48/132 patients) developed VARI 
(Chapter 5) but its mortality was very low: no patients died among 14 patients with VAP, and 
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only one patient (2.9%) died in 34 patients with other VARI (not VAP). After tetanus patients 
were excluded from the analysis for mortality, 28-day mortality in VAP patients was much 
higher at 45.5% (Table 6 – 8). This rate was similar with mortalities of VAP patients reported 
from Thailand (44.4%) [51], China (41.9% and 43.2%) [47], and Europe (35% - 51%) [205]. 
However, mortality of non-tetanus patients with VAP was much higher than mortality of 
30.5% in the United State reported by Rello et al. [67].  
Mortality in patients with other VARI (not VAP) was significantly lower than that in patients 
with VAP both in total patients and in non-tetanus patients (Table 6 – 8). This could be 
because other VARI patients were treated with less severe and earlier infection than VAP 
patients. Earlier treatment of VARI may have prevented subsequent VAP and thereby 
reduced mortality. Jordi Rello and colleagues proposed that VAP could develop from VAT 
(or other VARI) [37]. Martin-Loeches et al. performed a multicentre, prospective, 
observational study at 114 ICUs on 2690 eligible patients (age > 18 years, ventilated for > 48 
hours) from September 1st 2013 to July 31st 2014 [32]. There were 689 (23%) patients 
developed VARI, of which 320 (11%) VAT and 369 (12%) VAP. The authors found that 
secondary VAP from VAT patient was 8% (19/250) in VAT patients received appropriate 
VAT treatment and 29% (20/70) in VAT patients with inappropriate VAT treatment. In 
addition, Dallas et al. found that there was no statistically significant difference in hospital 
mortality between patients with VAP or VAT, and mortality in VAP patients was even lower 
than in VAT patients (19.3% vs 21.4% respectively, p = 0.789) [31]. An international survey 
found that half of physicians participated believed VAT could increase risk of mortality [28]. 
In our study, mortality in patients with other VARI was lower than in patients without VARI, 
although it did not reach statistically significant. The reason for lower rate of mortality in 
patients with other VARI could be due to heterogeneity of study population which masked 
real impact of VARI on mortality. In subgroup analysis in patients with sepsis & septic shock 
and tetanus, mortality with other VARI was higher than in patients without VARI (Table 6 – 
9).  
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Mortality in patients with VARI was higher than in patients without VARI among each type 
of admission diagnosis categories, although these differences were not statistically significant. 
In a multivariate analysis adjusting for admission diagnosis and severity of disease, VARI 
status had similar impact on mortality as in univariate with no statistically significant effect 
(Table 6 – 13). Only increase in APACHE II score were statistically associated with mortality 
increase and tetanus patients had statistically lower risk for death in compared with CNS 
infection patients.  
Melsen et al. in a systematic review found that there was no evidence for association between 
VAP and mortality in ARDS or trauma patients [171]. Mathai et al. conducted a prospective 
observational study at an adult ICU of a tertiary hospital in North India from 1st December 
2010 to 30th November 2011 on adult patients ventilated for > 48 hours with total 250 patients 
enrolled, of which 95 patients developed VAP. Authors reported that there was no difference 
in mortality between patients with VAP and patients without VAP overall (68.4% vs 61.3%, 
respectively, p = 0.200), but patients with higher admission APACHE II scores had 
significantly higher mortality (p = 0.010) [46]. Arabi et al. in systematic review on VAP 
found that crude mortality in VAP patients ranged from 16% to 94% in compared with 
mortality of 0.2% to 51% in patients without VAP [48]. 
In our study, no significant difference in mortality between those with or without appropriate 
antibiotic therapy was found (Table 6 – 10). Inchai et al. found that early or late inappropriate 
initial antibiotics treatment was associated with higher risk for 30 day mortality in compared 
with early appropriate initial treatment, odds ratios (95% CI) were 2.05 (1.58 – 2.83), p < 
0.001 and 1.96 (1.17 – 3.30), p = 0.011 respectively [51]. However, in multivariate analysis 
they found that early inappropriate initial treatment was not statistically higher risk for 
mortality, but late inappropriate initial treatment was statistically significant higher risk for 
death in compared with early appropriate treatment. Nihal Piskin et al. conducted a 
retrospective study at a tertiary hospital in Turkey from January 2005 to January 2008 on 
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initial antibiotics treatment of HAP and VAP [200]. Similar to our study they found no 
differences in 28-day mortality of patients with VAP who received adequate and inadequate 
initial treatment This could be explained by the fact that those with more severe condition 
when VARI diagnosed were more likely to receive active broad spectrum antibiotics. 
Therefore, these patients received adequate empiric antibiotics therapy. However, their more 
severity status leaded to their high mortality. Furthermore in our study, patients often already 
had a bacterial culture result before the decision to diagnose VAP and start antibiotics was 
made, therefore relatively few were treated with inappropriate antibiotics.  
Conclusion  
The majority of pathogens associated with VARI were A. baumannii, P. aeruginosa, and K. 
pneumonia with considerable high rate of carbapenems resistance. Not only VAP but also the 
other VARI resulted in nearly doubling the ICU stay, ventilation time, antibiotics 
consumption, and ICU cost compared with patients without VARI. Therefore, infection 
control practice should firstly focus on VARI to confine and decrease these huge issues and 
also risk of spread high antibiotics resistance bacteria to community. VARI did not showed 
significant impact on mortality. However VAP was associated with an increased risk of death 
at 28 days with an estimated attributable mortality of 10.3% in overall and 20.2% in subgroup 
of non-tetanus patients.  
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Chapter 7 
General discussion and recommendations 
At the time the work in this thesis was done there was no national surveillance system for 
hospital acquired infections in Vietnam. The little data available on HAI came from small 
number of tertiary hospitals and showed a high prevalence of HAI in ICUs with high 
proportion of the associated pathogens showing resistance to even the broadest spectrum 
antibiotics. These limited data suggested that the burden of HAI and antibiotic resistance in 
Vietnamese ICUs was high. However, more compelling, systematic and far reaching evidence 
on the prevalence of HAI, associated antibiotic resistance, and risk factors was needed to 
present to policy makers. The research in this thesis comprises the largest study exploring 
HAI in Vietnamese ICUs, with 3287 patients in 15 ICUs of 14 hospitals. These research 
activities have played an important part in raising awareness of HAI, overuse of antibiotics, 
and the antibiotic resistance situation in Vietnamese hospitals in general, and ICUs in 
particular.  Furthermore, the hospitals involved in this work have become the core of a new 
national surveillance system for antibiotic resistance in Vietnam, established in May 2016.  
The study, results detailed in chapters 3 & 4, confirmed the high prevalence of HAI in 
Vietnam ICUs, in average 29.5% of ICU patients was suffering from at least one HAI 
everyday with 80% of those HAIs was hospital acquired pneumonia. All invasive devices 
were associated with higher risk for HAI, e.g. intubation, central vascular catheterization, 
urinary catheterization, and even peripheral vascular catheter. The study found that a large 
proportion of HAI (31.6%) was acquired in another department before ICU admission, 
showing a need for interventions outside the ICU setting. All these factors should be targets to 
explore for HAI prevention programmes. Where there are locally applicable data to show that 
an intervention is likely to succeed in reducing HAI, that intervention should be explored and 
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evaluated. Where there is no locally relevant data, research is urgently needed to provide 
solutions. 
 The second study, results detailed in chapters 5 & 6, showed that VARI has substantial 
impact on patients, with increased ICU stays of 11 days on average (27 vs 16 days), increased 
ventilation duration of 12.5 days (21.5 vs 9 days), increased antibiotic consumption of 11 
DOT/patient (28 vs 17 DOT/patient); and an increase in ICU cost of 2189 US$ (4723 vs 2534 
US$) compared with patients without VARI.  
Given an estimated 22,570 patients admitted to the ICUs of 14 surveyed hospitals in the year 
2012 and VARI prevalence of 24.6% as in the second study, we would expect 5,552 patients 
developed VARI leading to an extra 69,403 ventilation days, 61,074 ICU days, 61,074 DOT 
antibiotic consumption, and 12,153,810 US$ ICU direct costs. With a total of 40 tertiary and 
304 provincial acute care hospitals across Vietnam, the extra cost for VARI nationally would 
be many times higher and could account for a significant proportion of total health 
expenditure in 2012 (~ 4.7 billion US$) [101]. Clearly such a calculation is simplistic, and 
based on assumptions that may not be true, however it is clear that the cost of VARI even in 
simple financial terms is significant at a national level, highlighting the need for urgent action.  
Hospital acquired pneumonia was by far the most common HAI reported (~ 80% of HAI). 
Given the limited resource in middle income countries such as Vietnam, this should be the 
first priority to resolve. Many measures have been implemented in high income countries, 
such as VAP bundles, new endotracheal tube designs (for example with subglottic suction 
ports and polyurethane cuffs), minimization of sedatives, and others. Differences in hospital 
and ICU infrastructure, medical equipment, staffing, infection control facilities bring into 
question whether these measures would have positive results in countries like Vietnam. Given 
the resource implications for most of these interventions, further studies to establish firm 
evidence are needed before expanding to national application.  
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These studies have also demonstrated the high level of antibiotic use in Vietnamese ICUs, 
both through the high proportion of patients on antibiotics (84.8%) and the high antibiotic 
consumption (average 173.7 DOT/100 PD) as detailed in chapter 4. This level of antibiotic 
consumption could be a result of the admissions having a high prevalence of infectious 
diseases, which was the reason for ICU admission for 46.3% patients in ICU. However, a 
more important factor is the high proportion of antibiotics used with no clear indication 
(overall 14.9%, up to 46.0% in an individual ICUs), suggesting widespread misuse. Antibiotic 
use is an important factor for the  development of resistance to antibiotics [153]. In addition, 
the consumption of 23.9 and 5.7 DOT/100 PD respectively of the ‘last resort’ antibiotics 
carbapenems and colistin on average (rising to 81.9 and 66 DOT/100 PD in one ICU) is 
highly alarming. These data suggest that antibiotic stewardship is urgently needed to avoid 
inappropriate use of antibiotics. Currently few hospital ICUs have such programmes, and 
fewer still have active, daily input from infectious diseases or microbiology specialists into 
appropriate diagnostics and antibiotic prescribing.  
The high prevalence of carbapenem resistance among HAI pathogens described is associated 
with the increased use of these last resort antibiotics. The high ESBL prevalence rate in 
Vietnam, drives the higher carbapenem consumption [206]. However, now we are reaching 
unacceptable high levels of carbapenem resistance, significantly diminishing our arsenal of 
effective drugs. Approaches to address this problem include exploring the use of alternatives 
to carbapenems where suitable (such as temocillin as an alternative treatment for ESBL 
producing Enterobacteriaceae) and strict infection control to limit spread of carbapenem 
resistant organisms within hospitals. With inadequate infrastructure and limited staff, simple 
measures (such as hand hygiene, cleaning and disinfection of the hospital environment) 
should be strictly implemented first. More complicated measures (e.g. changes to the 
infrastructure of hospital including provision of adequate side rooms, changes to systems that 
may encourage antibiotic use and investment in rapid diagnosis of highly resistant pathogens 
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to aid infection control) need to be evaluated carefully, including costs, before systematic 
application.  
Additionally, actions to prevent or delay the development of antibiotic resistance also play an 
essential role. Antibiotic use is the most important condition for the evolution of antibiotic 
resistance. However, antibiotic use is essential for the treatment of infectious diseases. 
Therefore, appropriate use of antibiotics is especially important to limit antibiotic 
consumption. Inappropriate antibiotic use fuels the development of resistance without any 
benefit. Although not in the scope of this thesis, an understanding that hospitals and ICUs are 
not in isolation is needed. So addressing this inappropriate use of antibiotics requires 
measures applied not only to human health in hospitals and the community but also to 
agriculture. It requires systematic cooperation of many ministries including the Ministry of 
Health and Ministry of Agriculture and Rural Development in Vietnam.  
In hospitals, two main types of measures are appropriate antibiotic use and effective infection 
prevention (infection control practice). To improve appropriate antibiotic use needs to 
develop national and institutional guidelines on diagnosis and treatment infectious diseases 
based on their current data on pathogen and antibiotic resistance, establish and enhance 
antibiotic stewardship programmes, monitoring and feedback on antibiotic use and antibiotic 
resistance. Ideally these data and if possible certain important bacteria, should be sent to a 
central national reference laboratory to continually monitor levels of resistance in important 
bacteria and assess whether policy interventions are having impact in control. 
Infection control programmes need to be supplied adequate resources for efficient practice 
and will likely need new evidence to inform policies in these settings of high levels of 
resistance but limited resources and poor infrastructure for infection control purposes. A 
certainty is that as Vietnamese medical care improves, with more patients having complex 
surgeries, chemotherapy etc the burden of antibiotic resistance will become more severe. 
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There is certainly no little difficulty but these measures really could be done if there are active 
involvement of both government and community. 
In conclusion, this thesis includes the largest point prevalence survey on hospital acquired 
infection and antimicrobial use in ICUs in Vietnam and an observational study on ventilator 
associated pneumonia and other ventilator associated respiratory infections. The thesis 
provides evidence of the high burden of HAI in Vietnam ICUs along with substantial impacts 
on ventilation duration, ICU stay, antibiotic use, and cost. In addition, the high proportion of 
carbapenems resistance among HAI pathogens is clear evidence for resources to enable the 
enhancement of infection control practice in Vietnamese ICUs. 
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Appendix A: Supplementary Tables 
Table A – 1: Basic characteristics of participating hospitals and ICUs.  
 
Hospital 
Code 
Basic hospital information Basic ICU information 
Total 
bed 
patients 
/year 
patient 
days 
/year 
Alcohol 
hand rub 
per year 
(litres) 
Infection control Type of 
ICUa 
Patients 
No. 
/year  
Patient 
days 
/year  
Mean 
ICU 
stay 
(day) 
Alcohol 
hand rub 
per year 
(litres) 
Alcohol 
use per 
patient 
day (ml) 
Total 
beds 
No. 
Room 
Single 
room 
No. 
doctors 
No. 
nurses 
Doctor/
bed 
Nurse/
Bed 
Nurses Doctors 
H01 280 7,365 76,342 1,030 0 2 I-ICU 497 4,631 9.3 130 28.1 18 6 2 4 22 0.22 1.22 
H02 1900 114,000 1,290,0
00 
6,152 12 2 G-ICU 1,345 14,007 10.4 1,408 100.5 38 12 6 13 55 0.34 1.45 
H04 841 42,074 287,323 400 4 2 M-ICU 1,240 5,904 4.8 140 16.9 20 4 0 7 25 0.35 1.25 
S-ICU 1,228 5,904 4.8 100 23.7 17 4 0 4 24 0.24 1.41 
H05 1050 41,106 366,828 1,200 29 11 S-ICU 696 5,064 7.3 336 66.4 16 2 0 4 40 0.25 2.50 
H06 900 41,430 356,356 3,500 0 1 M-ICU 1,052 5,704 5.4 500 87.7 16 5 0 11 24 0.69 1.50 
H07 750 34,848 183,885 2,996 2 1 G-ICU 751 3,508 4.7 482 137.4 10 4 0 7 18 0.70 1.80 
H08 1050 15,000 60,000 1,000 12 6 M-ICU 1,674 6,418 3.8 480 74.8 20 5 0 5 22 0.25 1.10 
H09 1500 85,054 712,844 5640 25 1 G-ICU 3,049 20,772 6.8 2,210 106.4 47 7 0 13 38 0.28 0.81 
H10 2362 85,608 891,908 10,500 10 2 M-ICU 2,530 16,280 6.4 1,200 73.7 60 7 6 11 66 0.18 1.10 
H11 1000 57,523 373,910 650 6 0 M-ICU 2,356 12,323 5.2 480 39.0 34 1 0 15 48 0.44 1.41 
H12 750 48,049 290,215 110 2 1 G-ICU 2,374 12,218 5.1 110 9.0 20 4 0 9 32 0.45 1.60 
H13 1800 123,850 918,026 13,066 3 2 G-ICU 1,196 11,901 10.0 500 42.0 31 3 0 15 54 0.48 1.74 
H15 550 41,751 288,696 1,113 3 1 I-ICU 540 8,651 16.0 900 104.0 23 5 1 8 48 0.35 2.09 
H16 800 49,248 326,723 7,200 5 1 G-ICU 2,042 18,786 9.2 360 19.2 30 1 0 16 33 0.53 1.10 
a I: infectious, G: general (mixed), M: medical, S: surgical.
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Table A – 2: Patient Characteristics 
Characteristics Tertiary hospitals Provincial hospitals Total  
Hospital code H01 H02 H05 H10 H13 H16 H04 H04 H06 H07 H08 H09 H11 H12 H15 
ICU type I-ICU G-ICU S-ICU G-ICU G-ICU G-ICU S-ICU M-ICU M-ICU G-ICU M-ICU G-ICU M-ICU G-ICU I-ICU 
No.  patients, n 203 223 138 578 277 214 89 54 148 145 187 403 223 223 182 3287 
Age (years) Mean 
(median, 
IQR) 
52.5  
(53, 43 – 
65) 
54.7  
(57, 39 – 
71) 
47.5 (47, 
27 – 64.2) 
56.5 (56, 
40 – 76) 
59.6 (64, 
44 – 76) 
68.3  
(72, 57.7 – 
83) 
54.1 (57, 
38 – 70) 
70.7 (73, 
62 – 81) 
65.8 (68, 
54.5 – 
79.7) 
59.2 (64, 
45.5 – 76) 
67.3 (73, 
53 – 79) 
64.5 (68, 
50 – 80) 
60.8 (63, 
48 – 78) 
57.8 (59, 
37 – 80) 
51.9 (54, 
35 – 65) 
59.2  
(61, 45 – 
77) 
Missing  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Gender, n (%) Male 145 (71.4) 145 (65) 111 (80.4) 415 (71.8) 145 (52.3) 111 (51.9) 61 (68.5) 31 (57.4) 96 (64.9) 114 (78.6) 118 (63.1) 210 (52.1) 138 (61.9) 143 (64.1) 118 (64.8) 2101(63.9) 
Female 58 (28.6) 78 (35) 27 (19.6) 163 (28.2) 132 (47.7) 103 (48.1) 28 (31.5) 23 (42.6) 52 (35.1) 31 (21.4) 69 (36.9) 193 (47.9) 85 (38.1) 80 (35.9) 64 (35.2) 1186(36.1) 
Missing  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Comorbidity, n 
(%) 
Yes 82 (40.6) 131 (59.5) 8 (5.8) 107 (18.5) 121 (43.7) 126 (59.1) 28 (31.5) 34 (63) 104 (70.3) 87 (60) 93 (49.7) 141 (37) 43 (36.4) 83 (37.2) 61(30.1) 1249(39.6) 
No 120 (59.4) 89 (40.5) 129 (94.2) 471 (81.5) 156 (56.3) 87 (40.9) 61 (68.5) 20 (37) 44 (29.7) 58 (40) 94 (50.3) 240 (63) 75 (63.6) 140 (62.8) 118 (69.9) 1902(60.4) 
Missing  1 3 1 0 0 1 0 0 0 0 0 22 105 0 3 136 
Source of ICU 
admission, n (%) 
Commu_
nity  
0 59 (26.8) 10 (10.1) 424 (73.4) 19 (6.9) 79 (36.9) 26 (29.2) 47 (87) 99 (67.3) 78 (53.8) 102 (54.5) 207 (53.6) 23 (28.7) 197 (89.1) 57 (31.8) 1427(46.2) 
Current 
hospital 
115 (57.2) 85 (38.6) 94 (85.5) 90 (15.6) 159 (57.4) 66 (30.8) 27 (30.3) 3 (5.6) 37 (25.2) 40 (27.6) 45 (24.1) 101 (26.2) 32 (40) 16 (7.2) 20 (11.2) 930 (30.1) 
Other 
hospital 
86 (42.8) 76 (34.5) 6 (5.5) 64 (11.1) 96 (34.7) 69 (32.2) 22 (24.7) 3 (5.6) 8 (5.4) 27 (18.6) 40 (21.4) 26 (6.7) 8 (10) 6 (2.7) 101 (56.4) 638 (20.7) 
Other  0 0 0 0 3 (1.1) 0 14 (15.7) 1 (1.9) 3 (2.0) 0 0 52 (13.5) 17 (21.3) 2 (0.9) 1 (0.6) 93 (3) 
Missing  2 3 28 0 0 0 0 0 1 0 0 17 143 2 3 199 
Reason for 
admission, n (%) 
Medical  1 (0.5) 82 (37.3) 3 (2.8) 368 (63.7) 32 (11.6) 100 (46.7) 11 (12.6) 31 (57.4) 99 (68.3) 57 (39.3) 46 (24.7) 189 (49.7) 42 (52.5) 139 (63.2) 3 (1.7) 1203(39.1) 
Infection  200 (99.5) 123 (55.9) 6 (5.5) 88 (15.2) 159 (57.4) 114 (53.3) 13 (14.9) 23 (42.6) 46 (31.7) 37 (25.5) 140 (75.3) 188 (49.5) 31 (38.8) 81 (36.8) 174 (97.8) 1423(46.3) 
Surgery 0 15 (6.8) 100 (91.7) 122 (21.1) 86 (31) 0 63 (72.4) 0 0 51 (35.2) 0 3 (0.8) 7 (8.8) 0 1 (0.6) 448 (14.6) 
Missing  2 3 29 0 0 0 2 0 3 0 1 23 143 3 4 213 
Surgery since 
admission, n (%) 
None 118 (58.1) 160 (72.7) 4 (2.9) 541 (93.6) 127 (45.8) 156 (72.9) 28 (31.5) 52 (96.3) 136 (91.9) 94 (64.8) 186 (99.5) 375 (93.1) 154 (69.1) 218 (97.8) 121 (66.5) 2470(75.2) 
Minor 85 (41.9) 31 (14.1) 0 3 (0.5) 43 (15.5) 29 (13.6) 3 (3.4) 1 (1.9) 9 (6.1) 5 (3.4) 1 (0.5) 9 (2.2) 45 (20.2) 2 (0.9) 61 (33.5) 327 (10) 
Major 0 29 (13.2) 134 (97.1) 34 (5.9) 107 (38.6) 29 (13.6) 58 (65.2) 1 (1.9) 3 (2.0) 46 (31.7) 0 19 (4.7) 24 (10.8) 3 (1.3) 0 487 (14.8) 
Missing 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 3 
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Characteristics Tertiary hospitals Provincial hospitals Total  
Hospital code H01 H02 H05 H10 H13 H16 H04 H04 H06 H07 H08 H09 H11 H12 H15 
ICU type I-ICU G-ICU S-ICU G-ICU G-ICU G-ICU S-ICU M-ICU M-ICU G-ICU M-ICU G-ICU M-ICU G-ICU I-ICU 
No.  patients, n 203 223 138 578 277 214 89 54 148 145 187 403 223 223 182 3287 
Intubation, n (%) Yes 165 (81.3) 98 (43.9) 138 (100) 184 (31.8) 241 (87) 160 (74.8) 45 (50.6) 7 (13) 76 (51.4) 81 (55.9) 117 (62.6) 189 (46.9) 92 (41.3) 50 (22.4) 76 (41.8) 1719(52.3) 
No 38 (18.7) 125 (56.1) 0 394 (68.2) 36 (13) 54 (25.2) 44 (49.4) 47 (87) 72 (48.6) 64 (44.1) 70 (37.4) 214 (53.1) 131 (58.7) 173 (77.6) 106 (58.2) 1568(47.7) 
Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Central vascular 
catheter, n (%) 
Yes 99 (48.8) 129 (57.9) 133 (96.4) 49 (8.5) 213 (76.9) 31 (14.5) 44 (49.4) 3 (5.6) 38 (25.7) 13 (9) 7 (3.7) 79 (19.6) 17 (7.6) 31 (13.9) 35 (19.2) 921 (28) 
No 104 (51.2) 94 (42.1) 5 (3.6) 529 (91.5) 64 (23.1) 183 (85.5) 45 (50.6) 51 (94.4) 110 (74.3) 132 (91) 180 (96.3) 324 (80.4) 206 (92.4) 192 (86.1) 147 (80.8) 2366 (72) 
Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Urinary catheter, 
n (%) 
Yes 170 (83.7) 133 (59.6) 137 (99.3) 71 (12.3) 246 (88.8) 107 (50) 69 (77.5) 11 (20.4) 51 (34.5) 65 (44.8) 33 (17.6) 265 (65.8) 68 (30.5) 128 (57.4) 62 (34.1) 1616(49.2) 
No 33 (16.3) 90 (40.4) 1 (0.7) 507 (87.7) 31 (11.2) 107 (50) 20 (22.5) 43 (79.6) 97 (65.5) 80 (55.2) 154 (82.4) 138 (34.2) 155 (69.5) 95 (42.6) 120 (65.9) 1671(50.8) 
Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Peripheral 
vascular catheter, 
n (%) 
Yes 126 (62.1) 188 (84.3) 5 (3.6) 532 (92) 182 (65.7) 213 (99.5) 67 (75.3) 45 (83.3) 100 (67.6) 106 (73.1) 169 (90.4) 391 (97) 216 (96.9) 217 (97.3) 166 (91.2) 2723(82.8) 
No 77 (37.9) 35 (15.7) 133 (96.4) 46 (8) 95 (34.3) 1 (0.5) 22 (24.7) 9 (17.6) 48 (32.4) 39 (26.9) 18 (9.6) 12 (3) 7 (3.1) 6 (2.7) 16 (8.8) 564 (17.2) 
Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Dialysis, n (%) Yes 13 (6.4) 75 (33.6) 0 4 (0.7) 57 (20.6) 25 (11.7) 0 0 19 (12.8) 9 (6.2) 2 (1.1) 21 (5.2) 34 (15.2) 7 (3.1) 4 (2.2) 270 (82) 
No 190 (93.6) 148 (66.4) 138 (100) 574 (99.3) 220 (79.4) 189 (88.3) 89 (100) 54 (100) 129 (87.2) 136 (93.8) 185 (98.9) 382 (94.8) 189 (84.8) 216 (96.9) 178 (97.8) 3017(91.8) 
Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Family support in 
patient care, n (%) 
Yes 198 (97.5 220 (98.7) 2 (1.4) 573 (99.1) 6 (2.2) 2 (0.9) 89 (100) 54 (100) 148 (100) 142 (97.9) 187 (100) 5 (1.2) 222 (99.6) 221 (99.1) 3 (1.6) 2072(63.0) 
No 5 (2.5) 3 (1.3) 136 (98.6) 5 (0.9) 271 (97.8) 212 (99.1) 0 0 0 3(2.1) 0 398 (98.8) 1 (0.4) 2 (0.9) 179 (98.4) 1215(37.0) 
Antibiotic use, n 
(%) 
Yes 155 (76.4) 184 (82.5) 134 (97.1) 577 (99.8) 250 (90.3) 175 (81.8) 83 (93.3) 27 (50) 131 (88.5) 89 (61.4) 148 (79.1) 383 (95) 188 (84.3) 136 (61) 127 (69.8) 2787(84.8) 
No 48 (23.6) 39 (17.5) 4 (2.9) 1 (0.2) 27 (9.7) 39 (18.2) 6 (6.7) 27 (50) 17 (11.5) 56 (38.6) 39 (20.9) 20 (5) 35 (15.7) 87 (39) 55 (30.2) 500 (15.2) 
Missing 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Hospital acquired 
infection, n (%) 
Yes 68 (33.5) 84 (38.5) 84 (60.9) 40 (6.9) 140 (50.5) 126 (59.2) 12 (13.5) 3 (5.6) 43 (30.5) 21 (14.5) 40 (21.4) 146 (36.8) 81 (36.5) 36 (16.1) 41 (22.7) 965 (29.5) 
No 135 (66.5) 134 (61.5) 54 (39.1) 538 (93.1) 137 (49.5) 87 (40.8) 77 (86.5) 51 (94.4) 98 (69.5) 124 (85.5) 147 (78.6) 251 (63.2) 141 (63.5) 187 (83.9) 140 (77.3) 2301(70.5) 
Missing 0 5 0 0 0 1 0 0 7 0 0 6 1 0 1 21 
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Table A – 3: Antimicrobials Combinations 
combination of 2 antimicrobials combination of 3 antimicrobials Combination of 4 antimicrobials 
Antimicrobial combinations  
(n = 1343) 
% (n) Antimicrobial combinations (n = 552) % (n) Antimicrobial combinations (n=159) % (n) 
J01DD Third-
generation 
cephalosporins 
J01MA 
Fluoroquinolones 
19.1 
(257) 
J01DD Third-
generation 
cephalosporins 
J01MA 
Fluoroquinolones 
J01XA 
Glycopeptide 
antibacterials 
13.6 
(75) 
J01DE Fourth-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
13.2 
(21) 
J01DH 
Carbapenems 
J01MA 
Fluoroquinolones 
10.8 
(145) 
J01DD Third-
generation 
cephalosporins 
J01MA 
Fluoroquinolones 
J01XD Imidazole 
derivatives 
6.0 
(33) 
J01DD Third-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
10.7 
(17) 
J01DD Third-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
7.8 
(105) 
J01DH 
Carbapenems 
J01MA 
Fluoroquinolones 
J01XA 
Glycopeptide 
antibacterials 
6.0 
(33) 
J01CR Combinations 
of penicillins included 
beta-lactamase 
inhibitors 
J01DD Third-
generation 
cephalosporins 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
3.1 (5) 
J01DH 
Carbapenems 
J01XA 
Glycopeptide 
antibacterials 
5.0 
(67) 
J01DD Third-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
J01MA 
Fluoroquinolones 
5.6 
(31) 
J01DC Second-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
2.5 (4) 
J01DE Fourth-
generation 
cephalosporins 
J01MA 
Fluoroquinolones 
4.8 
(65) 
J01DE Fourth-
generation 
cephalosporins 
J01MA 
Fluoroquinolones 
J01XA 
Glycopeptide 
antibacterials 
4.9 
(27) 
J01DD Third-
generation 
cephalosporins 
J01FA Macrolides 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
2.5 (4) 
J01DH 
Carbapenems 
J01XB Polymyxins 
(colistin injection) 
4.5 
(61) 
J01DD Third-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
J01XA 
Glycopeptide 
antibacterials 
2.9 
(16) 
J01DD Third-
generation 
cephalosporins 
J01MA 
Fluoroquinolones 
J01XA 
Glycopeptide 
antibacterials 
J01XD Imidazole 
derivatives 2.5 (4) 
J01DH 
Carbapenems 
J01XD Imidazole 
derivatives 
4.4 
(59) 
J01DE Fourth-
generation 
cephalosporins 
J01GB Other 
aminoglycosides 
J01MA 
Fluoroquinolones 
2.5 
(14) J01DH Carbapenems 
J01GB Other 
aminoglycosides 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
2.5 (4) 
J01DD Third-
generation 
cephalosporins 
J01XD Imidazole 
derivatives 
4.2 
(57) 
J01DH 
Carbapenems 
J01MA 
Fluoroquinolones 
J01XD Imidazole 
derivatives 
2.5 
(14) 
J01CR Combinations 
of penicillins included 
beta-lactamase 
inhibitors 
J01DE Fourth-
generation 
cephalosporins 
J01FA 
Macrolides 
J01MA 
Fluoroquinolones 1.9 (3) 
J01DH 
Carbapenems 
J01XX Other 
antibacterials 
3.4 
(46) 
J01DH 
Carbapenems 
J01XA 
Glycopeptide 
antibacterials 
J01XD Imidazole 
derivatives 
2.2 
(12) 
J01CR Combinations 
of penicillins included 
beta-lactamase 
inhibitors 
J01DE Fourth-
generation 
cephalosporins 
J01MA 
Fluoroquinolone
s 
J01XA 
Glycopeptide 
antibacterials 
1.9 (3) 
J01DH 
Carbapenems 
J01GB Other 
aminoglycosides 
2.8 
(38) 
J01DH 
Carbapenems 
J01XA 
Glycopeptide 
antibacterials 
J01XB 
Polymyxins 
2.0 
(11) 
J01DE Fourth-
generation 
cephalosporins 
J01FA Macrolides J01GB Other aminoglycosides 
J01XA 
Glycopeptide 
antibacterials 
1.9 (3) 
Other 91 combinations 33.0 (443) 
Other 137 combinations 51.8 
(286) Other 77 combinations 
57.2 
(97) 
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Table A – 4: The Common Antimicrobial Agents Used 
Patients used two antimicrobials 
(n = 1343 patient) 
Patients used three antimicrobials 
(n = 552 patients) 
Patients used four antimicrobials 
(n = 159 patients) 
Total antimicrobials used (n=5590) 
Antimicrobial group % (n) Antimicrobial group % (n) Antimicrobial group % (n) Antimicrobial group % (n) 
J01MA Fluoroquinolones 21.1 
(556) 
J01MA Fluoroquinolones 21.1 
(350) 
J01MA Fluoroquinolones 19.3 
(123) 
J01DD Third-generation 
cephalosporins 
20.1 
(1126) 
J01DD Third-generation 
cephalosporins 
19.8 
(533) 
J01XA Glycopeptide 
antibacterials 
15.5 
(257) 
J01XA Glycopeptide 
antibacterials 
17.3 
(110) 
J01MA Fluoroquinolones 19.4 
(1082) 
J01DH Carbapenems 16.6 
(445) 
J01DD Third-generation 
cephalosporins 
13.6 
(225) 
J01GB Other aminoglycosides 15.1 
(96) 
J01DH Carbapenems 14.1 
(786) 
J01GB Other aminoglycosides 9.2 
(247) 
J01GB Other 
aminoglycosides 
10.3 
(171) 
J01DD Third-generation 
cephalosporins 
8.8  
(56) 
J01XA Glycopeptide 
antibacterials 
9.6 
(536) 
J01XA Glycopeptide 
antibacterials 
5.7 
(153) 
J01DH Carbapenems 10.3 
(170) 
J01DE Fourth-generation 
cephalosporins 
8.6  
(55) 
J01GB Other aminoglycosides 9.3 
(521) 
J01XD Imidazole derivatives 5.5 
(149) 
J01XD Imidazole 
derivatives 
6.4 
(106) 
J01DH Carbapenems 5.8  
(37) 
J01DE Fourth-generation 
cephalosporins 
5.5 
(310) 
J01DE Fourth-generation 
cephalosporins 
4.4 
(118) 
J01DE Fourth-generation 
cephalosporins 
5.3  
(87) 
J01XD Imidazole derivatives 4.6  
(29) 
J01XD Imidazole derivatives 5.2 
(289) 
J01XB Polymyxins 4.2 
(112) 
J01XB Polymyxins 3.6  
(60) 
J01FA Macrolides 3.9  
(25) 
J01CR Combinations of 
penicillins included beta-
lactamase inhibitors 
3.5 
(194) 
J01CR Combinations of 
penicillins included beta-
lactamase inhibitors 
3.3  
(88) 
J01CR Combinations of 
penicillins included beta-
lactamase inhibitors 
1.8  
(29) 
J01CR Combinations of 
penicillins included beta-
lactamase inhibitors 
3.3  
(21) 
J01XB Polymyxins 3.3 
(186) 
J01XX Other antibacterials 3.1  
(83) 
J01DC Second-generation 
cephalosporins 
1.7  
(28) 
J01DC Second-generation 
cephalosporins 
2.8  
(18) 
J01XX Other antibacterials 2.2 
(122) 
18 other antibacterial groups 7.1 
(192) 
18 other antibacterial groups 10.4 
(173) 
16 other 16 antibacterial 
groups 
10.4 
(66) 
12 other antibacterial groups 7.8 
(438) 
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Table A – 5: Antimicrobials resistance of pathogens for HAIs originated from surveyed hospitals 
Antimicrobial resistance of 
isolates 
Tertiary ICUs Provincial ICUs Total 
H01 H02 H05 H10 H13 H16 H04 H06 H07 H08 H09 H11 H12 H15 
Total isolates with 
susceptibility available  
51 37 117 22 91 50 2 21 16 40 67 27 17 34 592 
K. pneumoniae C3-R, % (C3-
R/isolates) 
50.0 
(5/10) 
100.0 
(3/3) 
66.7 
(6/9) 
100.0 
(5/5) 
75.0 
(3/4) 
81.8 
(9/11) 
0.0 
(0/0) 
50.0 
(1/2) 
0.0 
(0/0) 
0.0 
(0/2) 
81.8 
(9/11) 
100.0 
(2/2) 
100.0 
(3/3) 
16.7 
(1/6) 
69.1 
(47/68) 
K. pneumoniae Car-R, % 
(n/isolates) 
10.0 
(1/10) 
33.3 
(1/3) 
11.1 
(1/9) 
0.0 
(0/5) 
25.0 
(1/4) 
18.2 
(2/11) 
0.0 
(0/0) 
0.0 
(0/2) 
0.0 
(0/0) 
0.0 
(0/2) 
27.3 
(3/11) 
50.0 
(1/2) 
0.0 
(0/3) 
0.0 
(0/6) 
14.7 
(10/68) 
Klebsiella spp. C3-R, % 
(n/isolates) 
66.7 
(2/3) 
100.0 
(1/1) 
77.8 
(7/9) 
50.0 
(2/4) 
16.7 
(1/6) 
100.0 
(2/2) 
0.0 
(0/0) 
50.0 
(1/2) 
100.0 
(1/1) 
66.7 
(2/3) 
77.8 
(7/9) 
66.7 
(4/6) 
100.0 
(2/2) 
0.0 
(0/0) 
66.7 
(32/48) 
Klebsiella spp. Car-R, % 
(n/isolates) 
33.3 
(1/3) 
0.0 
(0/1) 
11.1 
(1/9) 
0.0 
(0/4) 
0.0 
(0/6) 
0.0 
(0/2) 
0.0 
(0/0) 
0.0 
(0/2) 
0.0 
(0/1) 
0.0 
(0/3) 
0.0 
(0/9) 
16.7 
(1/6) 
0.0 
(0/2) 
0.0 
(0/0) 
6.3 
(3/48) 
E. coli C3-R, % (n/isolates) 100.0 
(2/2) 
80.0 
(4/5) 
33.3 
(1/3) 
100.0 
(1/1) 
0.0 
(0/2) 
33.3 
(1/3) 
0.0 
(0/0) 
0.0 
(0/2) 
100.0 
(1/1) 
33.3 
(1/3) 
75.0 
(3/4) 
75.0 
(3/4) 
0.0 
(0/0) 
66.7 
(2/3) 
57.6 
(19/33) 
E. coli Car-R, % (n/isolates) 0.0 
(0/2) 
40.0 
(2/5) 
0.0 
(0/3) 
0.0 
(0/1) 
0.0 
(0/2) 
0.0 
(0/3) 
0.0 
(0/0) 
0.0 
(0/2) 
0.0 
(0/1) 
0.0 
(0/3) 
0.0 
(0/4) 
0.0 
(0/4) 
0.0 
(0/0) 
0.0 
(0/3) 
6.1 
(2/33) 
Other Enterobacteriaceae C3-
R, % (n/isolates) 
44.4 
(4/9) 
0.0 
(0/1) 
72.2 
(13/18) 
0.0 
(0/0) 
40.0 
(2/5) 
100.0 
(2/2) 
100.0 
(1/1) 
0.0 
(0/1) 
50.0 
(2/4) 
60.0 
(3/5) 
75.0 
(3/4) 
100.0 
(7/7) 
0.0 
(0/0) 
0.0 
(0/0) 
64.9 
(37/57) 
Other Enterobacteriaceae 
Car-R, % (n/isolates) 
0.0 
(0/9) 
0.0 
(0/1) 
11.1 
(2/18) 
0.0 
(0/0) 
0.0 
(0/5) 
50.0 
(1/2) 
100.0 
(1/1) 
0.0 
(0/1) 
0.0 
(0/4) 
0.0 
(0/5) 
0.0 
(0/4) 
0.0 
(0/7) 
0.0 
(0/0) 
0.0 
(0/0) 
7.0 
(4/57) 
Total Enterobacteriaceae C3-
R, % (n/isolates) 
54.2 
(13/24) 
80.0  
(8/10) 
69.2  
(27/39) 
80.0  
(8/10) 
35.3  
(6/17) 
77.8  
(14/18) 
100.0  
(1/1) 
28.6  
(2/7) 
66.7  
(4/6) 
50.0  
(6/12) 
78.6  
(22/28) 
84.2  
(16/19) 
100.0  
(5/5) 
33.3  
(3/9) 
65.5  
(135/206) 
Total Enterobacteriaceae 
Car-R, % (n/isolates) 
8.3  
(2/24) 
30.0  
(3/10) 
10.3  
(4/39) 
20.0  
(2/10) 
5.9  
(1/17) 
16.7  
(3/18) 
100.0  
(1/1) 
0.0  
(0/7) 
0.0  
(0/6) 
0.0  
(0/12) 
10.7  
(3/28) 
10.5  
(2/19) 
0.0  
(0/5) 
0.0  
(0/9) 
9.2  
(19/206) 
A. baumannii Car-R, % 
(n/isolates) 
94.1 
(16/17) 
100.0 
(20/20) 
100.0 
(18/18) 
100.0 
(7/7) 
97.8 
(44/45) 
100.0 
(13/13) 
0.0 
(0/0) 
25.0 
(1/4) 
0.0 
(0/0) 
20.0 
(1/5) 
73.3 
(11/15) 
50.0 
(1/2) 
33.3 
(1/3) 
83.3 
(5/6) 
89.0 
(138/155) 
Acinetobacter spp Car-R, % 
(n/isolates) 
0.0 
(0/1) 
0.0 
(0/0) 
95.7 
(22/23) 
0.0 
(0/0) 
0.0 
(0/0) 
0.0 
(0/0) 
0.0 
(0/0) 
0.0 
(0/0) 
0.0 
(0/0) 
37.5 
(3/8) 
0.0 
(0/1) 
100.0 
(3/3) 
0.0 
(0/0) 
75.0 
(6/8) 
77.3 
(34/44) 
P. aeruginosa Car-R, % 
(n/isolates) 
71.4 
(5/7) 
100.0 
(4/4) 
64.3 
(9/14) 
66.7 
(2/3) 
71.4 
(5/7) 
33.3 
(2/6) 
0.0 
(0/0) 
25.0 
(1/4) 
28.6 
(2/7) 
36.4 
(4/11) 
83.3 
(5/6) 
0.0 
(0/0) 
14.2 
(1/7) 
0.0 
(0/2) 
51.9 
(41/79) 
Methicillin resistant S. 
aureus, % (n/isolates) 
0.0 
(0/1) 
100.0 
(1/1) 
100.0 
(4/4) 
0.0 
(0/0) 
85.7 
(6/7) 
87.5 
(7/8) 
0.0 
(0/0) 
0.0 
(0/1) 
100.0 
(2/2) 
100.0 
(2/2) 
25.0 
(1/4) 
100.0 
(2/2) 
0.0 
(0/0) 
100.0 
(3/3) 
77.8 
(28/36) 
Enterococcus spp. Glyco-R, 
% (n/isolates) 
0.0 
(0/0) 
100.0 
(1/1) 
42.9 
(3/7) 
0.0 
(0/0) 
33.3 
(2/6) 
0.0 
(0/0) 
0.0 
(0/0) 
0.0 
(0/0) 
0.0 
(0/0) 
100.0 
(1/1) 
100.0 
(4/4) 
0.0 
(0/0) 
0.0 
(0/0) 
75.0 
(3/4) 
60.9 
(14/23) 
C3-R: resistant to 3rd generation cephalosporins, Car-R: resistant to carbapenems, Glyco-R: resistant to glycopeptides 
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Table A – 6: Antibiotics use for patients with carbapenem resistance pathogens 
Combination with polymyxins (n =117) Combination without polymyxins (n = 94) Mono therapy (n = 30) 
Antibiotic agents N 
% AB use  
(n = 158)  Antibiotic agents N 
% AB use  
(n = 224)  Antibiotic agents N 
% AB use  
(n = 30)   
Meropenem 33 20.9% Meropenem 29 12.9% Polymyxins 11 36.7% 
Imipenem and enzyme inhibitor 29 18.4% Vancomycin (parenteral) 27 12.1% Cefoperazone, combinations 4 13.3% 
Cefoperazone, combinations 24 15.2% Imipenem and enzyme inhibitor 25 11.2% Imipenem and enzyme inhibitor 3 10.0% 
Vancomycin (parenteral) 24 15.2% Levofloxacin 24 10.7% Ampicillin and enzyme inhibitor 2 6.7% 
Piperacillin and enzyme inhibitor 8 5.1% Cefoperazone, combinations 22 9.8% Fosfomycin 2 6.7% 
Levofloxacin 7 4.4% Fosfomycin 15 6.7% Meropenem 2 6.7% 
Amikacin 5 3.2% Amikacin 13 5.8% Cefepime 1 3.3% 
Ampicillin and enzyme inhibitor 4 2.5% Ciprofloxacin 9 4.0% Ceftazidime 1 3.3% 
Ciprofloxacin 3 1.9% Doxycycline 8 3.6% Ceftriaxone 1 3.3% 
Doxycycline 3 1.9% Metronidazole (parenteral) 6 2.7% Ciprofloxacin 1 3.3% 
Fosfomycin 3 1.9% Netilmicin 6 2.7% Gentamicin 1 3.3% 
Netilmicin 3 1.9% Piperacillin and enzyme inhibitor 6 2.7% Piperacillin and enzyme inhibitor 1 3.3% 
Cefepime 2 1.3% Ceftazidime 5 2.2% 
   Sulfamethoxazole and trimethoprim 2 1.3% Cefepime 3 1.3% 
   Teicoplanin 2 1.3% Ceftriaxone 3 1.3% 
   Ceftazidime 1 0.6% Rifampicin 3 1.3% 
   Doripenem 1 0.6% Ampicillin and enzyme inhibitor 2 0.9% 
   Metronidazole (parenteral) 1 0.6% Clindamycin 2 0.9% 
   Moxifloxacin 1 0.6% Moxifloxacin 2 0.9% 
   Rifampicin 1 0.6% Sulfamethoxazole and trimethoprim 2 0.9% 
   Trimethoprim 1 0.6% The other antibiotics 12 5.4% 
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Appendix B: Clinical Research Forms 
B - 1: Clinical Research Forms for the Point Prevalence Survey 
1. Hospital baseline form  
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2. ICU baseline form 
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3. Patient form 
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B – 2: Clinical Research Form for VAP Study 
 
1. Assessment Schedule  
 
Summary of Data Collection Baseline 
D
0 
D
3 
D
7 D14 
Completio
n 
Discharg
e 
28-day 
follow-
up 
Informed consent form M O       
Daily assessment Daily, until a defined endpoint is met.   
Clinical assessment (CRF) M M M M M M   
Antibiotic use M     M   
Assessment of pneumonia/VAP M        
APACHE M        
SOFA M M M M M    
Cost of treatment       M  
Photograph chest x-rays M*      M  
28-day follow-up        M 
Non-microbiology investigations 
Arterial blood gas (3ml blood) M M M M M    
Complete blood count, CRP (5 ml 
blood) M M M M M    
Creatinine, Bilirubin (6 ml blood) M M M M M    
Urea, Na, K, Glucose, Albumin, LDH M        
Chest x ray M* M O M M    
Microbiology investigations (request susceptibility testing on all positive cultures) 
Blood culture   M     Update 
additional 
culture 
results 
 
Tracheal aspirate or sputum for culture  M M  M    
Bronchoscopy for culture  O      
M – Mandatory; O – Optional; M* Mandatory repeat CXR after 48hrs if initial CXR 
abnormal lung fields. 
Mandatory investigations on day of assessment: arterial blood gas, complete blood 
count and differential, CRP, Creatinine, total bilirubin, Urea, Na, K, Glucose, Albumin, 
LDH, chest x-ray 
  
2. Baseline Assessment form 
 
Participant number: 07RS-[__|__]-[__|__|__] 
 
INCLUSION Criteria (all answers must be YES) 
1. Aged ≥ 18 years      O Yes  O
 No 
2. Intubation or tracheostomy present   O Yes  O No 
3. Date of intubation/trache clearly documented  O Yes  O No 
4. Admission to ICU within the last 48 hours  O Yes  O No 
EXCLUSION criteria (Answer must be NO) 
Evidence / suspicion of Ventilator Associated Pneumonia O Yes  O No 
CONSENT (Answer must be YES) 
Patient/representative has given consent   O Yes  O No 
 
TIME POINTS DATE  (dd/mm/yy) TIME  (24hr clock) 
1. Admission to this hospital [__|__]/[__|__]/[__|__] [__|__]:[__|__] 
2. Date and time of intubation  [__|__]/[__|__]/[__|__] [__|__]:[__|__] 
3. Baseline assessment by study staff [__|__]/[__|__]/[__|__] [__|__]:[__|__] 
Study staff (family name, given name)  
 160 
 
GENERAL INFORMATION 
1. Sex:  ¡ Male    ¡ Female 
2. Date of birth  (dd/mm/yyyy): [__|__]/[__|__]/[__|__|__|__] 
If not available, record age:                                      [__|__] years 
3. Patient’s family name, given name*: [_______________________________________] 
4. Patient’s telephone*:  [_______________________________________] 
5. Next of kin* Name: [_______________________________________] 
 Telephone: [_______________________________________] 
 Relationship to patient: [_______________________________________] 
6. Hospital number: [_______________________] 
a. Ward: ¡ ICU NHTD ¡ ICU Bach Mai  
  ¡ ICU HTD  ¡ Other 
____________________ 
7. Health Insurance: ¡ Yes  ¡ No  
8. Weight if scale available (kg): [__|__] 9. Height (cm): [__|__|__] 
* Information will not be entered in the database 
 
MEDICAL HISTORY 
1. Myocardial infarction                                                                              ¡ Yes   ¡ No ¡ Don’t know 
2. Congestive heart failure                                                                           ¡ Yes   ¡ No ¡ Don’t know 
a. NYHA class IV?                                                                               ¡ Yes   ¡ No ¡ Don’t know 
3. Peripheral vascular disease                                                                      ¡ Yes   ¡ No ¡ Don’t know 
4. Cerebrovascular disease                                                                           ¡ Yes   ¡ No ¡ Don’t know 
5. Hemiplegia                                                                                               ¡ Yes   ¡ No ¡ Don’t know 
6. Dementia                                                                                                  ¡ Yes   ¡ No ¡ Don’t know 
7. Chronic pulmonary disease:                                                                     ¡ Yes   ¡ No ¡ Don’t know 
restrictive, obstructive, or vascular 
a. ANY of severe exercise restriction; documented hypoxemia  
or hypercapnia; secondary polycythemia; severe pulmonary  
hypertension (>40 mmHg); ventilator dependence                          ¡ Yes   ¡ No ¡ Don’t know 
8. Connective tissue disease                                                                        ¡ Yes   ¡ No ¡ Don’t know 
9. Peptic ulcer disease                                                                                 ¡ Yes   ¡ No ¡ Don’t know 
10. Mild liver disease:  Chronic hepatitis or  
cirrhosis without portal hypertension                                                     ¡ Yes   ¡ No ¡ Don’t know 
11. Severe liver disease:  Cirrhosis with portal hypertension                      ¡ Yes   ¡ No ¡ Don’t know 
12. Biopsy proven cirrhosis and documented portal hypertension;   
past upper GI bleeding attributed to portal hypertension;   
prior hepatic failure;  OR prior hepatic encephalopathy                        ¡ Yes   ¡ No ¡ Don’t know 
13. Chronic renal disease:  Usual creatinine >175µmol/L                           ¡ Yes   ¡ No ¡ Don’t know 
a. chronic dialysis?                                                                              ¡ Yes   ¡ No ¡ Don’t know 
14. Diabetes with no end-organ damage                                                        ¡ Yes   ¡ No ¡ Don’t know 
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MEDICAL HISTORY 
15. Diabetes with end-organ damage:   
Nephropathy, retinopathy, or neuropathy                                               ¡ Yes   ¡ No ¡ Don’t know 
16. Solid tumour without metastases:  diagnosed in the last 5 yrs                ¡ Yes   ¡ No ¡ Don’t know 
Excluding non-melanoma skin cancer 
17. Leukemia or lymphoma                                                                           ¡ Yes   ¡ No ¡ Don’t know 
18. Metastatic cancer                                                                                     ¡ Yes   ¡ No ¡ Don’t know 
19. Alcohol addiction                                                                                     ¡ Yes   ¡ No ¡ Don’t know 
20. AIDS                                                                                                        ¡ Yes   ¡ No ¡ Don’t know 
21. Immunosuppression: chemotherapy, radiation therapy,  
long-term or recent high-dose steroids                                                    ¡ Yes   ¡ No ¡ Don’t know 
 
DIAGNOSIS:  Use ICD9 
1. ICU admission diagnosis: [________________________________________________] 
2. Status post-surgery?  ¡ No    ¡ Elective  ¡ Emergent 
3. Other diagnoses 
1.  
2.  
3.  
 
RECENT ADMISSIONS 
4. Admission to any hospital for another illness in the last 90 days: ¡ Yes     ¡ No    ¡ Don’t know 
5. Admission to another hospital for this illness before this hospital:  ¡ Yes     ¡ No    ¡ Don’t know 
a. If yes, hospital type:  ¡ Tertiary  ¡ Provincial  ¡ District  
b. Date of admission to that hospital:  [__|__]/[__|__]/[__|__](dd/mm/yy) 
 
ANTIMICROBIAL USE 
6. Antimicrobial use for another illness in the last 90 days: ¡ Yes     ¡ No    ¡ Don’t know 
7. Antimicrobial use for this illness (home/ referral hospital): ¡ Yes     ¡ No    ¡ Don’t know 
Generic name (or ‘unknown’)  Start date (dd/mm/yy) End date (dd/mm/yy) 
1.  [__|__]/[__|__]/[__|__] [__|__]/[__|__]/[__|__] 
2.  [__|__]/[__|__]/[__|__] [__|__]/[__|__]/[__|__] 
3.  [__|__]/[__|__]/[__|__] [__|__]/[__|__]/[__|__] 
4.  [__|__]/[__|__]/[__|__] [__|__]/[__|__]/[__|__] 
5.  [__|__]/[__|__]/[__|__] [__|__]/[__|__]/[__|__] 
 
INDICATION FOR INTUBATION (Check all that apply)  
8. Unable to maintain or protect airway (e.g. decreased level of consciousness, airway 
obstruction) ¨ 
9. Ventilation problem (e.g. high pCO2, depressed respiratory rate, weak respiratory muscles) ¨ 
10. Oxygenation problem (low paO2) ¨ 
11. Other reason, please describe. ¨ 
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GCS Before 
intubation Most recent value taken on day of assessment  
12. Eyes [__]/ 4 [__]/ 4 4 spontaneously open, 3 open to voice, 2 open to pain, 1 nil 
13. Verbal  [__]/ 5 [__]/ 5 5 oriented, 4 confused, 3 random words, 2 sounds, 1 nil; ‘T’ if intubated 
14. Motor   [__]/ 6 [__]/ 6 6 obey commands, 5 localize pain, 4 withdraw to pain, 3 flexion, 2 extension, 1 nil 
PHYSIOLOGICAL ASSESSMENT (most recent value taken on day of assessment) 
1. Temperature [__|__].[__]°C 
  ¡ Oral  ¡ Tympanic  ¡ Axillary  ¡ Rectal 
2. Heart Rate [__|__|__] bpm 3. Blood Pressure [__|__|__]/[__|__|__] mmHg 
4. Actual mean arterial pressure, if 
available [__|__|__] mmHg 
5. Vasopressors (highest dose, mcg/kg/min) 
a. dobutamine ¡  No   ¡  Yes 
b. dopamine ¡  No   ¡  ≤ 5  ¡  > 5  ¡  > 15  
c. noradrenaline ¡  No   ¡  ≤ 0.1 ¡  > 0.1 ¡  >0.25 
d. adrenaline ¡  No   ¡  ≤ 0.1  ¡  > 0.1  ¡  >0.25 
6. Respiratory Rate [__|__] bpm 
7. 24-hour IV fluid infused* [__|__|__|__] ml 8. 24-hour Urine Output* [__|__|__|__] ml 
*: record the routine value from clinical chart for the 24h period to enrolment time. 
 
ARTERIAL BLOOD GAS  (most recent value taken on day of assessment) 
9.FiO2 [__|__|__] % 12.HCO3  [__|__] mmol/L 
10.pH [__].[__|__] 13.A-a gradient [__|__|__] mmHg 
11.PaO2 [__|__|__] mmHg 14.PaCO2 [__|__|__] mmHg 
 
LABORATORY RESULTS  (most recent value taken on day of assessment ) 
Hematology           Biochemistry                
15.White cell count  [__|__].[__] 109/L 20. Creatinine [__|__|__].[__] µmol/L 
a. Neutrophils [__|__].[__] % a. Acute renal failure? ¡ Yes     ¡ No 
b. Lymphocytes  [__|__].[__] % 21. Urea  [__|__].[__] mmol/L 
16.Hematocrit  [__|__].[__]% 22. Na+  [__|__|__] mmol/L 
17.Hemoglobin [__|__|__] g/L 23. K+  [__|__].[__] mmol/L 
18.Red blood cell  [__].[__|__] 1012/L 24. Glucose [__|__].[__] mmol/L 
19.Platelet count  [__|__|__] 109/L 25. Total bilirubin [__|__|__] mg/L 
  26. Albumin [__|__].[__] g/L       
  27. LDH [__|__|__|__] U/L 
  28. CRP  [__|__|__] µmol/L 
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5 
4 
3 
2 
1 
 
CHEST X-RAY (most recent film taken on day of assessment) 
1. Circle any infiltrates on diagram to the right. 
2. Consolidation: ¡ Yes  ¡ No 
3. Cavitation:  ¡ Yes  ¡ No 
4. CXR photograph taken: ¡ Yes  
5. CXR reader 1 (family name, given name):  
______________________________ 
6. CXR reader 2 (family name, given name):  
______________________________ 
 
Next step:  Proceed to CRF daily assessment. 
 
  164 
3. Daily Assessment form 
Participant number: 07RS-[__|__]-[__|__|__] Page ___ of ___  
Date  (dd/mm/yy) __ / __ / ___ __ / __ / ___ __ / __ / ___ __ / __ / ___ __ / __ / ___ __ / __ / ___ __ / __ / ___ 
1. Location  ICU/ward ICU / ward ICU / ward ICU / ward ICU / ward ICU / ward ICU / ward ICU / ward 
2. Intubated?  Yes/No/T (tracheostomy) Yes / No / T Yes / No / T Yes / No / T Yes / No / T Yes / No / T Yes / No / T Yes / No / T 
3. Ventilated?  Yes/No Yes / No Yes / No Yes / No Yes / No Yes / No Yes / No Yes / No 
4. None/Sedation/Paralysis/Both No/ S / P / B No/ S / P / B No/ S / P / B No/ S / P / B No/ S / P / B No/ S / P / B No/ S / P / B 
Systemic Criteria 
5. Max. temperature (oC) [__|__].[__] [__|__].[__] [__|__].[__] [__|__].[__] [__|__].[__] [__|__].[__] [__|__].[__] 
6. Max. WBC or n/a        
7. Min. WBC         
Ventilation & secretions 
8. Min. PEEP  (mmH2O) or n/a        
9. Min. FiO2  (%) or n/a        
10. Increase in purulent secretions?  Yes/No Yes / No Yes / No Yes / No Yes / No Yes / No Yes / No Yes / No 
11. Gram stain neutrophils ≥25/lpf  Yes/No/ na Yes / No / na Yes / No / na Yes / No / na Yes / No / na Yes / No / na Yes / No / na Yes / No / na 
12. Tracheal aspirate (TA)/ Sputum (S)/ Bronchoscopy (B) TA / S / B TA / S / B TA / S / B TA / S / B TA / S / B TA / S / B TA / S / B 
13. Suspect VAP?  Yes/No Yes / No Yes / No Yes / No Yes / No Yes / No Yes / No Yes / No 
Antibiotic Use 
On antibiotics Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No 
If yes, give indication code        
If yes give antibiotic code        
Initials of study doctor        
“NO VAP” endpoint if: Patient well 48h after extubation OR Transferred to 
another hospital, death while intubated, or discharged home. 
à Go to CRF Completion 
Suspect VAP if :   
Deterioration in ventilation AND systemic signs AND secretions 
Go to ‘CRF CXR’ to see if VAP is confirmed. 
CODES 
“Deterioration in ventilation” at least one of 
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PEEP criteria: ≥ 2 days of stable or decreasing daily minimum PEEP followed by a rise in daily minimum PEEP of ≥ 2.5 cm H2O, sustained for ≥ 2 calendar days; 
or 
FiO2 Criteria: ≥ 2 days of stable or decreasing daily minimum FiO2 followed by a rise in daily minimum FiO2  of ≥ 0.15 points, sustained for ≥ 2 calendar days 
 
“Systemic signs” at least one of  
Fever >38ºC or <36ºC  
or 
WBC >12x109/L or <4x109/L 
 
“Secretions” at least one of 
Increased/new purulent secretions  
or  
>25 neutrophils per low power (x10) field on Gram stain of ET aspirate 
 
Indication Codes 
CNS infection of central nervous system    PNEU Pneumonia  
BAC Laboratory confirmed bacteraemia    BRON Acute bronchitis, trachea-bronchitis, excacerbation of chronic bronchitis 
CSEP Clinical sepsis      EYE Endopthalmitis 
ENT Infection of ear, nose, throat    CVS Endocarditis, vascular graft infection 
IA Intra-abdominal sepsis     GI Gastrointestinal infection (eg salmonellosis, antibiotic associated colitis) 
SST Skin or soft tissue infection    BJ Bone or joint infection 
CYS Lower urinary tract (eg cystitis)    PYE Upper urinary tract (pyelonephritis) 
ASB Asymptomatic bacteruria    OBGY Obstetric/gynaecological infection/STI in women  
GUM STI in men, prostatitis, epididymo-orchitis etc   SIRS systemic inflammatory response wityh no clear anatomical site 
FN Febrile neutropenia     UND site with no systemic inflammation 
 
Antibiotic codes (can put more than one) 
1 Colistin  2 Carbapenem  3 Aminoglycoside 4 Fourth gen cephalosporin or βlactam+ βlactamase inhibitor 5 Other 
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4. Chest X-Ray Assessment form 
Participant number: 07RS-[__|__]-[__|__|__] 
Date of assessment:  [__|__]/[__|__]/[__|__] (dd/mm/yy) 
Time of assessment:  [__|__]:[__|__] (hh:mm – 24hr clock) 
CHEST X-RAY 
1. Date of last chest x-ray for comparison: 
[__|__]/[__|__]/[__|__] (dd/mm/yy) 
2. Is there a new infiltrate on this chest x-ray? 
¡ Yes  ¡ No  ¡ Not done
     
3. Circle all infiltrates on diagram to the 
right. 
4. Consolidation:  ¡ Yes     ¡ No 
5. Cavitation:  ¡ Yes     ¡ No 
6. CXR photograph taken: ¡ Yes 
7. CXR reader 1 (family name, given name): 
______________________________ 
8. CXR reader 2 (family name, given name): ______________________________ 
 
Q2 Outcome – Was there new infiltrates on the CXR? 
Yes: VAP, go to ‘CRF VAP case’. 
No or not done: Go to question 9 
 
9. Has a new antibiotic been started for a respiratory tract infection within the last 48 
hrs: 
Yes: VAP, go to ‘CRF VAP case’. 
No: continue with “Daily assessment CRF” 
  
5 
4 
3 
2 
1 
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5. Additional Microbiology Assessment form 
CRF Additional Microbiology  MICRO 
Participant number: 07RS-[__|__]-[__|__|__] Page __ of __ 
1. Blood Culture 
a. Laboratory specimen number: [_____________________] 
b. Date taken:    [__|__]/[__|__]/[__|__] (dd/mm/yy) 
c. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
d. Culture report (attach copy of susceptibility test) 
[_________________________________________________________________] 
OR, Negative culture after 5 days  c 
2. Respiratory culture 
a. Collection:  ¡ Bronchoscopy ¡ Tracheal Aspirate  ¡ 
Sputum 
b. Sputum: adequate specimen? (≥25 polymorphs and ≤10 squamous cells): ¡ Yes         ¡ 
No 
c. Tracheal aspirate: ≥25 polymorphs? ¡ Yes         ¡ No 
d. Laboratory specimen number: [________________________________] 
e. Date taken: [__|__]/[__|__]/[__|__] (dd/mm/yy) 
f. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
g. Gram stain morphology: [___________________________________________] 
h. Culture report (bacteria and amount of growth e.g. 1+/2+;  attach copy of susceptibility 
test) 
[________________________________________________________________] 
OR, Negative culture c 
 
07RS - Ventilator-Associated Pneumonia Study 
CRF Additional Microbiology  MICRO 
Participant number: 07RS-[__|__]-[__|__|__] Page __ of __ 
1. Blood Culture 
a. Laboratory specimen number: [_____________________] 
b. Date taken:    [__|__]/[__|__]/[__|__] (dd/mm/yy) 
c. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
d. Culture report (attach copy of susceptibility test) 
[_________________________________________________________________] 
OR, Negative culture after 5 days  c 
2. Respiratory culture 
a. Collection:  ¡ Bronchoscopy ¡ Tracheal Aspirate  ¡ 
Sputum 
b. Sputum: adequate specimen? (≥25 polymorphs and ≤10 squamous cells): ¡ Yes         ¡ 
No 
c. Tracheal aspirate: ≥25 polymorphs? ¡ Yes         ¡ No 
d. Laboratory specimen number: [________________________________] 
e. Date taken: [__|__]/[__|__]/[__|__] (dd/mm/yy) 
f. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
g. Gram stain morphology: [___________________________________________] 
h. Culture report (bacteria and amount of growth e.g. 1+/2+;  attach copy of susceptibility 
test) 
[_________________________________________________________________] 
OR, Negative culture c 
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6. VAP Assessment form 
DAY OF VAP DIAGNOSIS (DAY 0) 
1. Participant number: 07RS-[__|__]-[__|__|__] 
2. Date of assessment:  [__|__]/[__|__]/[__|__] (dd/mm/yy) 
3. Time of assessment:  [__|__]:[__|__] (hh:mm – 24hr clock) 
4. Study staff  (family name, given name): 
[___________________________________________] 
Mandatory investigations on VAP day 0: arterial blood gas, complete blood count and 
differential, CRP, Creatinine, total bilirubin, chest x-ray, blood culture and 
susceptibility, tracheal aspirate/sputum for culture and susceptibility 
Optional investigations: bronchoscopy for bronchoalveolar lavage à culture and 
susceptibility 
 
5. GCS  (most recent value taken on VAP day 0) 
a. Eyes [__]/ 
4 4 spontaneously open, 3 open to voice, 2 open to pain, 1 nil 
b.Verbal  [__]/ 
5 5 oriented, 4 confused, 3 random words, 2 sounds, 1 nil; write ‘T’ if intubated 
c. Motor   [__]/ 
6 6 obey commands, 5 localize pain, 4 withdraw to pain, 3 flexion, 2 extension, 1 nil 
 
PHYSIOLOGICAL ASSESSMENT  (most recent value taken on VAP day 0) 
6. Temperature [__|__].[__]°C 
  ¡ Oral ¡ Tympanic  ¡ Axillary  ¡ Rectal 
7. Heart Rate [__|__|__] bpm 
8. Blood Pressure [__|__|__]/[__|__|__] 
mmHg 
9. Actual mean arterial pressure, if 
available [__|__|__] mmHg 
10. Vasopressors  (highest dose, mcg/kg/min) 
e. Dobutamine ¡  No   ¡  Yes 
f. Dopamine ¡  No   ¡  ≤ 5  ¡  > 5  ¡  > 15  
g. Noradrenaline ¡  No   ¡  ≤ 0.1 ¡  > 0.1 ¡  >0.25 
h. adrenaline ¡  No   ¡  ≤ 0.1  ¡  > 0.1  ¡  >0.25 
11. Respiratory Rate [__|__] bpm 
12. 24-hour IV fluid infused* 
[__|__|__|__] ml 
13. 24-hour Urine Output*
 [__|__|__|__] ml 
*: record the routine value from clinical chart for the 24h period which covers VAP day 0. 
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23. Blood Culture 
e. Laboratory specimen number: [_____________________] 
f. Date taken:    [__|__]/[__|__]/[__|__] (dd/mm/yy) 
g. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
h. Culture report (attach copy of susceptibility test) 
[_________________________________________________________________] 
OR, Negative culture after 5 days  c 
24. Respiratory culture 
i. Collection:  ¡ Bronchoscopy ¡ Tracheal Aspirate  ¡ 
Sputum 
j. Sputum: adequate specimen? (≥25 polymorphs and ≤10 squamous cells): ¡ Yes         ¡ 
No 
k. Tracheal aspirate: ≥25 polymorphs? ¡ Yes         ¡ No 
l. Laboratory specimen number: [________________________________] 
m. Date taken: [__|__]/[__|__]/[__|__] (dd/mm/yy) 
n. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
o. Gram stain morphology: [___________________________________________] 
p. Culture (bacteria and amount of growth e.g. 1+/2+;  attach copy of susceptibility test) 
[_________________________________________________________________] 
OR, Negative culture c 
25. Respiratory culture  
a. Collection:  ¡ Bronchoscopy ¡ Tracheal Aspirate  ¡ 
Sputum 
b. Sputum: adequate specimen? (≥25 polymorphs and ≤10 squamous cells): ¡ Yes         ¡ 
No 
c. Tracheal aspirate: ≥25 polymorphs? ¡ Yes         ¡ No 
d. Laboratory specimen number: [________________________________] 
e. Date taken: [__|__]/[__|__]/[__|__] (dd/mm/yy) 
f. Any antibiotics received before specimen taken? ¡ Yes         ¡ No 
g. Gram stain morphology: [___________________________________________] 
h. Culture (bacteria and amount of growth e.g. 1+/2+;  attach copy of susceptibility test) 
[_________________________________________________________________] 
OR, Negative culture c.
LABORATORY RESULTS  (most recent value taken on VAP day 0) 
Hematology         Biochemistry                
14. White cell count  [__|__].[__] 109/L 18. Creatinine [__|__|__].[__] µmol/L 
a. Neutrophils [__|__].[__] % 19. Total bilirubin [__|__|__] mg/L 
b. Lymphocytes  [__|__].[__] % 20. CRP  [__|__|__] µmol/L 
15. Hematocrit  [__|__].[__]%   
16. Hemoglobin [__|__|__] g/L Arterial blood gas  
17. Red blood cell  [__].[__|__] 1012/L 21. PaO2 [__|__|__] mmHg 
18. Platelet count  [__|__|__] 109/L 22. FiO2 [__|__|__] % 
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DAY 3 AFTER VAP DIAGNOSIS 
1. Participant number: 07RS-[__|__]-[__|__|__] 
2. Date of assessment:  [__|__]/[__|__]/[__|__] (dd/mm/yy) 
3. Time of assessment:  [__|__]:[__|__] (hh:mm – 24hr clock) 
4. Study staff  (family name, given name): 
[_________________________________________] 
Update culture results from VAP day 0: ¨  Yes 
Mandatory investigations on VAP day 3: arterial blood gas, complete blood count and 
differential, CRP, Creatinine, total bilirubin 
Optional investigations: chest x-ray 
 
5. GCS (most recent value taken on VAP day 3) 
a. Eyes [__]/ 4 4 spontaneously open, 3 open to voice, 2 open to pain, 1 nil 
b.Verbal  [__]/ 5 5 oriented, 4 confused, 3 random words, 2 sounds, 1 nil; write ‘T’ if intubated 
c. Motor   [__]/ 6 6 obey commands, 5 localize pain, 4 withdraw to pain, 3 flexion, 2 extension, 1 nil 
 
PHYSIOLOGICAL ASSESSMENT (most recent value taken on VAP day 3) 
6. Temperature [__|__].[__]°C 
  ¡ Oral ¡ Tympanic  ¡ Axillary  ¡ Rectal 
7. Heart Rate [__|__|__] bpm 
8. Blood Pressure [__|__|__]/[__|__|__] 
mmHg 
9. Actual mean arterial pressure, if 
available [__|__|__] mmHg 
10. Vasopressors  (highest dose, mcg/kg/min) 
a. dobutamine ¡  No   ¡  Yes 
b. dopamine ¡  No   ¡  ≤ 5  ¡  > 5  ¡  > 
15  
c. noradrenaline ¡  No   ¡  ≤ 0.1 ¡  > 0.1 ¡  
>0.25 
d. adrenaline ¡  No   ¡  ≤ 0.1  ¡  > 0.1  ¡  
>0.25 
11. Respiratory Rate [__|__] bpm 
12. 24-hour IV fluid infused* 
[__|__|__|__] ml 
13. 24-hour Urine Output*
 [__|__|__|__] ml 
*: record the routine value from clinical chart for the 24h period which covers VAP day 3. 
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CHEST X-RAY (Optional; most recent film taken on VAP day 3) 
1. Date of last chest x-ray for comparison: 
[__|__]/[__|__]/[__|__]  (dd/mm/yy) 
2. Compared to last chest-x-ray (overall 
impression): 
¡ better ¡ worse ¡ same 
3. Circle all infiltrates on diagram to the right. 
4. Consolidation:  ¡ Yes  ¡ No 
5. Cavitation:  ¡ Yes  ¡ No 
6. CXR photograph taken: ¡ Yes 
7. CXR reader 1 (family name, given name): 
______________________________ 
8. CXR reader 2 (family name, given name): 
______________________________ 
LABORATORY RESULTS (most recent value taken on VAP day 3) 
Hematology         Biochemistry                
14. White cell count  [__|__].[__] 
109/L 
19. Creatinine [__|__|__].[__] µmol/L 
c. Neutrophils [__|__].[__] % 
20. Total 
bilirubin [__|__|__] mg/L 
d. Lymphocyte
s  [__|__].[__] % 
21. CRP  [__|__|__] µmol/L 
15. Hematocrit  [__|__].[__]%   
16. Hemoglobin [__|__|__] g/L Arterial blood gas  
17. Red blood cell  [__].[__|__] 
1012/L 
22. PaO2 [__|__|__] mmHg 
18. Platelet count  [__|__|__] 109/L 23. FiO2 [__|__|__] % 
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DAY 7 AFTER VAP DIAGNOSIS 
1. Participant number: 07RS-[__|__]-[__|__|__] 
2. Date of assessment:  [__|__]/[__|__]/[__|__] (dd/mm/yy) 
3. Time of assessment:  [__|__]:[__|__] (hh:mm – 24hr clock) 
4. Study staff  (family name, given name):  
[_____________________________________] 
Update culture results from VAP day 3: ¨  Yes 
Mandatory investigations on VAP day 7: arterial blood gas, complete blood count and 
differential, CRP, Creatinine, total bilirubin, chest x-ray 
 
5. GCS  (most recent value taken on VAP day 7) 
a. Eyes [__]/ 4 4 spontaneously open, 3 open to voice, 2 open to pain, 1 nil 
b.Verbal  [__]/ 5 5 oriented, 4 confused, 3 random words, 2 sounds, 1 nil; write ‘T’ if intubated 
c. Motor   [__]/ 6 6 obey commands, 5 localize pain, 4 withdraw to pain, 3 flexion, 2 extension, 1 nil 
 
PHYSIOLOGICAL ASSESSMENT  (most recent value taken on VAP day 7) 
6. Temperature [__|__].[__]°C 
  ¡ Oral ¡ Tympanic  ¡ Axillary  ¡ Rectal 
7. Heart Rate [__|__|__] bpm 
8. Blood Pressure [__|__|__]/[__|__|__] 
mmHg 
9. Actual mean arterial pressure, if 
available [__|__|__] mmHg 
10. Vasopressors  (highest dose, mcg/kg/min) 
a. dobutamine ¡  No   ¡  Yes 
b. dopamine ¡  No   ¡  ≤ 5  ¡  > 5  ¡  > 
15  
c. noradrenaline ¡  No   ¡  ≤ 0.1 ¡  > 0.1 ¡  
>0.25 
d. adrenaline ¡  No   ¡  ≤ 0.1  ¡  > 0.1  ¡  
>0.25 
11. Respiratory Rate [__|__] bpm 
12. 24-hour IV fluid infused* 
[__|__|__|__] ml 
13. 24-hour Urine Output*
 [__|__|__|__] ml 
*: record the routine value from clinical chart for the 24h period which covers VAP day 7. 
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CHEST X-RAY (most recent film taken on VAP day 7) 
7. Date of last chest x-ray for comparison: 
[__|__]/[__|__]/[__|__]  (dd/mm/yy) 
8. Compared to last chest-x-ray (overall 
impression): 
¡ better ¡ worse ¡ same 
9. Circle all infiltrates on diagram to the right. 
10. Consolidation:  ¡ Yes  ¡ No 
11. Cavitation:  ¡ Yes  ¡ No 
12. CXR photograph taken: ¡ Yes 
13. CXR reader 1 (family name, given name): 
______________________________ 
14. CXR reader 2 (family name, given name): 
______________________________ 
LABORATORY RESULTS (most recent value taken on VAP day 7) 
Hematology  Biochemistry                
14. White cell count  [__|__].[__] 109/L 19. Creatinine [__|__|__].[__] µmol/L 
a. Neutrophils [__|__].[__] % 20. Total bilirubin [__|__|__] mg/L 
b. Lymphocyte
s  [__|__].[__] % 21. CRP  [__|__|__] µmol/L 
15. Hematocrit  [__|__].[__]%   
16. Hemoglobin [__|__|__] g/L Arterial blood gas  
17. Red blood cell  [__].[__|__] 
1012/L 22. PaO2 [__|__|__] mmHg 
18. Platelet count  [__|__|__] 109/L 23. FiO2 [__|__|__] % 
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DAY 14 AFTER VAP DIAGNOSIS 
1. Participant number: 07RS-[__|__]-[__|__|__] 
2. Date of assessment:  [__|__]/[__|__]/[__|__] (dd/mm/yy) 
3. Time of assessment:  [__|__]:[__|__] (hh:mm – 24hr clock) 
4. Study staff  (family name, given name):  
Update antibiotics and culture results from VAP day 7: ¨  Yes 
Mandatory investigations on VAP day 14: arterial blood gas, complete blood count and 
differential, CRP, Creatinine, total bilirubin, chest x-ray 
 
5. GCS  (most recent value taken on VAP day 14) 
a. Eyes [__]/ 4 4 spontaneously open, 3 open to voice, 2 open to pain, 1 nil 
b. Verbal  [__]/ 5 5 oriented, 4 confused, 3 random words, 2 sounds, 1 nil; write ‘T’ if intubated 
c. Motor   [__]/ 6 6 obey commands, 5 localize pain, 4 withdraw to pain, 3 flexion, 2 extension, 1 nil 
 
PHYSIOLOGICAL ASSESSMENT (most recent value taken on VAP day 14) 
6. Temperature [__|__].[__]°C 
  ¡ Oral ¡ Tympanic  ¡ Axillary  ¡ Rectal 
7. Heart Rate [__|__|__] bpm 
8. Blood Pressure [__|__|__]/[__|__|__] 
mmHg 
9. Actual mean arterial pressure, if 
available [__|__|__] mmHg 
10. Vasopressors (highest dose, mcg/kg/min) 
a. dobutamine ¡  No   ¡  Yes 
b. dopamine ¡  No   ¡  ≤ 5  ¡  > 5  ¡  > 15  
c. noradrenaline ¡  No   ¡  ≤ 0.1 ¡  > 0.1 ¡  >0.25 
d. adrenaline ¡  No   ¡  ≤ 0.1  ¡  > 0.1  ¡  >0.25 
11. Respiratory Rate [__|__] bpm 
12. 24-hour IV fluid infused* 
[__|__|__|__] ml 
13. 24-hour Urine Output* [__|__|__|__] 
ml 
*: record the routine value from clinical chart for the 24h period which covers VAP day 
14. 
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CHEST X-RAY (most recent film taken on VAP day 14) 
1. Date of last chest x-ray for comparison: 
[__|__]/[__|__]/[__|__]  (dd/mm/yy) 
2. Compared to last chest-x-ray (overall 
impression): 
a. ¡ better ¡ worse ¡ same 
3. Circle all infiltrates on diagram to the right. 
4. Consolidation:  ¡ Yes  ¡ No 
5. Cavitation:  ¡ Yes  ¡ No 
6. CXR photograph taken: ¡ Yes 
7. CXR reader 1 (family name, given name): 
______________________________ 
8. CXR reader 2 (family name, given name): 
______________________________ 
 
 
 
Next step:  go to CRF completion 
 
  
LABORATORY RESULTS (most recent value taken on VAP day 14) 
Hematology           Biochemistry                
14. White cell count  [__|__].[__] 109/L 19. Creatinine [__|__|__].[__] µmol/L 
a. Neutrophils [__|__].[__] % 20. Total bilirubin [__|__|__] mg/L 
a. Lymphocytes  [__|__].[__] % 21. CRP  [__|__|__] µmol/L 
15. Hematocrit  [__|__].[__]%   
16. Hemoglobin [__|__|__] g/L Arterial blood gas  
17. Red blood cell  [__].[__|__] 1012/L 22. PaO2 [__|__|__] mmHg 
18. Platelet count  [__|__|__] 109/L 23. FiO2 [__|__|__] % 
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7. Complete Assessment form 
1. Participant number: 07RS-[__|__]-[__|__|__] 
2. Date of assessment:  [__|__]/[__|__]/[__|__] (dd/mm/yy) 
3. Time of assessment: [__|__]:[__|__] (hh:mm – 24hr clock) 
4. Study staff  (family name, given name): 
[____________________________________________] 
 
STUDYCOMPLETION  choose one only  Date  (dd/mm/yy) 
5. VAP: Day 28  after VAP 
diagnosis 
• Patient remains in hospital  [__|__]/[__|__]/[__|__] 
• Discharged already [__|__]/[__|__]/[__|__] 
6. No VAP: Day 28 after 
enrolment 
• Patient well 48h after extubation or 
still intubated  [__|__]/[__|__]/[__|__] 
• Discharged already [__|__]/[__|__]/[__|__] 
 
DISCHARGE DETAILS 
7. Discharge Date [__|__]/[__|__]/[__|__] 
DISCHARGE REASON (choose only one) 
8. Discharged home, stable ¡ Yes 9. Transferred to another hospital ¡ Yes 
10. Discharged home to die  ¡ Yes 11. Death in hospital, respiratory cause ¡ Yes 
12. Death in hospital, non-respiratory cause or unclear cause ¡ Yes 
 
13. Diagnoses: final admission diagnosis and any additional diagnoses after 
admission: refer to baseline assessment;  (e.g. meningitis, endocarditis) 
i.  
ii.  
iii.  
14. Additional positive cultures from blood, sputum, or tracheal aspirate?  ¡ Yes         
¡ No 
• If yes, please complete “additional cultures” form 
• Attach copies of all susceptibility testing to the CRF  ¨ Yes  
15. Chest x-rays: photograph and save all chest x-rays ¨ Yes 
 
16. GCS (most recent value taken on day of completion) 
a. Eyes [__]/ 4 4 spontaneously open, 3 open to voice, 2 open to pain, 1 nil 
b. Verbal  [__]/ 5 5 oriented, 4 confused, 3 random words, 2 sounds, 1 nil; write ‘T’ if intubated 
c. Motor   [__]/ 6 6 obey commands, 5 localize pain, 4 withdraw to pain, 3 flexion, 2 extension, 1 nil 
 
INTUBATION enter all dates as(dd/mm/yy)  VENTILATION ICU stay 
Start date  Stop date  Extubation intentional? Start 
date 
Stop date  Start date  Stop date 
  ¡ Yes ¡ No     
  ¡ Yes ¡ No     
  ¡ Yes ¡ No     
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ANTIBIOTICS USED  in this hospital, until study outcome reached 
Brand or generic 
name§ Indication* 
Amount 
per 
dose 
Doses 
per 
day 
Start date 
(dd/mm/yy) 
End date 
(dd/mm/yy) 
Treatment 
ongoing? 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
      ¡ Yes 
§ For tuberculosis, write “TB treatment”. 
*Indication: CI: community-acquired infection; LI: infection acquired at a long-term or chronic- care facility; 
VAP: ventilator-associated pneumonia; HI: hospital-acquired infection, not VAP; SP: surgical prophylaxis; 
MP: medical prophylaxis; O: other; UI: unknown indication (medical team suspect infection but source 
unclear); UNK: truly unknown to study doctor completing CRF 
        OTHER MEDICATIONS  (Yes if ever used) 
17. Sedatives (e.g. benzodiazepines, anti-psychotics, anti-
convulsants) 
¡ Yes ¡ No 
18. Neuromuscular blockade ¡ Yes ¡ No 
19. Antacids (e.g. H2-blocker or proton pump inhibitor) ¡ Yes ¡ No 
20. Insulin ¡ Yes ¡ No 
21. Steroids ¡ Yes ¡ No 
22. Vasopressors ¡ Yes ¡ No 
        MEDICAL INTERVENTION  (Yes if ever used) 
23. Hemodialysis ¡ Yes ¡ No 
24. Transfusion of blood products ¡ Yes ¡ No 
25. Tracheostomy 
a. if Yes, date of insertion [__|__]/[__|__]/[__|__]  
(dd/mm/yy) 
¡ Yes ¡ No 
26. Thoracentesis ¡ Yes ¡ No 
Other, specify: 
¡ Yes ¡ No COSTS FOR TREATMENT  (attach copy of itemized costs ¨ Yes) 
27. Total cost (VND): [________________] 
28. Amount covered by health insurance: [________________] 
PHONE FOLLOW-UP AT 28 DAYS  if discharged or transferred beforehand 
29. Date of assessment:  [__|__]/[__|__]/[__|__]  (dd/mm/yy) 
30. Study staff  (family name, given name): [________________________________] 
31. Outcome ¡ Death 
¡ Alive,  If alive:   ¡ home  ¡ another hospital 
¡ Unable to reach patient or next of kin 
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